PT J
AU Kang, HS
   Jeong, D
   Kim, DI
   Lee, MS
AF Kang, Hyun-Sun
   Jeong, Daun
   Kim, Dong-Il
   Lee, Myeong Soo
TI The use of acupuncture for managing gynaecologic conditions: An overview of
SO Maturitas
LA English
DT Journal Article
AB Acupuncture is increasingly popular for the treatment of many medical complaints,  including gynaecologic conditions. The aim of this study was to summarise the  evidence from systematic reviews (SRs) and meta-analyses assessing the efficacy  of acupuncture in treating common gynaecologic conditions. Six electronic  databases, including two major English-language databases (PubMed and the  Cochrane Library) and four Korean databases, were systematically searched for SRs  and meta-analyses concerned with acupuncture and common gynaecologic diseases.  The following English search terms were used: (gynaecologic disease in MeSH  terms) AND (acupuncture or acup*) AND (systematic review OR meta-analysis). In  addition, three Korean traditional medicine journals (The Journal of the Korean  Acupuncture and Moxibustion Society, The Journal of Korean Oriental Medicine and  The Journal of Oriental Obstetrics and Gynaecology) were searched. The quality of  the included studies was assessed using the Overview Quality Assessment  Questionnaire. Of the 55 potentially relevant studies that were found, 16 SRs  were included in this report. These reviews evaluated the efficacy of acupuncture  for treating the side effects of breast cancer chemotherapy, menstrual  disturbances, menopausal symptoms, female infertility, uterine fibroids and  polycystic ovary syndrome. Acupuncture was clearly beneficial in the management  of chemotherapy-induced nausea and vomiting. In addition, current evidence  suggests that acupuncture administered close to embryo transfer during in vitro  fertilisation treatment improves the rates of pregnancy and live birth. In  conclusion, there is no convincing evidence of the efficacy of acupuncture except  for specific conditions, which include acupuncture administered with embryo  transfer to improve the outcome of in vitro fertilisation and acupuncture for the  management of chemotherapy-induced nausea and vomiting. More well-designed trials  using rigorous methodology are required to evaluate the efficacy of acupuncture  in treating gynaecologic conditions.
C1 Department of Obstetrics & Gynecology, College of Korean Medicine, Dongguk University, Ilsan, South Korea.
NR 0
TC 0
SN 1873-411
EI 
J9 Maturitas
PD MAR 8
PY 2011
VL 68
IS 4
BP 346
EP 54
DI 10.1016/j.maturitas.2011.02.001
PG -292
WC Acupuncture Therapy; Antineoplastic Agents; adverse effects; Breast Neoplasms; drug therapy; Dysmenorrhea; therapy; Female; Humans; Infertility, Female; therapy; Leiomyoma; therapy; Live Birth; Menopause; Meta-Analysis as Topic; Nausea; chemically induced; Polycystic Ovary Syndrome; therapy; Pregnancy; Review Literature as Topic; Vomiting; chemically induced
UT PubMed:21376483
PM 21376483
DA 2011-03-08
ER

PT J
AU Noor, MT
   Vaiphei, K
   Nagi, B
   Singh, K
   Kochhar, R
AF Noor, Mohd Talha
   Vaiphei, Kim
   Nagi, Birinder
   Singh, Kartar
   Kochhar, Rakesh
TI Role of needle knife assisted ampullary biopsy in the diagnosis of periampullary
SO World journal of gastrointestinal endoscopy
LA English
DT Journal Article
DE Carcinoma; Endoscopic ultrasound; Endoscopy; Needle knife; Papillotomy; Periampullary
AB AIM: To study the role of needle knife assisted ampullary biopsy in the diagnosis  of periampullary carcinoma. METHODS: In this study the authors retrospectively  analyzed clinical records of patients with periampullary tumors diagnosed by  ampullary biopsy taken after needle knife papillotomy in whom surface ampullary  biopsies were non contributory. RESULTS: Between January 2008 and December 2010,  38 patients with periampullary tumors were seen by us and initial side viewing  endoscopy with surface biopsy from the papilla was positive for malignancy in 25  patients. Thirteen patients with a negative surface biopsy for malignancy  underwent a repeat ampullary biopsy following needle knife papillotomy. There  were 8 (61.5%) males and 5 (38.5%) females. The most common presenting symptom  was jaundice (100%), followed by fever (46.2%), melena (38.5%), abdominal pain  (30.8%) and weight loss (30.8%). All the patients had hyperbilirubinemia with a  mean ± SD serum bilirubin of (11.2 ± 1.9) mg/dL (normal value < 1 mg%) and the  mean ± SD serum alkaline phosphatase was (288.0 ± 94.3) IU/L (normal value < 129  IU/L). Serum CA 19.9 level estimation was done in 11 patients; it was elevated  (cut off value > 70.5 IU/L) in all of them with a median of 1200 IU/L (inter  quartile range 274-3500). Side viewing endoscopy showed a bulky papilla in all of  them. Adequate tissue was obtained in all of the 13 patients for histological  evaluation; 12 of the 13 patients were reported to have adenocarcinoma while one  patient had adenoma. There were no complications from the needle knife  papillotomy in any of the patients. CONCLUSION: Needle knife assisted ampullary  biopsy appears to be a safe and effective diagnostic modality for periampullary  carcinoma.
C1 Mohd Talha Noor, Kim Vaiphei, Birinder Nagi, Kartar Singh, Rakesh Kochhar, Department of Gastroenterology, Postgraduate Institute of Medical Education andResearch, Sector 12, Chandigarh 160012, India.
NR 0
TC 0
SN 1948-519
EI 1948-519
J9 World J Gastrointest Endosc
PD NOV 24
PY 2011
VL 3
IS 11
BP 220
EP 4
DI 10.4253/wjge.v3.i11.220
PG -216
UT PubMed:22110838
PM 22110838
DA 2011-11-24
ER

PT J
AU Enblom, A
   Tomasson, A
   Hammar, M
   Steineck, G
   Börjeson, S
AF Enblom, Anna
   Tomasson, Annica
   Hammar, Mats
   Steineck, Gunnar
   Borjeson, Sussanne
TI Pilot testing of methods for evaluation of acupuncture for emesis during radiotherapy: a randomised single subject experimental design
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
ID quality-of-life; induced nausea; functional assessment; cancer-chemotherapy; placebo needle; complementary; prophylaxis; electroacupuncture; rehabilitation; acupressure
AB Background Many acupuncture studies are of weak methodological quality, possibly due to lack of pilot testing. This pilot study tested design features, including test of feasibility, compliance to treatment and data collection, level of blinding success and the patients' potential perceived effects of the treatment, in preparation for an efficacy study. Method A modified single subject experimental design was conducted. 10 cancer patients were randomised to verum penetrating acupuncture or non-penetrating sham needles for 30 min 2-3 times/week during radiotherapy over abdomen/pelvis. They answered test-retested emesis questions (r=0.527-1.0) covering nausea, vomiting, use of antiemetics, wellbeing and activities of daily living. Results Overall, the patients completed 98% of the 345 emesis-questionnaire days and 101 of the 115 offered treatments. All patients believed they received verum acupuncture. 10 patients experienced antiemetic effects, seven relaxation, five pain-reduction and five experienced sleep improvement. Two types of nausea questions showed absolute concordance (r=1.0) (n of observations=456). Nausea was experienced by one of five verum acupuncture treated patients (duration median 0% of the radiotherapy-days) and four of five sham acupuncture treated patients (duration median 24% of the radiotherapy-days). Patients experiencing nausea rated decreased wellbeing and performance of daily activities compared to patients free from nausea. Conclusions All patients were blinded, complied with verum/sham treatments and data-collection, and believed they had effects of the received treatment. The methods for verum/sham treatment and data collection may thus be used in an adequately powered randomised controlled study of the effect of acupuncture for radiotherapy-induced emesis.
C1 [Enblom, Anna; Borjeson, Sussanne] Linkoping Univ, Dept Med & Hlth Sci, Div Nursing Sci, Linkoping, Sweden.
   [Tomasson, Annica] Cty Council Ostergotland, Linkoping, Sweden.
   [Hammar, Mats] Linkoping Univ, Dept Clin & Expt Med, Div Obstet & Gynecol, Linkoping, Sweden.
   [Steineck, Gunnar] Karolinska Inst, Dept Oncol, Div Clin Canc Epidemiol, Stockholm, Sweden.
   [Steineck, Gunnar] Sahlgrens Acad, Dept Oncol, Div Clin Canc Epidemiol, Gothenburg, Sweden.
   [Borjeson, Sussanne] Linkoping Univ Hosp, Ctr Surg & Oncol, Dept Oncol, S-58185 Linkoping, Sweden.
C3 Linkoping University; City Council Ostergotland; Linkoping University; Karolinska Institutet; University of Gothenburg; Linkoping University
RP Enblom, A (corresponding author), IMH Omvardnad, C-O S Borjeson BSP Plan 12, SE-58185 Linkoping, Sweden.
EM anna.enblom@ki.se
FU Vardal Foundation-for Health Care Sciences and Allergy Research; Vardal Institute; County Council of Ostergotland; University of Linkoping
CR Anna E, 2008, COMPLEMENT THER MED, V16, P288, DOI 10.1016/j.ctim.2008.02.012
   Ashing-Giwa KT, 2008, QUAL LIFE RES, V17, P147, DOI 10.1007/s11136-007-9276-3
   Backman CL, 1997, ARCH PHYS MED REHAB, V78, P1145, DOI 10.1016/S0003-9993(97)90142-8
   Bengali MK, 1998, AM J OCCUP THER, V52, P650, DOI 10.5014/ajot.52.8.650
   Bernhardsson S, 2011, CLIN REHABIL, V25, P69, DOI 10.1177/0269215510376005
   Bonomi AE, 1996, QUAL LIFE RES, V5, P309, DOI 10.1007/BF00433915
   Boogaerts JG, 2000, ACTA ANAESTH SCAND, V44, P470, DOI 10.1034/j.1399-6576.2000.440420.x
   Börjeson S, 2002, J PAIN SYMPTOM MANAG, V24, P345, DOI 10.1016/S0885-3924(02)00543-2
   Borjeson S, 1997, CANCER NURS, V20, P260
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Choo SP, 2006, J ALTERN COMPLEM MED, V12, P963, DOI 10.1089/acm.2006.12.963
   Dincer F, 2003, COMPLEMENT THER MED, V11, P235, DOI 10.1016/S0965-2299(03)00124-9
   DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508
   Enblom A, 2009, SUPPORT CARE CANCER, V17, P23, DOI 10.1007/s00520-008-0445-x
   Feyer PC, 2005, SUPPORT CARE CANCER, V13, P122, DOI 10.1007/s00520-004-0705-3
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Vaz AF, 2008, ARCH GYNECOL OBSTET, V278, P215, DOI 10.1007/s00404-007-0549-4
   Horiot JC, 2004, EUR J CANCER, V40, P979, DOI 10.1016/j.ejca.2003.12.023
   Hui Kathleen K S, 2007, BMC COMPLEMENT ALTERN MED, V7, P33, DOI 10.1186/1472-6882-7-33
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   JENNS K, 1994, CANCER NURS, V17, P488
   Johnstone PAS, 2002, PALLIATIVE MED, V16, P235, DOI 10.1191/0269216302pm540oa
   Kolstad A, 2004, SUPPORT CARE CANCER, V12, P312, DOI 10.1007/s00520-004-0590-9
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Maranzano E, 1999, INT J RADIAT ONCOL, V44, P619, DOI 10.1016/S0360-3016(99)00055-3
   Marklund I, 2006, CLIN REHABIL, V20, P568, DOI 10.1191/0269215506cr973oa
   Melchart D, 2006, SUPPORT CARE CANCER, V14, P878, DOI 10.1007/s00520-006-0028-7
   Miller FG, 2004, JAMA-J AM MED ASSOC, V291, P599, DOI 10.1001/jama.291.5.599
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   Mystakidou K, 2006, MED ONCOL, V23, P251, DOI 10.1385/MO:23:2:251
   Nystrom E, 2008, ACUPUNCT MED, V26, P27, DOI 10.1136/aim.26.1.27
   Onelov E, 2007, ACTA ONCOL, V46, P810, DOI 10.1080/02841860601156124
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Park J, 2005, ARCH INTERN MED, V165, P2026, DOI 10.1001/archinte.165.17.2026
   Park J, 1999, ACUPUNCT MED, V17, P110
   Perdices M, 2009, NEUROPSYCHOL REHABIL, V19, P904, DOI 10.1080/09602010903040691
   Rhodes VA, 2001, CA-CANCER J CLIN, V51, P232, DOI 10.3322/canjclin.51.4.232
   Sagar SM, 2008, CURR TREAT OPTION ON, V9, P117, DOI 10.1007/s11864-008-0063-3
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Shun SC, 2008, SUPPORT CARE CANCER, V16, P1059, DOI 10.1007/s00520-007-0384-y
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Streitberger K, 2003, CLIN CANCER RES, V9, P2538
   Takakura N, 2010, ACUPUNCT MED, V28, P144, DOI 10.1136/aim.2009.001230
   Takakura Nobuari, 2007, BMC COMPLEMENT ALTERN MED, V7, P31, DOI 10.1186/1472-6882-7-31
   Xia YS, 2000, INT J CLIN ACUPUNCTU, V11, P145
   Zhan S, 2001, DISABIL REHABIL, V23, P1, DOI 10.1080/09638280150211202
NR 48
TC 14
Z9 15
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD JUN 15
PY 2011
VL 29
IS 2
BP 94
EP 102
DI 10.1136/aim.2010.003384
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 769KE
UT WOS:000291010600004
PM 21460396
DA 2026-01-16
ER

PT J
AU Ouyang, BS
   Gao, J
   Che, JL
   Zhang, Y
   Li, J
   Yang, HZ
   Hu, TY
   Yang, M
   Wu, YJ
   Ji, LL
AF Ouyang Ba-si
   Gao Jie
   Che Jian-li
   Zhang Yin
   Li Jun
   Yang Hai-zhou
   Hu Tian-yan
   Yang Man
   Wu Yuan-jian
   Ji Ling-ling
TI Effect of electro-acupuncture on tumor necrosis factor-α and vascular endothelial growth factor in peripheral blood and joint synovia of patients with rheumatoid arthritis
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE electro-acupuncture; needling; rheumatoid arthritis; tumor necrosis factor; vascular endothelial growth factor
ID cytokines
AB To observe the effect of electro-acupuncture (EA) on tumor necrosis factor-alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) in peripheral blood and joint synovia in patients with rheumatoid arthritis (RA) to verify the clinical efficacy of EA. Adopting randomized controlled principle, the 63 RA patients enrolled were assigned to two groups, the 32 patients in the EA group were treated with EA, and the 31 patients in the simple needling (SN) group treated with simple needling. According to the integral-local combining method, the acupoints were selected mainly from yang-meridian and local Ashi points (pain-point). EA or SN was applied every other day, 10 times as a course, and each patient received a total of 3 courses of treatment. Blood and synovial levels of TNF-alpha and VEGF were reduced significantly after treatment in both groups. The lowering (absolute value and difference value) of TNF-alpha as well as the absolute value of VEGF, either in blood or in synovia, were similar in the two groups (P > 0.05); but the lowering of VEGF after treatment was more significant in the EA group than that in the SN group (P < 0.05). EA could effectively lower the contents of TNF-alpha and VEGF in peripheral blood and joint synovia to improve the internal environment for genesis and development of RA, so as to enhance the clinical therapeutic effectiveness.
C1 [Ouyang Ba-si; Gao Jie; Zhang Yin; Li Jun; Yang Hai-zhou] Suzhou Hosp Tradit Chinese Med, Suzhou 215003, Jiangsu Prov, Peoples R China.
   [Che Jian-li] Soochow Univ, Affiliated Hosp 1, Suzhou 215007, Jiangsu Prov, Peoples R China.
   [Hu Tian-yan] Soochow Univ, Childrens Hosp, Suzhou 215003, Jiangsu Prov, Peoples R China.
   [Yang Man; Wu Yuan-jian; Ji Ling-ling] Nanjing Univ Tradit Chinese Med, Nanjing 210009, Peoples R China.
C3 Soochow University - China; Soochow University - China; Nanjing University of Chinese Medicine
RP Ouyang, BS (corresponding author), Suzhou Hosp Tradit Chinese Med, Suzhou 215003, Jiangsu Prov, Peoples R China.
EM oybasi@163.com
FU Suzhou Municipal Developing Plan of Sciences and Technology (Social Development and Three-drug Keystone) [SS0528]
CR FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602
   HENDERSON B, 1989, CLIN EXP IMMUNOL, V75, P306
   LI SF, 2007, HENAN MED RES, V16, P59
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Macías I, 2005, J RHEUMATOL, V32, P2102
   Mikuls Ted, 2002, CURR RHEUMATOL REP, V4, P193, DOI 10.1007/s11926-002-0064-3
   Nagashima M, 2000, J RHEUMATOL, V27, P2339
   REDICH KP, 2002, ARTHRITIS RES S, V4, P0
   TANG HH, 1998, CHIN J RHEUMATOL, V2, P236
   WAND CH, 2007, J CELL MOL IMMUNOL, V23, P426
   [谢建民 XIE Jian-min], 2009, 中国病理生理杂志 CHINESE JOURNAL OF PATHOPHYSIOLOGY, V25, P1181
   [谢建民 Xie Jianmin], 2006, 中华风湿病学杂志 CHINESE JOURNAL OF RHEUMATOLOGY, V10, P495
NR 13
TC 43
Z9 57
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1672-0415
EI 
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD JUL 15
PY 2011
VL 17
IS 7
BP 505
EP 509
DI 10.1007/s11655-011-0783-2
PG 5
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 786KA
UT WOS:000292305400004
PM 21725875
DA 2026-01-16
ER

PT J
AU Kalder, M
   Knoblauch, K
   Hrgovic, I
   Münstedt, K
AF Kalder, Matthias
   Knoblauch, Katrin
   Hrgovic, Igor
   Muenstedt, Karsten
TI Use of complementary and alternative medicine during pregnancy and delivery
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Complementary and alternative medicine (CAM); Obstetrics; Pregnancy; Birth
ID obstetrics; therapy; knowledge; attitudes; midwives; pain
AB To assess the use of complementary and alternative medicine (CAM) during pregnancy and birth and the reasons behind it from the patient's perspective. In a prospective study, we assessed the use of CAM before and during pregnancy as well as during delivery in women by means of a self-report questionnaire. Some 205 patients completed the questionnaire at a response rate of 43.2% (205/475) and 104 women used CAM during pregnancy, especially homoeopathy, acupuncture, and phytotherapy. Stepwise regression analysis identified CAM use prior to pregnancy, greater income, and nationality as the most important predictors of CAM use. In accordance with earlier studies from Germany, we determined the most important methods used in the field of obstetrics. Interestingly, these are not evidence-based and those methods which are evidence-based are not now used. Also, the predictors of CAM use in pregnancy were similar to those in oncology. Future studies should focus on the safety and efficacy of CAM in pregnancy.
C1 [Knoblauch, Katrin; Hrgovic, Igor; Muenstedt, Karsten] Univ Giessen, Dept Obstet & Gynaecol, D-35385 Giessen, Germany.
   [Kalder, Matthias] Univ Marburg, Dept Gynaecol Gynaecol Endocrinol & Oncol, Marburg, Germany.
C3 Justus Liebig University Giessen; Philipps University Marburg
RP Münstedt, K (corresponding author), Univ Giessen, Dept Obstet & Gynaecol, Klinikstr 32, D-35385 Giessen, Germany.
EM karsten.muenstedt@gyn.med.uni-giessen.de
CR Adams Jon, 2006, COMPLEMENT THER CLIN PRACT, V12, P40, DOI 10.1016/j.ctcp.2005.09.003
   Adams J, 2009, BIRTH-ISS PERINAT C, V36, P237, DOI 10.1111/j.1523-536X.2009.00328.x
   Allaire AD, 2000, OBSTET GYNECOL, V95, P19, DOI 10.1016/S0029-7844(99)00481-0
   Bayles BP, 2007, J MIDWIFERY WOM HEAL, V52, P473, DOI 10.1016/j.jmwh.2007.03.023
   BISHOP FL, 2008, EVID BASED COMPLEMEN, V0, P0
   Boivin J, 2009, HUM REPROD, V24, P1626, DOI 10.1093/humrep/dep077
   Dog TL, 2009, ALTERN THER HEALTH M, V15, P54
   Field T, 2008, ALTERN THER HEALTH M, V14, P28
   Gaffney L, 2004, AUST NZ J OBSTET GYN, V44, P24, DOI 10.1111/j.1479-828X.2004.00161.x
   Hammarberg K, 2008, HUM REPROD UPDATE, V14, P395, DOI 10.1093/humupd/dmn030
   Hodgson DM, 2007, FORSCH KOMP KLAS NAT, V14, P92, DOI 10.1159/000100958
   Hofberg K, 2003, POSTGRAD MED J, V79, P505, DOI 10.1136/pmj.79.935.505
   Holst L, 2009, J ALTERN COMPLEM MED, V15, P787, DOI 10.1089/acm.2008.0467
   Kalder M, 2009, GEBURTSH FRAUENHEILK, V69, P687, DOI 10.1055/s-0029-1185975
   Kappauf H, 2000, SUPPORT CARE CANCER, V8, P314, DOI 10.1007/s005209900111
   Mårtensson L, 2008, J MIDWIFERY WOM HEAL, V53, P115, DOI 10.1016/j.jmwh.2007.09.008
   Münstedt K, 2009, EUR J OBSTET GYN R B, V146, P50, DOI 10.1016/j.ejogrb.2009.05.013
   Münstedt K, 2009, FORSCH KOMPLEMENTMED, V16, P111, DOI 10.1159/000208918
   Munstedt K, 1996, ARCH GYNECOL OBSTET, V258, P81
   Newell S, 2000, MED J AUSTRALIA, V172, P110, DOI 10.5694/j.1326-5377.2000.tb127933.x
   Nordeng H, 2005, ACTA OBSTET GYN SCAN, V84, P26, DOI 10.1111/j.0001-6349.2005.00648.x
   Nordeng H, 2004, PHARMACOEPIDEM DR S, V13, P371, DOI 10.1002/pds.945
   Skouteris H, 2008, AUST NZ J OBSTET GYN, V48, P384, DOI 10.1111/j.1479-828X.2008.00865.x
   Smith C, 2003, COCHRANE DB SYST REV, V4, PCD003399, DOI 10.1002/14651858.CD003399
   Smith CA, 2009, BIRTH-ISS PERINAT C, V36, P246, DOI 10.1111/j.1523-536X.2009.00329.x
   Tournaire M, 2007, EVID-BASED COMPL ALT, V4, P409, DOI 10.1093/ecam/nem012
   Wang SM, 2005, J ALTERN COMPLEM MED, V11, P459, DOI 10.1089/acm.2005.11.459
NR 27
TC 60
Z9 70
U1 0
U2 16
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD MAR 15
PY 2011
VL 283
IS 3
BP 475
EP 482
DI 10.1007/s00404-010-1388-2
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 718RV
UT WOS:000287144700011
PM 20177901
DA 2026-01-16
ER

PT J
AU Wasserman, AM
AF Wasserman, Amy M.
TI Diagnosis and Management of Rheumatoid Arthritis
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
ID modifying antirheumatic drugs; american-college; risk-factors; disease; susceptibility; acupuncture; predictors; disability; outcm; adults
AB Rheumatoid arthritis is the most commonly diagnosed systemic inflammatory arthritis. Women, smokers, and those with a family history of the disease are most often affected. Criteria for diagnosis include having at least one joint with definite swelling that is not explained by another disease. The likelihood of a rheumatoid arthritis diagnosis increases with the number of small joints involved. In a patient with inflammatory arthritis, the presence of a rheumatoid factor or anti-citrullinated protein antibody, or elevated C-reactive protein level or erythrocyte sedimentation rate suggests a diagnosis of rheumatoid arthritis. Initial laboratory evaluation should also include complete blood count with differential and assessment of renal and hepatic function. Patients taking biologic agents should be tested for hepatitis B, hepatitis C, and tuberculosis. Earlier diagnosis of rheumatoid arthritis allows for earlier treatment with disease-modifying antirheumatic agents. Combinations of medications are often used to control the disease. Methotrexate is typically the first-line drug for rheumatoid arthritis. Biologic agents, such as tumor necrosis factor inhibitors, are generally considered second-line agents or can be added for dual therapy. The goals of treatment include minimization of joint pain and swelling, prevention of radiographic damage and visible deformity, and continuation of work and personal activities. Joint replacement is indicated for patients with severe joint damage whose symptoms are poorly controlled by medical management. (Am Fam Physician. 2011;84(11):1245-1252. Copyright (C) 2011 American Academy of Family Physicians.)
C1 Boston Univ, Sch Med, Boston, MA 02118 USA.
C3 Boston University
RP Wasserman, AM (corresponding author), Boston Univ, Sch Med, 72 E Concord St,Evans 501, Boston, MA 02118 USA.
EM amywass@bu.edu
CR AHRQ, 2008, CHOOS MED RHEUM ARTH, V0, P0
   Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI 10.1136/ard.2010.138461
   Allaire S, 2009, ARTHRIT RHEUM-ARTHR, V61, P321, DOI 10.1002/art.24281
   Unknown -, 2002, COCHRANE DATABASE SYST REV, V0, P0
   Unknown -, 2004, **DROPPED REF**, V0, P0
   Atzeni F, 2010, AUTOIMMUN REV, V9, P835, DOI 10.1016/j.autrev.2010.07.018
   Baecklund E, 2006, ARTHRITIS RHEUM, V54, P692, DOI 10.1002/art.21675
   Baillet A, 2009, RHEUMATOLOGY, V48, P410, DOI 10.1093/rheumatology/ken511
   Balsa A, 2010, ARTHRITIS RES THER, V12, P0, DOI 10.1186/ar2975
   Bang SY, 2010, ARTHRITIS RHEUM-US, V62, P369, DOI 10.1002/art.27272
   Brodin N, 2008, ARTHRIT RHEUM-ARTHR, V59, P325, DOI 10.1002/art.23327
   Cameron M, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002948.pub2
   Casimiro L, 2002, COCHRANE DATABASE SYST REV, V0, PCD003787
   Choy EHS, 2005, RHEUMATOLOGY, V44, P1414, DOI 10.1093/rheumatology/kei031
   Costenbader KH, 2006, AM J MED, V119, P503, DOI 10.1016/j.amjmed.2005.09.053
   Deighton C, 2009, BRIT MED J, V338, P0, DOI 10.1136/bmj.b702
   Evans S, 2011, TRIALS, V12, P0, DOI 10.1186/1745-6215-12-19
   Firestein GS, 2009, KELLYS TEXTBOOK OF RHEUMATOLOGY, V0, PP1035, DOI 10.1016/B978-0-323-31696-5.00069-3
   Friedewald VE, 2010, AM J CARDIOL, V106, P442, DOI 10.1016/j.amjcard.2010.04.005
   Guthrie KA, 2010, ARTHRITIS RHEUM-US, V62, P1842, DOI 10.1002/art.27459
   Hagen KB, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006400.pub2
   Hurkmans E, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006853.pub2
   Kaaja RJ, 2005, JAMA-J AM MED ASSOC, V294, P2751, DOI 10.1001/jama.294.21.2751
   Karlson EW, 2008, ARTHRIT RHEUM-ARTHR, V59, P1589, DOI 10.1002/art.24194
   Karlson EW, 2004, ARTHRITIS RHEUM-US, V50, P3458, DOI 10.1002/art.20621
   Katchamart W, 2010, ARTHRIT CARE RES, V62, P1128, DOI 10.1002/acr.20188
   Kelly RB, 2009, AM FAM PHYSICIAN, V80, P481
   MacGregor AJ, 2000, ARTHRITIS RHEUM, V43, P30, DOI 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B
   McClure A, 2009, RHEUMATOLOGY, V48, P1369, DOI 10.1093/rheumatology/kep272
   Mochan E, 2008, AM FAM PHYSICIAN, V77, P1451
   Orozco G, 2010, EXPERT REV CLIN IMMU, V6, P61, DOI 10.1586/ECI.09.72
   Ravelli A, 2005, ARTHRITIS RHEUM, V52, P826, DOI 10.1002/art.20945
   Saag KG, 2008, ARTHRIT RHEUM-ARTHR, V59, P762, DOI 10.1002/art.23721
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4
   Smedslund G, 2010, J AM DIET ASSOC, V110, P727, DOI 10.1016/j.jada.2010.02.010
   Tehlirian C V, 2008, PRIMER ON THE RHEUMATIC DISEASE, V13th, P114
   van der Helm-van Mil AHM, 2007, ARTHRITIS RHEUM-US, V56, P433, DOI 10.1002/art.22380
   Wang CC, 2008, ARTHRIT RHEUM-ARTHR, V59, P1249, DOI 10.1002/art.24009
   WILDER RL, 1991, CLIN ORTHOP RELAT R, V0, P36
   Wilson A, 2004, AM J MED, V116, P50, DOI 10.1016/j.amjmed.2003.12.012
   Wolfe F, 1998, ARTHRITIS RHEUM, V41, P1072, DOI 10.1002/1529-0131(199806)41:6<1072::AID-ART14>3.0.CO;2-G
NR 41
TC 230
Z9 278
U1 0
U2 26
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD DEC 1
PY 2011
VL 84
IS 11
BP 1245
EP 1252
DI 
PG 8
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 980AP
UT WOS:000306866300010
PM 22150658
DA 2026-01-16
ER

PT J
AU Burnstock, G
AF Burnstock, Geoffrey
TI Therapeutic potential of purinergic signalling for diseases of the urinary tract.
SO BJU international
LA English
DT Journal Article
AB This review begins with background information about the discovery and conceptual  steps contributing to our current knowledge of purinergic signalling. It then  deals with several topics concerned with the physiology and pathophysiology of  the lower urinary tract, including: the involvement in the voiding reflex of ATP  released as a co-transmitter with acetylcholine from parasympathetic nerves  supplying the bladder and ATP released from urothelial cells during bladder  distension to initiate the voiding reflex via P2X₃ receptors on suburothelial  low-threshold sensory nerve fibres; this latter mechanosensory transduction  pathway is also involved via high-threshold fibres in the initiation of pain.  Treatment of prostate and bladder cancer with ATP not only appears to be  effective against the primary tumours, but also improves the systemic symptoms  associated with advanced malignancy. There is dual control of the tone of blood  vessels: constriction by ATP released as a co-transmitter from sympathetic nerves  and vasodilatation via ATP released from endothelial cells during shear stress  acting on endothelial P2 receptors to release nitric oxide. A purinergic  hypothesis is discussed for the mechanism underlying acupuncture, widely used for  the treatment of urinary disorders.
C1 Autonomic Neuroscience Centre, University College Medical School, London, UK. g.burnstock@ucl.ac.uk
NR 0
TC 0
SN 1464-410
EI 
J9 BJU Int
PD JAN 7
PY 2011
VL 107
IS 2
BP 192
EP 204
DI 10.1111/j.1464-410X.2010.09926.x
PG 12
WC Adenosine Triphosphate; physiology; Female; Humans; Male; Nitric Oxide; metabolism; Purinergic P2X Receptor Antagonists; therapeutic use; Signal Transduction; physiology; Urination; physiology; Urologic Diseases; physiopathology
UT PubMed:21208364
PM 21208364
DA 2011-01-07
ER

PT J
AU Gilmour, J
   Harrison, C
   Asadi, L
   Cohen, MH
   Vohra, S
AF Gilmour, Joan
   Harrison, Christine
   Asadi, Leyla
   Cohen, Michael H.
   Vohra, Sunita
TI Informed Consent: Advising Patients and Parents About Complementary and Alternative Medicine Therapies
SO PEDIATRICS
LA English
DT Article
DE complementary therapies; evidence-based practice; acupuncture; nausea; neoplasms
ID chemotherapy-induced nausea; pediatric oncology; acupuncture; pain; acupressure; efficacy; children; legal
AB Although research on complementary and alternative medicine (CAM) therapies is still limited, systematic reviews have revealed sufficient evidence to conclude that CAM can be effective for certain conditions. In this article we discuss clinicians' responsibilities to inform parents/patients about CAM alternatives and use the example of acupuncture for chemotherapy-induced nausea and vomiting. Chemotherapy-induced nausea and vomiting remain significant adverse effects of cancer therapy, and some patients cannot find relief with standard therapies. When making decisions for a child with a life-threatening illness, parents must consider all reasonable options and decide what is in the child's best interests. A physician's failure to provide parents with relevant information regarding therapies with the prospect of therapeutic benefit impedes their ability to make an informed decision. Physicians have the ethical duty of beneficence; they must be aware of current research in pain and symptom management and other aspects of care. A physician's duty of care does not necessarily include the obligation to provide information about therapies outside the range of conventional treatment or those not yet supported in the medical literature. However, as CAM therapies such as acupuncture become better studied and their safety and efficacy are established, the scope of disclosure required may expand to include them. The legal and ethical obligation to obtain informed consent to treatment requires disclosure and discussion of therapies when there is reliable evidence of potential therapeutic benefit. At the same time, the more limited state of knowledge regarding effects of a particular therapy in the pediatric population must be factored into decision-making when treating a child. Pediatrics 2011;128:S187-S192
C1 [Gilmour, Joan] York Univ, Osgoode Hall Law Sch, Toronto, ON M3J 2R7, Canada.
   [Harrison, Christine] SickKids Hosp, Dept Bioeth, Toronto, ON, Canada.
   [Asadi, Leyla] Univ Alberta, Dept Med, Fac Med, Edmonton, AB, Canada.
   [Vohra, Sunita] Univ Alberta, Dept Pediat, Fac Med, Edmonton, AB, Canada.
   [Cohen, Michael H.] Fenton Nelson LLP, Los Angeles, CA USA.
   [Vohra, Sunita] Stollery Childrens Hosp, CARE Program Integrat Hlth & Healing, Edmonton, AB, Canada.
C3 York University - Canada; University of Toronto; Hospital for Sick Children (SickKids); University of Alberta; University of Alberta; Stollery Children's Hospital
RP Vohra, S (corresponding author), Edmonton Gen Hosp, 8B19-11111 Jasper Ave, Edmonton, AB T5K 0L4, Canada.
EM svohra@ualberta.ca
FU SickKids Foundation (Toronto, Ontario, Canada); Alberta Heritage Foundation for Medical Research; Canadian Institutes of Health Research
CR AlFaleh K, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005496.pub2
   Attig T, 1996, J PALLIATIVE CARE, V12, P20, DOI 10.1177/082585979601200305
   Barnes PM, 2008, NATL HLTH STAT REPOR, V0, P0, DOI DOI 10.1037/E623942009-001
   CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104
   Cohen MH, 2005, PEDIATRICS, V115, P774, DOI 10.1542/peds.2004-1093
   Cohen MH, 2007, BIOMED ETHICS REV, V0, PP167, DOI 10.1007/978-1-59745-381-3_6
   Dibble SL, 2007, ONCOL NURS FORUM, V34, P815, DOI 10.1188/07.ONF.813-820
   DUNDEE JW, 1987, LANCET, V1, P1083
   Ernst E, 1997, PAIN, V71, P123, DOI 10.1016/S0304-3959(97)03368-X
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Gilmour J, 2011, PEDIATRICS, V128, PS149, DOI 10.1542/peds.2010-2720B
   Gilmour J, 2011, PEDIATRICS, V128, PS181, DOI 10.1542/peds.2010-2720G
   Gottschling S, 2008, KLIN PADIATR, V220, P365, DOI 10.1055/s-0028-1086039
   Harrison C, 2004, PAEDIATRIC CHILD HEALTH, V9, P99, DOI 10.1093/PCH/9.2.99
   Harrison C, 2007, PAED CHILD HEALT-CAN, V12, P379, DOI 10.1093/pch/12.5.379
   Highfield ES, 2005, J ALTERN COMPLEM MED, V11, P373, DOI 10.1089/acm.2005.11.373
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Jones Emily, 2008, J SOC INTEGR ONCOL, V6, P141
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kemper KJ, 2000, PEDIATRICS, V105, P941
   Knoll Andrew M, 2004, J CONTEMP HEALTH LAW POLICY, V20, P329
   KOHRMAN A, 1995, PEDIATRICS, V95, P314
   Linde K, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD000448.pub3
   MacPherson H, 1999, J ALTERN COMPLEM MED, V5, P47, DOI 10.1089/acm.1999.5.47
   Martel D, 2005, PEDIATR BLOOD CANCER, V44, P660, DOI 10.1002/pbc.20205
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   Pellegrino EdmundD, 1988, FOR THE PATIENTS GOOD: THE RESTORATION OF BENEFICENCE IN HEALTH CARE, V0, P0
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Reindl TK, 2006, SUPPORT CARE CANCER, V14, P172, DOI 10.1007/s00520-005-0846-z
   Roscoe JA, 2009, J PAIN SYMPTOM MANAG, V38, P381, DOI 10.1016/j.jpainsymman.2008.09.006
   Rudolph CD, 2003, RUDOLPHS PEDIATRICS, V21st, P0
   Smallwood Christopher, 2005, ROLE COMPLEMENTARY A, V0, P0
   King JS, 2006, AM J LAW MED, V32, P429, DOI 10.1177/009885880603200401
   WALCO GA, 1994, NEW ENGL J MED, V331, P541, DOI 10.1056/NEJM199408253310812
   Weiger WA, 2002, ANN INTERN MED, V137, P889, DOI 10.7326/0003-4819-137-11-200212030-00010
   White A, 2001, ACUPUNCT MED, V19, P84
   Zeltzer LK, 2002, J PAIN SYMPTOM MANAG, V24, P437, DOI 10.1016/S0885-3924(02)00506-7
NR 45
TC 25
Z9 26
U1 1
U2 12
PU AMER ACAD PEDIATRICS
PI Itasca
PA 345 Park Boulevard, Itasca, IL, UNITED STATES
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD NOV 15
PY 2011
VL 128
IS 
BP S187
EP S192
DI 10.1542/peds.2010-2720H
PG 6
WC Pediatrics
SC Pediatrics
GA 846RW
UT WOS:000296921900007
PM 22045862
DA 2026-01-16
ER

PT J
AU Mi, WL
   Mao-Ying, QL
   Wang, XW
   Li, X
   Yang, CJ
   Jiang, JW
   Yu, J
   Wang, J
   Liu, Q
   Wang, YQ
   Wu, GC
AF Mi, Wen-Li
   Mao-Ying, Qi-Liang
   Wang, Xiao-Wei
   Li, Xiu
   Yang, Chang-Jiang
   Jiang, Jian-Wei
   Yu, Jin
   Wang, Jun
   Liu, Qiong
   Wang, Yan-Qing
   Wu, Gen-Cheng
TI Involvement of Spinal Neurotrophin-3 in Electroacupuncture Analgesia and Inhibition of Spinal Glial Activation in Rat Model of Monoarthritis
SO JOURNAL OF PAIN
LA English
DT Article
DE Monoarthritis; electroacupuncture; neurotrophin-3; glia; proinflammatory cytokines
ID neuropathic pain; down-regulation; gfr-alpha-1 expression; thermal hyperalgesia; pathological pain; controlled-trial; nt-3 expression; sensory neurons; acupuncture; osteoarthritis
AB Although electroacupuncture (EA) has been proven to effectively relieve pain associated with arthritis, the underlying mechanism of EA analgesia requires further investigation. Here, the involvement of spinal neurotrophin-3 (NT-3) in EA's analgesic effects on complete Freund's adjuvant (CFA)-induced inflammatory pain was examined. The present study demonstrated that: 1) repeated EA stimulation of ipsilateral GB30 and GB34 acupoints remarkably suppressed CFA-induced hyperalgesia; 2) EA treatment markedly enhanced the upregulation of spinal NT-3 mRNA and protein levels following CFA injection; 3) antisense oligodeoxynucleotides (ODN) specifically against NT-3 intrathecally administered during EA treatment for 7 days significantly attenuated the EA analgesia; and 4) the suppressed expression of spinal GFAP (astrocytic marker), OX-42 (microglial marker) as well as proinflammatory cytokines, interleukin (IL)-1 beta, IL-6 and tumor necrosis factor (TNF)-alpha by EA treatment was significantly attenuated following NT-3 antisense ODN delivery. These results suggested that endogenous NT-3 may be involved in the analgesic effect of EA on inflammatory pain in rats, mediated through the inhibition of spinal glial activity as well as proinflammatory cytokine production. Perspective: The present study may initiate a discussion on the possible roles of NT-3/glia/cytokines in the therapeutic effects of acupuncture and provide insight on the mechanism underlie the analgesic effects of acupuncture on pain associated with arthritis. (C) 2011 by the American Pain Society
C1 [Mi, Wen-Li; Mao-Ying, Qi-Liang; Wang, Xiao-Wei; Li, Xiu; Yang, Chang-Jiang; Jiang, Jian-Wei; Yu, Jin; Wang, Jun; Liu, Qiong; Wang, Yan-Qing; Wu, Gen-Cheng] Fudan Univ, Dept Integrat Med & Neurobiol, Inst Acupuncture Res, State Key Lab Med Neurobiol,Inst Brain Sci,Shangh, Shanghai 200032, Peoples R China.
C3 Fudan University
RP Wang, YQ (corresponding author), Fudan Univ, Dept Integrat Med & Neurobiol, Inst Acupuncture Res, State Key Lab Med Neurobiol,Inst Brain Sci,Shangh, POB 291,138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.
EM wangyanqing@shmu.edu.cn
FU National Natural Science Foundation [30970975, 30821002, 30800332, 31000495]; National Key Basic Research Program of China [2006CB504509, 2007CB512502]; Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT) [IRT0522]; Research Fund for the Doctoral Program of Higher Education of China [20100071120046]; Fundamental Research Funds for the Central Universities; Young Scientist Foundation of Fudan University
CR Agrawal S, 1998, CURR OPIN CHEM BIOL, V2, P519, DOI 10.1016/S1367-5931(98)80129-4
   Akhtar S, 1997, TRENDS PHARMACOL SCI, V18, P12, DOI 10.1016/S0165-6147(96)01002-4
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   Brune K, 2007, CURR MED RES OPIN, V23, P2985, DOI 10.1185/030079907X242584
   Cao H, 2008, NEUROSCI BIOBEHAV R, V32, P972, DOI 10.1016/j.neubiorev.2008.03.009
   Chen J, 2007, NEUROSCI RES, V59, P399, DOI 10.1016/j.neures.2007.08.006
   Dong ZQ, 2006, NEUROPHARMACOLOGY, V50, P393, DOI 10.1016/j.neuropharm.2005.09.015
   Dong ZQ, 2006, BRAIN RES BULL, V69, P30, DOI 10.1016/j.brainresbull.2005.08.027
   Du Jing, 2008, ZHEN CI YAN JIU, V33, P37
   Elkabes S, 1996, J NEUROSCI, V16, P2508
   Gandhi R, 2004, J NEUROSCI, V24, P9405, DOI 10.1523/JNEUROSCI.0899-04.2004
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2
   Mi WL, 2008, BRAIN RES BULL, V77, P98, DOI 10.1016/j.brainresbull.2008.04.008
   Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533
   RUDGE JS, 1992, EUR J NEUROSCI, V4, P459, DOI 10.1111/j.1460-9568.1992.tb00896.x
   Shan S, 2007, NEUROBIOL DIS, V26, P558, DOI 10.1016/j.nbd.2007.02.007
   SKRABANEK P, 1984, LANCET, V1, P220
   Sun S, 2006, EXP NEUROL, V198, P294, DOI 10.1016/j.expneurol.2005.11.011
   Todd KJ, 2007, EUR J NEUROSCI, V25, P1287, DOI 10.1111/j.1460-9568.2007.05385.x
   Tzeng SF, 2005, J NEUROSCI RES, V81, P666, DOI 10.1002/jnr.20586
   Tzeng SF, 2003, J CELL BIOCHEM, V90, P227, DOI 10.1002/jcb.10658
   Vas J, 2004, BMJ-BRIT MED J, V329, P1216, DOI 10.1136/bmj.38238.601447.3A
   Wang CC, 2008, ARTHRIT RHEUM-ARTHR, V59, P1249, DOI 10.1002/art.24009
   Wang TH, 2008, NEUROCHEM RES, V33, P1, DOI 10.1007/s11064-007-9398-6
   Wang TH, 2007, NEUROCHEM RES, V32, P1415, DOI 10.1007/s11064-007-9326-9
   Watanabe M, 2000, NEUROSCI LETT, V282, P61, DOI 10.1016/S0304-3940(00)00842-9
   Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3
   White DM, 2000, BRAIN RES, V885, P79, DOI 10.1016/S0006-8993(00)02940-1
   Wieland HA, 2005, NAT REV DRUG DISCOV, V4, P331, DOI 10.1038/nrd1693
   Wilson-Gerwing TD, 2005, J NEUROSCI, V25, P758, DOI 10.1523/JNEUROSCI.3909-04.2005
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 33
TC 37
Z9 39
U1 0
U2 24
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
EI 
J9 J PAIN
JI J. Pain
PD SEP 15
PY 2011
VL 12
IS 9
BP 974
EP 984
DI 10.1016/j.jpain.2011.03.002
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 819ZZ
UT WOS:000294876600004
PM 21680256
DA 2026-01-16
ER

PT J
AU Hu, QS
   Zhang, QR
   Jia, CS
   Peng, Y
   Tan, L
AF Hu, Qiu-sheng
   Zhang, Qing-ru
   Jia, Chun-sheng
   Peng, Yang
   Tan, Liang
TI [Randomized controlled clinical trials of red-hot filiform needle puncturing for
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
AB OBJECTIVE: To observe the effect of red-hot filiform needle puncturing on the  pain severity of knee ostarthritis (OA) and the inflammatory cytokine levels in  the knee articular cavity (KAC) fluid in senile knee OA patients so as to find a  better therapy for knee OA. METHODS: A total of 200 senile knee OA outpatients  (who signed an informed consent) were randomized into treatment group and control  group (n = 100/group) according to a random number table and their visiting  sequence. Futu (LI 18), Neixiyan (EX-LE 4), Yanglingquan (GB 34), Yinlingquan (SP  9), Zusanli (ST 36), etc. on the affected side of the body were punctured with  red-hot filiform needles (cauterized on an alcohol burner) or routine filiform  needles, with the needles retained for 30 min. The treatment was conducted once  every other day, 15 sessions altogether. Before and after the treatment, the  patients' KAC fluid was sampled for assaying the contents of IL-1, IL-6 and tumor  necrosis factor (TNF)-alpha with enzyme-linked immunosorbent assay (ELISA). The  pain severity was tested by using visual analogue scale (VAS) and the  comprehensive therapeutic effect was evaluated by using clinical symptoms and  signs, functional activity and pain degrees. RESULTS: In comparison with  pre-treatment, IL-1, IL-6 and TNF-alpha contents in KAC fluid were decreased  significantly in both treatment and control groups (P < 0.01). The IL-1, IL-6 and  TNF-alpha levels were considerably lower in the treatment group than in the  control group following the treatment (P < 0.01), suggesting a marked relief of  inflammation in the affected knee joint. Compared to pre-treatment, the severity  scores of illness state of both treatment and control groups were decreased  remarkably (P < 0.01), and the VAS score of the treatment group was significantly  lower than that of the control group after the treatment (P < 0.05). Of the two  100 knee OA outpatients in the treatment and control groups, 29 (29%) and 21  (21%) were controlled in their symptoms and signs; 46 (46%) and 34 (34%)  experienced apparent improvement; 18 (18%) and 29 (29%) were effective; 7 (7%)  and 16 (16%) failed in the treatment. The comprehensive therapeutic effect of the  treatment group was significantly superior to that of the control group (P <  0.01). CONCLUSION: Red-hot filiform needle puncturing is superior to routine  filiform needle puncturing in relieving senile knee OA and in reducing  inflammatory cytokine levels in knee OA patients.
C1 Convalescent Center of Hebei Yiling Hospital, Shijiazhuang 050091, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JUL 2
PY 2011
VL 36
IS 2
BP 110
EP 5
DI 
PG -105
WC Acupuncture Therapy; Aged; Cartilage, Articular; immunology; Cytokines; immunology; Female; Humans; Knee Joint; immunology; Male; Middle Aged; Osteoarthritis, Knee; immunology; Synovial Fluid; immunology
UT PubMed:21717778
PM 21717778
DA 2011-07-02
ER

PT J
AU Harrington, JE
   Baker, BS
   Hoffman, CJ
AF Harrington, J E
   Baker, B S
   Hoffman, C J
TI Effect of an integrated support programme on the concerns and wellbeing of women
SO Complementary therapies in clinical practice
LA English
DT Journal Article
AB PURPOSE: To carry out a national service evaluation of the integrated cancer  support programme offered by The Haven using the Measure Yourself Concerns and  Wellbeing (MYCaW) outcome questionnaire. METHODS: Breast cancer survivors who  visited one of three Haven centres in the UK completed the MYCaW questionnaire  before and after 6 one-hour complementary therapy sessions. RESULTS:  Statistically significant decreases in mean baseline scores (indicating  improvement) for concerns and wellbeing were observed after treatment: concern 1  (5.09 ± 1.04 vs 3.17 ± 1.60, p < 0.0001, n = 402), concern 2 (4.69 ± 1.08 vs  3.08 ± 1.56, p < 0.0001, n = 372), and wellbeing (3.30 ± 1.41 vs 2.63 ± 1.28,  p < 0.0001, n = 402). The therapies most commonly used were acupuncture,  nutrition, massage and aromatherapy, shiatsu, counselling and reflexology. After  therapy, 91% of reported scores (n = 328) rated the concern as being a little  better, much better or gone. CONCLUSIONS: These findings suggest that women with  breast cancer find the Haven integrated support programme valuable for addressing  their main concerns and improving their feeling of wellbeing.
C1 The Haven, Effie Road, London SW6 1TB, UK. julia.harrington@thehaven.org.uk
NR 0
TC 0
SN 1873-694
EI 
J9 Complement Ther Clin Pract
PD DEC 27
PY 2011
VL 18
IS 1
BP 10
EP 5
DI 10.1016/j.ctcp.2011.05.002
PG -5
WC Analgesia; Breast Neoplasms; complications; Complementary Therapies; Fatigue; Female; Health Care Surveys; Hot Flashes; Humans; Pain; Patient Satisfaction; Program Evaluation; Stress, Psychological; Surveys and Questionnaires; United Kingdom; Women's Health; Women's Health Services; standards
UT PubMed:22196567
PM 22196567
DA 2011-12-27
ER

PT J
AU Lim, JTW
   Wong, ET
   Aung, SKH
AF Lim, Jan T. W.
   Wong, Erin T.
   Aung, Steven K. H.
TI Is there a role for acupuncture in the symptom management of patients receiving palliative care for cancer? A pilot study of 20 patients comparing acupuncture with nurse-led supportive care
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
ID sham acupuncture; controlled-trial; pain; validation; interventions; oncology; placebo; real
AB Purpose A pilot study to document changes in symptoms after acupuncture or nurse-led supportive care in patients with incurable cancer. Methods Patients receiving palliative care with estimated survival of at least 3 months were screened with the Edmonton Symptom Assessment System (ESAS). Patients (n = 20) with significant symptoms were randomised to receive weekly acupuncture or nurse-led supportive care for 4 weeks. ESAS scores were obtained before and after each treatment, and weekly for 6 weeks after treatment by telephone. Results 42 of 170 patients screened were eligible. 20 gave consent for recruitment. The compliance rate was 90% for acupuncture and 80% for nurse-led supportive care. Total symptom scores were reduced by an average of 22% after each acupuncture visit and by 14% after each supportive care visit. Compared with baseline, ESAS scores at the end of the follow-up period were reduced by 19% for the acupuncture arm and 26% for nurse-led supportive care. Conclusion Patients appear to benefit from incorporating acupuncture in the treatment of advanced incurable cancer. Acupuncture was well tolerated with no significant or unexpected side effects. Acupuncture had an immediate effect on all symptoms, whereas nurse-led supportive care had a larger impact 6 weeks after the final session. Both interventions appear helpful to this population and warrant further study.
C1 [Lim, Jan T. W.] Univ British Columbia, Dept Surg, Div Radiat Oncol, Vancouver, BC V6T 1W5, Canada.
   [Wong, Erin T.] Univ Toronto, Fac Med, Toronto, ON, Canada.
   [Aung, Steven K. H.] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada.
C3 University of British Columbia; University of Toronto; University of Alberta
RP Lim, JTW (corresponding author), 2410 Lee Ave, Victoria, BC V8R 6V5, Canada.
EM jlim@bccancer.bc.ca
FU Canadian Institute for Health Research New Emerging Team; British Columbia Cancer Foundation Vancouver Island Research and Development Catalyst
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Assefi NP, 2005, ANN INTERN MED, V143, P10, DOI 10.7326/0003-4819-143-1-200507050-00005
   AUNG SKH, 2007, CLIN INTRO MED ACUPU, V0, P24
   Cohen Andrea J, 2005, INTEGR CANCER THER, V4, P131, DOI 10.1177/1534735405276419
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   Downs NM, 2005, ARCH PHYS MED REHAB, V86, P1252, DOI 10.1016/j.apmr.2004.10.037
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Goddard G, 2005, J PAIN, V6, P237, DOI 10.1016/j.jpain.2004.12.009
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Johnstone PAS, 2002, PALLIATIVE MED, V16, P235, DOI 10.1191/0269216302pm540oa
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kreiner M, 2010, ACUPUNCT MED, V28, P33, DOI 10.1136/aim.2009.001735
   Lundeberg T, 2008, ACUPUNCT MED, V26, P239, DOI 10.1136/aim.26.4.239
   Mayer DJ, 2000, ANNU REV MED, V51, P49, DOI 10.1146/annurev.med.51.1.49
   Molsberger AF, 2004, EUR J MED RES, V9, P405
   Nekolaichuk C, 2008, PALLIATIVE MED, V22, P111, DOI 10.1177/0269216307087659
   Nystrom E, 2008, ACUPUNCT MED, V26, P27, DOI 10.1136/aim.26.1.27
   Sagar SM, 2005, CURR ONCOL, V12, P103
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   SOLA I, 2004, COCHRANE DB SYST REV, V4, P0
   Takakura N, 2010, ACUPUNCT MED, V28, P144, DOI 10.1136/aim.2009.001230
   Uitterhoeve RJ, 2004, BRIT J CANCER, V91, P1050, DOI 10.1038/sj.bjc.6602103
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Zeng LA, 2011, J PALLIAT MED, V14, P337, DOI 10.1089/jpm.2010.0438
NR 25
TC 19
Z9 23
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD SEP 15
PY 2011
VL 29
IS 3
BP 173
EP 179
DI 10.1136/aim.2011.004044
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 812XL
UT WOS:000294326700004
PM 21666275
DA 2026-01-16
ER

PT J
AU Kim, HS
   Park, IH
   Seo, SH
   Han, I
   Cho, HS
AF Kim, Han-Soo
   Park, Il Hyung
   Seo, Sung Hwa
   Han, Ilkyu
   Cho, Hwan Seong
TI Multifocal infection of mycobacterium other than tuberculosis mimicking a soft
SO Orthopedics
LA English
DT Journal Article
AB Mycobacterium other than tuberculosis infections rarely develop in healthy  individuals, but direct inoculation such as contaminated acupuncture can cause  mycobacteriosis even in an immunocompetent host. A 56-year-old woman gradually  developed pain on the anterior aspect of the left knee and the distal thigh after  hiking without trauma. She received acupuncture for 3 consecutive days on the  bilateral knees at the suprapatellar and infrapopliteal areas. After acupuncture,  mild localized heat and painful swelling developed around the knees bilaterally.  Magnetic resonance imaging (MRI) demonstrated soft tissue masses with a lobulated  contour at the prefemoral fat between the suprapatellar pouch and the distal  femur and at the proximal tibia behind the knee joint capsule. Fibromatosis,  pigmented villonodular synovitis, and soft tissue sarcoma were considered. On  pathologic examination, multiple granulomas with lymphoplasmatic infiltration  were evident, and acid-fast bacteria staining revealed acid-fast bacilli. A  mycobacterial culture confirmed Mycobacterium other than tuberculosis infection,  and a polymerase chain reaction-fragment length polymorphism assay identified the  isolates as Mycobacterium abscessus. After treatment with appropriate  antibiotics, the patient had no evidence of disease and reported no pain during  activities of daily living. Acupuncture is growing in prominence in Europe and  the United States, and the number of reports on complications increases with its  widespread use. Although the risk to an individual patient is difficult to  determine, acupuncture may cause serious complications in patients with  coagulopathy, heart valve disease, and immune deficiency. In addition, direct  inoculation such as contaminated acupuncture can cause mycobacteriosis even in an  immunocompetent host.
C1 Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, South Korea.
NR 0
TC 0
SN 1938-236
EI 
J9 Orthopedics
PD DEC 8
PY 2011
VL 34
IS 12
BP e952
EP 5
DI 10.3928/01477447-20111021-31
PG 1
WC Activities of Daily Living; Acupuncture Therapy; adverse effects; Anti-Bacterial Agents; therapeutic use; Diagnosis, Differential; Female; Humans; Immunocompetence; Knee Joint; microbiology; Magnetic Resonance Imaging; Middle Aged; Mycobacterium Infections, Nontuberculous; complications; Nontuberculous Mycobacteria; isolation & purification; Pain; etiology; Pain Management; Soft Tissue Neoplasms; diagnosis; Treatment Outcome
UT PubMed:22146217
PM 22146217
DA 2011-12-08
ER

PT J
AU Enblom, A
   Lekander, M
   Hammar, M
   Johnsson, A
   Onelöv, E
   Ingvar, M
   Steineck, G
   Börjeson, S
AF Enblom, Anna
   Lekander, Mats
   Hammar, Mats
   Johnsson, Anna
   Onelov, Erik
   Ingvar, Martin
   Steineck, Gunnar
   Borjeson, Sussanne
TI Getting the Grip on Nonspecific Treatment Effects: Emesis in Patients Randomized to Acupuncture or Sham Compared to Patients Receiving Standard Care
SO PLOS ONE
LA English
DT Article
ID chemotherapy-induced nausea; cancer-patients; controlled-trial; pain; prophylaxis; multicenter; acupressure; sickness; p6
AB Background: It is not known whether or not delivering acupuncture triggers mechanisms cited as placebo and if acupuncture or sham reduces radiotherapy-induced emesis more than standard care. Methodology/Principal Findings: Cancer patients receiving radiotherapy over abdominal/pelvic regions were randomized to verum (penetrating) acupuncture (n = 109; 99 provided data) in the alleged antiemetic acupuncture point PC6 or sham acupuncture (n = 106; 101 provided data) performed with a telescopic non-penetrating needle at a sham point 2-3 times/week during the whole radiotherapy period. The acupuncture cohort was compared to a reference cohort receiving standard care (n = 62; 62 provided data). The occurrence of emesis in each group was compared after a mean dose of 27 Gray. Nausea and vomiting were experienced during the preceding week by 37 and 8% in the verum acupuncture group, 38 and 7% in the sham acupuncture group and 63 and 15% in the standard care group, respectively. The lower occurrence of nausea in the acupuncture cohort (verum and sham) compared to patients receiving standard care (37% versus 63%, relative risk (RR) 0.6, 95 % confidence interval (CI) 0.5-0.8) was also true after adjustment for potential confounding factors for nausea (RR 0.8, CI 0.6 to 0.9). Nausea intensity was lower in the acupuncture cohort (78% no nausea, 13% a little, 8% moderate, 1% much) compared to the standard care cohort (52% no nausea, 32% a little, 15% moderate, 2% much) (p = 0.002). The acupuncture cohort expected antiemetic effects from their treatment (95%). Patients who expected nausea had increased risk for nausea compared to patients who expected low risk for nausea (RR 1.6; Cl 1.2-2.4). Conclusions/Significance: Patients treated with verum or sham acupuncture experienced less nausea and vomiting compared to patients receiving standard care, possibly through a general care effect or due to the high level of patient expectancy.
C1 [Enblom, Anna; Borjeson, Sussanne] Linkoping Univ, Div Nursing Sci, Dept Med & Hlth Sci, Linkoping, Sweden.
   [Enblom, Anna] Vardal Inst, Lund, Sweden.
   [Enblom, Anna; Lekander, Mats; Ingvar, Martin] Karolinska Inst, Dept Clin Neurosci, Osher Ctr Integrat Med, Stockholm, Sweden.
   [Lekander, Mats] Stockholm Univ, Stress Res Inst, S-10691 Stockholm, Sweden.
   [Hammar, Mats] Linkoping Univ, Dept Clin & Expt Med Obstet & Gynecol, Linkoping, Sweden.
   [Johnsson, Anna] Univ Lund Hosp, Dept Oncol, Div Physiotherapy, S-22185 Lund, Sweden.
   [Onelov, Erik; Steineck, Gunnar] Karolinska Inst, Dept Oncol, Div Clin Canc Epidemiol, Stockholm, Sweden.
   [Steineck, Gunnar] Sahlgrens Acad, Dept Oncol, Div Clin Canc Epidemiol, Gothenburg, Sweden.
   [Borjeson, Sussanne] Linkoping Univ Hosp, Ctr Surg & Oncol, S-58185 Linkoping, Sweden.
C3 Linkoping University; Karolinska Institutet; Stockholm University; Linkoping University; Lund University; Skane University Hospital; Karolinska Institutet; University of Gothenburg; Linkoping University
RP Enblom, A (corresponding author), Linkoping Univ, Div Nursing Sci, Dept Med & Hlth Sci, Linkoping, Sweden.
EM anna.enblom@ki.se
FU Swedish Cancer Society; Vardal Institute; County Council of Ostergotland; University of Linkoping; Cancer and Traffic Injury Fund; Vardal Foundation for Health Care Sciences and Allergy Research; Vinnova; Swedish Strategic Research Foundation
CR AGLIETTI L, 1990, CANCER CHEMOTH PHARM, V26, P239, DOI 10.1007/BF02897209
   Arving Cecilia, 2007, CANCER NURS, V30, PE10, DOI 10.1097/01.NCC.0000270709.64790.05
   Börjeson S, 2002, J PAIN SYMPTOM MANAG, V24, P345, DOI 10.1016/S0885-3924(02)00543-2
   Borjeson S, 1997, CANCER NURS, V20, P260
   Dibble S L, 2000, ONCOL NURS FORUM, V27, P41
   DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508
   ENBLOM A, 2008, 1088 LINK U MED DISS, V0, P0
   Enblom A, 2009, SUPPORT CARE CANCER, V17, P23, DOI 10.1007/s00520-008-0445-x
   FEYER PC, 2009, SUPPORT CAR IN PRESS, V0, P0
   Goldman RH, 2008, CLIN J PAIN, V24, P211, DOI 10.1097/AJP.0b013e31815ec20f
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Higgins SC, 2007, SUPPORT CARE CANCER, V15, P171, DOI 10.1007/s00520-006-0113-y
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Lu Weidong, 2005, SEMIN ONCOL NURS, V21, P190, DOI 10.1016/j.soncn.2005.04.008
   Luebbert K, 2001, PSYCHO-ONCOLOGY, V10, P490, DOI 10.1002/pon.537
   Maranzano E, 1999, INT J RADIAT ONCOL, V44, P619, DOI 10.1016/S0360-3016(99)00055-3
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   Myers Cynthia D, 2008, J SOC INTEGR ONCOL, V6, P19
   Mystakidou K, 2006, MED ONCOL, V23, P251, DOI 10.1385/MO:23:2:251
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Park J, 1999, ACUPUNCT MED, V17, P110
   Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941
   Roscoe JA, 2003, J PAIN SYMPTOM MANAG, V26, P731, DOI 10.1016/S0885-3924(03)00254-9
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Shin YH, 2004, CANCER NURS, V27, P267, DOI 10.1097/00002820-200407000-00002
   Shun SC, 2008, SUPPORT CARE CANCER, V16, P1059, DOI 10.1007/s00520-007-0384-y
   Steineck G, 2006, ACTA ONCOL, V45, P421, DOI 10.1080/02841860600649293
   Streitberger K, 2003, CLIN CANCER RES, V9, P2538
   Xia YS, 2000, INT J CLIN ACUPUNCTU, V11, P145
   Young SD, 2007, IEEE T VIS COMPUT GR, V13, P422, DOI 10.1109/TVCG.2007.1041
   Zachariae R, 2007, PSYCHOTHER PSYCHOSOM, V76, P376, DOI 10.1159/000107566
NR 34
TC 31
Z9 33
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD MAR 23
PY 2011
VL 6
IS 3
BP 
EP 
DI 10.1371/journal.pone.0014766
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 740QW
UT WOS:000288810500001
PM 21448267
DA 2026-01-16
ER

PT J
AU Enblom, A
   Johnsson, A
   Hammar, M
   Onelöv, E
   Steineck, G
   Börjeson, S
AF Enblom, A
   Johnsson, A
   Hammar, M
   Onelöv, E
   Steineck, G
   Börjeson, S
TI Acupuncture compared with placebo acupuncture in radiotherapy-induced nausea--a
SO Annals of oncology : official journal of the European Society for Medical
LA English
DT Journal Article
AB BACKGROUND: It is not known if verum (real) acupuncture is effective for nausea  and vomiting (emesis) during radiotherapy. PATIENTS AND METHODS: We randomly  treated 215 blinded cancer patients with verum: penetrating 'deqi' creating  acupuncture (n = 109) or non-penetrating sham needles (n = 106) two to three  times per week. The patients documented emesis daily during the radiotherapy  period. Primary end point was the number of patients with at least one episode of  nausea. RESULTS: In the verum and the sham acupuncture group, 70% and 62%  experienced nausea at least once during the radiotherapy period (relative risk  1.1, 95% CI 0.9-1.4) for a mean number of 10.1 and 8.7 days. Twenty five percent  and 28% vomited, and 42% and 37% used antiemetic drugs at least once,  respectively. Ninety-five percent in the verum acupuncture group and 96% in the  sham acupuncture group believed that the treatment had been effective against  nausea. In both groups, 67% experienced positive effects on relaxation, mood,  sleep or pain reduction and 89% wished to receive the treatment again.  CONCLUSION: Acupuncture creating deqi is not more effective than sham in  radiotherapy-induced nausea, but in this study, nearly all patients in both  groups experienced that the treatment was effective for nausea.
C1 Division of Nursing Science, Department of Medical and Health Sciences, Linköping University, Linköping
   The Swedish Institute for Health Sciences, LundUniversity, Lund
   Department of Clinical Neuroscience, Osher Centre forIntegrative Medicine, Karolinska Institute, Stockholm. 
   Department of Oncology, University Hospital, Lund.
   Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, Linköping University, Linköping.
   Division of Clinical Cancer Epidemiology, Department of Oncology-Pathology, Karolinska Institute, Stockholm.
   Division of Clinical Cancer Epidemiology, Department of Oncology-Pathology, Karolinska Institute, Stockholm
   Division of Clinical Cancer Epidemiology,Department of Oncology, Sahlgrenska Academy, Gothenburg.
   Division of Nursing Science, Department of Medical and Health Sciences, Linköping University, Linköping
   Centre of Surgery and Oncology, Department of Oncology,Linköping University Hospital, Linköping, Sweden.
EM nna.enblom@ki.se
NR 0
TC 0
SN 1569-804
EI 
J9 Ann Oncol
PD SEP 29
PY 2011
VL 23
IS 5
BP 1353
EP 1361
DI 10.1093/annonc/mdr402
PG 8
WC Acupuncture; methods; Acupuncture Points; Acupuncture Therapy; methods; Adult; Aged; Aged, 80 and over; Algorithms; Female; Humans; Male; Middle Aged; Nausea; etiology; Placebos; Radiotherapy; adverse effects; Single-Blind Method; Young Adult
UT PubMed:21948812
PM 21948812
DA 2011-09-29
ER

PT J
AU Burnstock, G
AF Burnstock, Geoffrey
TI Therapeutic potential of purinergic signalling for diseases of the urinary tract
SO BJU INTERNATIONAL
LA English
DT Review
DE ATP; co-transmitter; NANC; review; purinergic
ID refractory prostate-cancer; p2x(3) receptor expression; botulinum-toxin-a; guinea-pig; interstitial cystitis; extracellular nucleotides; adenosine-triphosphate; bladder dysfunction; carcinoma-cells; sensory neurons
AB Purinergic signalling, i.e. ATP acting as an extracellular messenger, has been implicated in control of urinary tract function since 1972. For example, it was shown to be a cotransmitter with acetylcholine in parasympathetic control of bladder contraction and purinoceptors on suburothelial sensory nerves mediating both reflex voiding and pain in response to ATP released from urothelial cells during bladder and ureter distension. The most recent studies of purinergic signalling in lower urinary tract pathology includes consideration of the therapeutic potential of purinergic compounds in incontinence, pain, cancer, and in acupuncture, widely used for the treatment of urinary disorders. This review begins with background information about the discovery and conceptual steps contributing to our current knowledge of purinergic signalling. It then deals with several topics concerned with the physiology and pathophysiology of the lower urinary tract, including: the involvement in the voiding reflex of ATP released as a co-transmitter with acetylcholine from parasympathetic nerves supplying the bladder and ATP released from urothelial cells during bladder distension to initiate the voiding reflex via P2X(3) receptors on suburothelial low-threshold sensory nerve fibres; this latter mechanosensory transduction pathway is also involved via high-threshold fibres in the initiation of pain. Treatment of prostate and bladder cancer with ATP not only appears to be effective against the primary tumours, but also improves the systemic symptoms associated with advanced malignancy. There is dual control of the tone of blood vessels: constriction by ATP released as a co-transmitter from sympathetic nerves and vasodilatation via ATP released from endothelial cells during shear stress acting on endothelial P2 receptors to release nitric oxide. A purinergic hypothesis is discussed for the mechanism underlying acupuncture, widely used for the treatment of urinary disorders.
C1 Univ Coll Med Sch, Auton Neurosci Ctr, London NW3 2PF, England.
C3 University of London; University College London
RP Burnstock, G (corresponding author), Univ Coll Med Sch, Auton Neurosci Ctr, Rowland Hill St, London NW3 2PF, England.
EM g.burnstock@ucl.ac.uk
CR Agteresch HJ, 2000, J NATL CANCER I, V92, P321, DOI 10.1093/jnci/92.4.321
   Agteresch HJ, 2000, EUR J CLIN PHARMACOL, V56, P49, DOI 10.1007/s002280050719
   AMBACHE N, 1970, J PHYSIOL-LONDON, V210, P761, DOI 10.1113/jphysiol.1970.sp009240
   Andersson KE, 2002, UROLOGY, V60, P13, DOI 10.1016/S0090-4295(02)01786-7
   Baqi Y, 2009, PURINERG SIGNAL, V5, P91, DOI 10.1007/s11302-008-9103-5
   Birder LA, 2004, AM J PHYSIOL-RENAL, V287, PF1084, DOI 10.1152/ajprenal.00118.2004
   Bo XN, 1999, NEUROREPORT, V10, P1107, DOI 10.1097/00001756-199904060-00037
   Boissier S, 1997, CANCER RES, V57, P3890
   BURNSTOCK G, 1972, BRIT J PHARMACOL, V44, P451, DOI 10.1111/j.1476-5381.1972.tb07283.x
   Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018-007-6497-0
   BURNSTOCK G, 1978, BRIT J PHARMACOL, V63, P125, DOI 10.1111/j.1476-5381.1978.tb07782.x
   Burnstock G, 2006, TRENDS PHARMACOL SCI, V27, P166, DOI 10.1016/j.tips.2006.01.005
   BURNSTOCK G, 1976, NEUROSCIENCE, V1, P239, DOI 10.1016/0306-4522(76)90054-3
   Burnstock G, 2010, CELL DEATH DIS, V1, P0, DOI 10.1038/cddis.2009.11
   Burnstock G, 2009, AUTONOMIC & AUTACOID PHARMACOLOGY, V29, P63, DOI 10.1111/j.1474-8673.2009.00435.x
   Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360
   Burnstock G, 2009, ACTA PHYSIOL, V195, P415, DOI 10.1111/j.1748-1716.2009.01957.x
   Burnstock G, 2001, HANDB EXP PHARM, V151, P423
   BURNSTOCK G, 1970, BRIT J PHARMACOL, V40, P668, DOI 10.1111/j.1476-5381.1970.tb10646.x
   BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1
   Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x
   BURNSTOCK G, 1972, PHARMACOL REV, V24, P509
   Burnstock G, 2001, TRENDS PHARMACOL SCI, V22, P182, DOI 10.1016/S0165-6147(00)01643-6
   BURNSTOCK G, 1987, BLOOD VESSELS, V24, P156
   Burnstock G, 2009, ASPECTS PHARM PYELOU, V0, P77
   Burnstock G, 1978, CELL MEMBRAIN RECEPT, V0, P107
   Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006
   Burnstock G, 2009, MOL PAIN, V5, P0, DOI 10.1186/1744-8069-5-69
   Burnstock G, 2009, MED HYPOTHESES, V73, P470, DOI 10.1016/j.mehy.2009.05.031
   Calvert RC, 2008, PURINERG SIGNAL, V4, P377, DOI 10.1007/s11302-008-9123-1
   Chancellor MB, 2008, NAT CLIN PRACT UROL, V5, P319, DOI 10.1038/ncpuro1124
   CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0
   Cockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519
   Donnelly-Roberts DL, 2007, BRIT J PHARMACOL, V151, P571, DOI 10.1038/sj.bjp.0707265
   Engberg S, 2009, J WOUND OSTOMY CONT, V36, P661, DOI 10.1097/WON.0b013e3181bd82dd
   FANG WG, 1992, J CLIN INVEST, V89, P191, DOI 10.1172/JCI115562
   Ford APDW, 2006, BRIT J PHARMACOL, V147, PS132, DOI 10.1038/sj.bjp.0706637
   Gever JR, 2006, PFLUG ARCH EUR J PHY, V452, P513, DOI 10.1007/s00424-006-0070-9
   Gever JR, 2010, BRIT J PHARMACOL, V160, P1387, DOI 10.1111/j.1476-5381.2010.00796.x
   Greig AVH, 2003, J INVEST DERMATOL, V121, P315, DOI 10.1046/j.1523-1747.2003.12379.x
   Harvey RA, 2002, J UROLOGY, V168, P1235, DOI 10.1016/S0022-5347(05)64632-0
   HOYLE CHV, 1989, EUR J PHARMACOL, V174, P115, DOI 10.1016/0014-2999(89)90881-9
   Janssens R, 2001, BRIT J PHARMACOL, V132, P536, DOI 10.1038/sj.bjp.0703833
   JORDAN AM, 1987, CANCER-AM CANCER SOC, V60, P2766, DOI 10.1002/1097-0142(19871201)60:11<2766::AID-CNCR2820601129>3.0.CO;2-0
   KASAKOV L, 1982, EUR J PHARMACOL, V86, P291, DOI 10.1016/0014-2999(82)90330-2
   Knight GE, 2002, AM J PHYSIOL-RENAL, V282, PF281, DOI 10.1152/ajprenal.00293.2000
   Korcok J, 2004, J BONE MINER RES, V19, P642, DOI 10.1359/JBMR.040108
   Langley JN, 1895, J PHYSL, V19, P71
   LEE YH, 1992, J UROLOGY, V147, P16, DOI 10.1016/S0022-5347(17)37121-5
   LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0
   MACKENZIE I, 1982, NEUROSCIENCE, V7, P997, DOI 10.1016/0306-4522(82)90056-2
   Mönkkönen H, 2008, ANTI-CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   Moore KH, 2001, J NEUROSCI, V21, P0, DOI 10.1523/JNEUROSCI.21-18-j0002.2001
   Nishiguchi J, 2004, EUR J NEUROSCI, V20, P474, DOI 10.1111/j.1460-9568.2004.03508.x
   ONeill M, 2006, PSYCHOPHARMACOLOGY, V184, P46, DOI 10.1007/s00213-005-0240-z
   OReilly BA, 2002, J UROLOGY, V167, P157, DOI 10.1016/S0022-5347(05)65403-1
   OReilly BA, 2001, J UROLOGY, V165, P1730, DOI 10.1016/S0022-5347(05)66403-8
   PALEA S, 1993, J UROLOGY, V150, P2007, DOI 10.1016/S0022-5347(17)35955-4
   Pawinski A, 1996, J UROLOGY, V156, P1934, DOI 10.1016/S0022-5347(01)65396-5
   Ralevic V, 1998, PHARMACOL REV, V50, P413
   RAPAPORT E, 1983, J CELL PHYSIOL, V114, P279, DOI 10.1002/jcp.1041140305
   Rocha I, 2001, AUTON NEUROSCI-BASIC, V88, P6, DOI 10.1016/S1566-0702(00)00284-8
   Rong WF, 2000, J PHYSIOL-LONDON, V524, P891, DOI 10.1111/j.1469-7793.2000.00891.x
   Rong WF, 2004, NEUROPHARMACOLOGY, V47, P1093, DOI 10.1016/j.neuropharm.2004.08.003
   Ryten M, 2002, J CELL BIOL, V158, P345, DOI 10.1083/jcb.200202025
   Shabbir M, 2008, BJU INT, V102, P108, DOI 10.1111/j.1464-410X.2008.07578.x
   Shabbir M, 2008, BJU INT, V101, P352, DOI 10.1111/j.1464-410X.2007.07293.x
   Shabbir M, 2008, BJU INT, V101, P106, DOI 10.1111/j.1464-410X.2007.07286.x
   Shabbir M, 2009, INT J UROL, V16, P143, DOI 10.1111/j.1442-2042.2008.02207.x
   Smith CP, 2005, NEUROCHEM INT, V47, P291, DOI 10.1016/j.neuint.2005.04.021
   Smith DJ, 1994, NEUROUROL URODYNAM, V13, P414
   Soe SHTE, 2009, MULT SCLER J, V15, P1376, DOI 10.1177/1352458509107020
   Sun Y, 2001, UROLOGY, V57, P131, DOI 10.1016/S0090-4295(01)01106-2
   Sun Y, 2004, J UROLOGY, V171, P448, DOI 10.1097/01.ju.0000099660.46774.3c
   Tempest HV, 2004, BJU INT, V93, P1344, DOI 10.1111/j.1464-410X.2004.04858.x
   Tong YQ, 2009, J ALTERN COMPLEM MED, V15, P905, DOI 10.1089/acm.2009.0062
   van der Weyden L, 2000, HYPERTENSION, V36, P1093, DOI 10.1161/01.HYP.36.6.1093
   Vlaskovska M, 2001, J NEUROSCI, V21, P5670, DOI 10.1523/JNEUROSCI.21-15-05670.2001
   White N, 2006, TRENDS PHARMACOL SCI, V27, P211, DOI 10.1016/j.tips.2006.02.004
   Yuping Wang, 2006, J TRADIT CHIN MED, V26, P106
   Zimmermann H, 2001, DRUG DEVELOP RES, V52, P44, DOI 10.1002/ddr.1097
NR 81
TC 53
Z9 62
U1 0
U2 20
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1464-4096
EI 
J9 BJU INT
JI BJU Int.
PD JAN 15
PY 2011
VL 107
IS 2
BP 192
EP 204
DI 10.1111/j.1464-410X.2010.09926.x
PG 13
WC Urology & Nephrology
SC Urology & Nephrology
GA 702UU
UT WOS:000285922200003
PM 21208364
DA 2026-01-16
ER

PT J
AU Wang, WJ
   Lu, J
   Niu, CS
   Huang, YR
   Ma, Q
   A, YG
   Hao, HW
   Li, LM
   Tu, Y
AF Wang, Wei-jun
   Lu, Jun
   Niu, Chuan-sen
   Huang, Yi-ran
   Ma, Qing
   A, Ying-ge
   Hao, Hong-wei
   Li, Lu-ming
   Tu, Ya
TI [Effects of electroacupuncture of unilateral and bilateral "zusanli" (ST 36) on
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
AB OBJECTIVE: To observe the effect of electroacupuncture (EA) on serum tumor  necrosis factor-alpha (TNF-alpha), IL-1 and IL-4 levels in rats with chronic  inflammatory pain, so as to investigate its underlying mechanism in relieving  pain. Methods Forty-eight SD rats were randomized into control, model,  EA-unilateral ST 36, and EA-bilateral ST 36 groups, with 12 rats in each. Chronic  inflammatory pain model was established by intradermal injection of Freund's  complete adjuvant (0.1 mL) into the right paw. EA (2 Hz/100 Hz, 1-2-3 mA) was  applied to the unilateral "Zusanli" (ST 36) and bilateral "Zusanli" (ST 36) for  30 min, once every 3 days and continuously for 4 weeks. Serum TNF-alpha, IL-1 and  IL-4 contents were detected by enzyme linked immunosorbent assay. Results  Compared with the control group, serum TNF-alpha, IL-1 and IL-4 contents of the  model group increased significantly (P < 0.01), while in comparison with the  model group, the levels of the 3 indexes were decreased considerably in both  unilateral and bilateral ST 36 groups (P < 0.01). No significant differences were  found between the unilateral ST 36 and bilateral ST 36 groups in serum TNF-alpha,  IL-1 and IL-4 contents (P > 0.05). CONCLUSION: EA can effectively lower serum  TNF-alpha, IL-1 and IL-4 levels in inflammatory pain rats, which may contribute  to its effect in relieving inflammatory pain.
C1 School of Acu-moxibustion and Massage, Beijing University of Chinese Medicine, Beijing 100029, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD MAR 8
PY 2011
VL 35
IS 6
BP 429
EP 32
DI 
PG -397
WC Acupuncture Points; Animals; Chronic Disease; therapy; Disease Models, Animal; Electroacupuncture; Humans; Interleukin-1; blood; Interleukin-4; blood; Male; Pain; blood; Pain Management; Random Allocation; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; blood
UT PubMed:21375016
PM 21375016
DA 2011-03-08
ER

PT J
AU Paley, CA
   Bennett, MI
   Johnson, MI
AF Paley, Carole A
   Bennett, Michael I
   Johnson, Mark I
TI Acupuncture for cancer-induced bone pain?
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB Bone pain is the most common type of pain in cancer. Bony metastases are common  in advanced cancers, particularly in multiple myeloma, breast, prostate or lung  cancer. Current pain-relieving strategies include the use of opioid-based  analgesia, bisphosphonates and radiotherapy. Although patients experience some  pain relief, these interventions may produce unacceptable side-effects which  inevitably affect the quality of life. Acupuncture may represent a potentially  valuable adjunct to existing strategies for pain relief and it is known to be  relatively free of harmful side-effects. Although acupuncture is used in  palliative care settings for all types of cancer pain the evidence-base is sparse  and inconclusive and there is very little evidence to show its effectiveness in  relieving cancer-induced bone pain (CIBP). The aim of this critical review is to  consider the known physiological effects of acupuncture and discuss these in the  context of the pathophysiology of malignant bone pain. The aim of future research  should be to produce an effective protocol for treating CIBP with acupuncture  based on a sound, evidence-based rationale. The physiological mechanisms  presented in this review suggest that this is a realistic objective.
C1 Faculty of Health, Leeds Metropolitan University, Leeds, UK.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD JUL 30
PY 2011
VL 2011
IS 
BP 671043
EP 671043
DI 10.1093/ecam/neq020
PG 0
UT PubMed:21799687
PM 21799687
DA 2011-07-30
ER

PT J
AU Gim, GT
   Lee, JH
   Park, E
   Sung, YH
   Kim, CJ
   Hwang, WW
   Chu, JP
   Min, BI
AF Gim, Gyeong-Taek
   Lee, Ji-Hye
   Park, Eunkuk
   Sung, Yun-Hee
   Kim, Chang-Ju
   Hwang, Wei-Wan
   Chu, Jong-Phil
   Min, Byung-Il
TI Electroacupuncture attenuates mechanical and warm allodynia through suppression
SO Brain research bulletin
LA English
DT Journal Article
AB Neuropathic pain remains one of the most difficult clinical pain syndromes to  treat. It is traditionally viewed as being mediated solely by neurons; however,  glial cells have recently been implicated as powerful modulators of pain. It is  known that the analgesic effects of electroacupuncture (EA) are mediated by  descending pain inhibitory systems, which mainly involve spinal opioid,  adrenergic, dopaminergic, serotonergic, and cholinergic receptors. However,  studies investigating the suppressive effects of EA on spinal glial activation  are rare. In the present study, we assessed the cumulative analgesic effects of  EA on mechanical and warm allodynia in a rat model of neuropathic pain. We  investigated the clinical efficacy of EA as long-term therapy and examined its  effects on spinal glia, matrix metalloproteinase (MMP)-9/MMP-2, proinflammatory  cytokines and serum immunoglobulin G (IgG) concentration. Rats were randomly  divided into four groups as follows: the operation group (OP), operation with  EA-non acupoint (EA-NA), operation with EA-ST36 acupoint (EA-ST36), and sham  operation (shamOP). Following neuropathic or sham surgery, repeated EA was  performed every other day after the behavioral test. On day 53 after the  behavioral test, rats were perfused for immunohistochemistry and Western blot  analysis to observe quantitative changes in spinal glial markers such as OX-42,  astrocytic glial fibrillary acidic protein (GFAP), MMP-9/MMP-2, and  proinflammatory cytokines. Allodynia and OX-42/GFAP/MMP-9/MMP-2/tumor necrosis  factor (TNF)-α/interleukin (IL)-1β activity in the EA-ST36 group was  significantly reduced, compared to the OP and EA-NA groups, and IgG in EA-ST36  rats significantly increased. Our results suggest that the analgesic effect of EA  may be partly mediated via inhibition of inflammation and glial activation and  repeated EA stimulation may be useful for treating chronic pain clinically.
C1 Department of East-West Medicine, Graduate School, Kyung Hee University, Seoul, South Korea.
NR 0
TC 0
SN 1873-274
EI 
J9 Brain Res Bull
PD OCT 1
PY 2011
VL 86
IS 5-6
BP 403
EP 11
DI 10.1016/j.brainresbull.2011.09.010
PG -392
WC Animals; Disease Models, Animal; Electroacupuncture; methods; Humans; Hyperalgesia; therapy; Immunoglobulin G; blood; Interleukin-1beta; metabolism; Interleukin-6; metabolism; Male; Matrix Metalloproteinase 2; metabolism; Matrix Metalloproteinase 9; metabolism; Neuralgia; physiopathology; Neuroglia; metabolism; Pain Measurement; Physical Stimulation; methods; Random Allocation; Rats; Rats, Sprague-Dawley; Spinal Cord; cytology; Temperature; Tumor Necrosis Factor-alpha; metabolism
UT PubMed:21958939
PM 21958939
DA 2011-10-01
ER

PT J
AU Paley, CA
   Johnson, MI
   Tashani, OA
   Bagnall, AM
AF Paley, Carole A.
   Johnson, Mark I.
   Tashani, Osama A.
   Bagnall, Anne-Marie
TI Acupuncture for cancer pain in adults
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID bone pain; management; metaanalysis; electroacupuncture; osteoarthritis; trials; neck
AB Background Forty percent of individuals with early or intermediate stage cancer and 90% with advanced cancer have moderate to severe pain and up to 70% of patients with cancer pain do not receive adequate pain relief. It has been claimed that acupuncture has a role in management of cancer pain and guidelines exist for treatment of cancer pain with acupuncture. Objectives To evaluate efficacy of acupuncture for relief of cancer-related pain in adults. Search strategy CENTRAL, MEDLINE, EMBASE, PsycINFO, AMED, and SPORTDiscus were searched up to November 2010 including non-English language papers. Selection criteria Randomised controlled trials (RCTs) evaluating any type of invasive acupuncture for pain directly related to cancer in adults of 18 years or over. Data collection and analysis It was planned to pool data to provide an overall measure of effect and to calculate the number needed to treat to benefit, but this was not possible due to heterogeneity. Two review authors (CP, OT) independently extracted data adding it to data extraction sheets. Quality scores were given to studies. Data sheets were compared and discussed with a third review author (MJ) who acted as arbiter. Data analysis was conducted by CP, OT and MJ. Main results Three RCTs (204 participants) were included. One high quality study investigated the effect of auricular acupuncture compared with auricular acupuncture at 'placebo' points and with non-invasive vaccaria ear seeds attached at 'placebo' points. Participants in two acupuncture groups were blinded but blinding wasn't possible in the ear seeds group because seeds were attached using tape. This may have biased results in favour of acupuncture groups. Participants in the real acupuncture group had lower pain scores at two month follow-up than either the placebo or ear seeds group. There was high risk of bias in two studies because of low methodological quality. One study comparing acupuncture with medication concluded that both methods were effective in controlling pain, although acupuncture was the most effective. The second study compared acupuncture, point-injection and medication in participants with stomach cancer. Long-term pain relief was reported for both acupuncture and point-injection compared with medication during the last 10 days of treatment. Although both studies have positive results in favour of acupuncture they should be viewed with caution due to methodological limitations, small sample sizes, poor reporting and inadequate analysis. Authors' conclusions There is insufficient evidence to judge whether acupuncture is effective in treating cancer pain in adults.
C1 [Paley, Carole A.] Airedale NHS Trust, Res & Effectiveness Dept, Airedale Gen Hosp, Keighley BD20 6TD, W Yorkshire, England.
   [Johnson, Mark I.; Tashani, Osama A.; Bagnall, Anne-Marie] Leeds Metropolitan Univ, Fac Hlth, Leeds LS1 3HE, W Yorkshire, England.
C3 Leeds Beckett University
RP Paley, CA (corresponding author), Airedale NHS Trust, Res & Effectiveness Dept, Airedale Gen Hosp, Keighley BD20 6TD, W Yorkshire, England.
EM biodynamics.physiotherapy@tesco.net
FU Leeds Metropolitan University, UK
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2010, SURGERY, V0, P0, DOI DOI 10.1016/J.SURG.2009.06.030
   Unknown -, 2008, CANC PAIN CLIN PAIN, V0, P0
   AUNG S, 1994, ACUPUNCT MED, V12, P37
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Bjordal JM, 2007, BMC MUSCULOSKEL DIS, V8, P0, DOI 10.1186/1471-2474-8-51
   Brainin-Mattos J, 2006, PAIN, V122, P174, DOI 10.1016/j.pain.2006.01.032
   Cata JP, 2006, MINERVA ANESTESIOL, V72, P151
   Chen Zhong-jie, 2008, ZHONGGUO ZHEN JIU, V28, P251
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Dang W, 1998, J TRADIT CHIN MED, V18, P31
   Davis MA, 2008, J PAIN, V9, P667, DOI 10.1016/j.jpain.2008.03.011
   Derry CJ, 2006, CLIN MED, V6, P381, DOI 10.7861/clinmedicine.6-4-381
   Dillon M, 1999, PALLIATIVE MED, V13, P253, DOI 10.1191/026921699667999073
   Ernst E, 2006, J INTERN MED, V259, P125, DOI 10.1111/j.1365-2796.2005.01584.x
   Ernst E, 2004, PAIN, V109, P203, DOI 10.1016/j.pain.2004.01.028
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Everdingen MHJVDBV, 2007, PAIN, V132, P312, DOI 10.1016/j.pain.2007.08.022
   Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8
   FILSHIE J, 1990, ACUPUNCT MED, V8, P38
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Furlan AD, 2005, SPINE, V30, P944, DOI 10.1097/01.brs.0000158941.21571.01
   Goudas L, 2001, EVID REP TECHNOL ASSESS (SUMM), V0, P1
   Gralow J, 2007, J PAIN SYMPTOM MANAG, V33, P462, DOI 10.1016/j.jpainsymman.2007.01.001
   Green S, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005319
   Guo R, 1995, J TRADIT CHIN MED, V15, P262
   He D, 2004, PAIN, V109, P299, DOI 10.1016/j.pain.2004.01.018
   Hopwood V, 2004, ACUPUNCTURE PHYSIOTH, V1st, P0
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Johnson Mark I, 2006, ACUPUNCT MED, V24, P71
   Keskinbora K, 2007, J PAIN SYMPTOM MANAG, V34, P183, DOI 10.1016/j.jpainsymman.2006.11.013
   Kwon YD, 2006, RHEUMATOLOGY, V45, P1331, DOI 10.1093/rheumatology/kel207
   Laird B, 2008, EUR J CANCER, V44, P1078, DOI 10.1016/j.ejca.2008.03.022
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lipton Allan, 2004, J SUPPORT ONCOL, V2, P205
   Lund Irene, 2009, CHIN MED, V4, P1, DOI 10.1186/1749-8546-4-1
   LUNDEBERG T, 2009, EVIDENCE BASED 0612, V0, P0
   Lundeberg T, 2008, ACUPUNCT MED, V26, P239, DOI 10.1136/aim.26.4.239
   Manheimer E, 2005, ANN INTERN MED, V142, P651, DOI 10.7326/0003-4819-142-8-200504190-00014
   Manheimer E, 2007, ANN INTERN MED, V146, P868, DOI 10.7326/0003-4819-146-12-200706190-00008
   Mao-Ying QL, 2006, EUR J PAIN, V10, P689, DOI 10.1016/j.ejpain.2005.11.001
   Mao-Ying Qi-liang, 2008, ZHONG XI YI JIE HE XUE BAO, V6, P830, DOI 10.3736/jcim20080812
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Minton O, 2007, J PAIN SYMPTOM MANAG, V33, P115, DOI 10.1016/j.jpainsymman.2006.09.011
   Petrut B, 2008, CURR ONCOL, V15, PS50, DOI 10.3747/co.v15i0.205
   POULAIN P, 1985, B CANCER, V72, P342
   Qaseem A, 2009, ANN INTERN MED, V150, P148
   Ripamonti C, 2000, CURR REV PAIN, V4, P187
   Sima L, 2009, J CLIN ONCOL, V27, P0
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   Trinh KV, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004870.pub3
   Urch CE, 2008, CLIN PAIN MANAGEMENT, V2nd ed., P3
   Vallerand AH, 2007, PAIN, V132, P82, DOI 10.1016/j.pain.2007.01.029
   White A, 2007, RHEUMATOLOGY, V46, P384, DOI 10.1093/rheumatology/kel413
   White A, 2008, ACUPUNCT MED, V26, P111, DOI 10.1136/aim.26.2.111
   White AR, 1999, RHEUMATOLOGY, V38, P143, DOI 10.1093/rheumatology/38.2.143
   XIA Y, 1986, JOURNAL OF TRADITIONAL CHINESE MEDICINE, V6, P23
   Yu G Q, 1992, J TRADIT CHIN MED, V12, P243
   Zhang Ting, 2006, CHIN J INTEGR MED, V12, P180
NR 69
TC 56
Z9 60
U1 0
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PD JUN 15
PY 2011
VL 0
IS 1
BP 
EP 
DI 10.1002/14651858.CD007753.pub2
PG 27
WC Medicine, General & Internal
SC General & Internal Medicine
GA 708VU
UT WOS:000286393200018
PM 21249694
DA 2026-01-16
ER

PT J
AU Schiller, DS
   Parikh, A
AF Schiller, Daryl S.
   Parikh, Ashish
TI Identification, Pharmacologic Considerations, and Management of Prostatitis
SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY
LA English
DT Review
DE Bacterial prostatitis; chronic prostatitis; NIH-CPSI; prostatitis
ID pelvic pain syndrome; institutes-of-health; community-based cohort; double-blind; nonbacterial prostatitis; symptom index; men; therapy; ciprofloxacin; prevalence
AB Background: Prostatitis is a collection of signs and symptoms that occur as a result of inflammation or swelling of the prostate gland. There are many different causes for prostatitis, including infection; occasionally no clear etiology for the inflammation is found. Effective treatment often depends on identification of the cause, but a microbiologic organism is not always detectable, especially in cases of chronic prostatitis. Objective: The aim of this article was to review identification and treatment options for prostatitis, including pharmacologic and nonpharmacologic interventions. Methods: Relevant information was identified through a search of MEDLINE (1966 June 2010), International Pharmaceutical Abstracts (1970 June 2010), and EMBASE (1947 June 2010). Randomized, controlled trials that examined prostate cancer, benign prostatic hypertrophy, or procedures related to the prostate (ie, biopsies) were excluded. Results: A working classification system for prostatitis was developed in 1999, but there are few randomized controlled trials that distinguish between the various treatment options. Bacterial prostatitis can be acute or chronic but always requires some degree of antimicrobial therapy. Pharmacologic features of fluoroquinolones make them the preferred agents for most patients. These antibiotics can become trapped in a chronically inflamed prostate due to pH differences between prostatic tissue and serum. Many fluoroquinolones have penetration ratios (prostate level:serum level) of up to 4:1. A study in European men (N = 117) who received levofloxacin 500 mg/d with a diagnosis of chronic bacterial prostatitis demonstrated clinical success rates of 92% (95% CI 84.8%-96.5%), 77.4% (95% CI, 68.2-84.9%), 66.0% (95% CI, 56.2%-75.0%), and 61.9% (95% CI, 51.9%-71.2%) at 5-12 days, 1 month, 3 months, and 6 months after treatment. Additionally, there have been numerous randomized, placebo-controlled trials in patients with chronic prostatitis that have studied alpha-blockers, steroid inhibitors, anti-inflammatory agents, and bioflavonoids. Treatment responses to a-blockers appear to be greater with longer durations of therapy in a-blocker nave patients (National Institutes of Health-Chronic Prostatitis Symptom Index [NIH-CPSI] score reduction of at least 3.6 points after 6 weeks of tamsulosin therapy [P = 0.04] and up to 14.3 and 9.9 point NIH-CPSI score reductions with 14 weeks of terazosin and 24 weeks of alfuzosin therapy, respectively [P = 0.01 for both]). Combination therapy with an a-blocker, an anti-inflammatory, and a muscle relaxant does not appear to offer significant advantages over monotherapy (12.7 vs 12.4 point reduction in NIH-CPSI scores) and a stepwise approach to therapy involving antibiotics followed by bioflavonoids and then a-blockers appears to effectively reduce symptoms for up to 1 year in patients with chronic prostatitis (mean NIH-CPSI point reduction of 9.5 points compared with baseline, P < 0.0001). Patients who have had multiple unsuccessful treatment regimens may benefit from direct stimulation of the pelvic muscles through electromagnetic or electroacupuncture therapy. Conclusions: Prostatitis can resemble various other medical conditions but proper classification and an understanding of the pharmacologic features and expectations of the medications used to treat it can help identify effective treatment strategies. Fluoroquinolones are the preferred agents for treating bacterial causes of prostatitis and have demonstrated efficacy in some cases of chronic prostatitis when an organism has not been identified. However, the use of agents with anti-inflammatory or antiadrenergic properties may be necessary in combination with or after trying antimicrobial agents. (Am J Geriatr Pharmacother. 2011;9:37-48) (C) 2011 Elsevier HS Journals, Inc. All rights reserved.
C1 [Schiller, Daryl S.] St Barnabas Hosp, Dept Pharm, BCPS ID, Livingston, NJ 07039 USA.
   [Parikh, Ashish] St Barnabas Hosp, Dept Med, Livingston, NJ 07039 USA.
RP Schiller, DS (corresponding author), St Barnabas Hosp, Dept Pharm, BCPS ID, 94 Old Short Hills Rd, Livingston, NJ 07039 USA.
EM dschiller@sbhcs.com
CR Alexander RB, 2004, ANN INTERN MED, V141, P581, DOI 10.7326/0003-4819-141-8-200410190-00005
   Barbalias G A, 1998, INT J UROL, V5, P157, DOI 10.1111/j.1442-2042.1998.tb00267.x
   BARZA M, 1984, EUR J CLIN MICROBIOL, V3, P503, DOI 10.1007/BF02013607
   Bundrick W, 2003, UROLOGY, V62, P537, DOI 10.1016/S0090-4295(03)00565-X
   Charalabopoulos K, 2003, CHEMOTHERAPY, V49, P269, DOI 10.1159/000074526
   Cheah PY, 2003, J UROLOGY, V169, P592, DOI 10.1016/S0022-5347(05)63960-2
   Cheah PY, 2003, UROLOGY, V61, P60, DOI 10.1016/S0090-4295(02)02081-2
   Chen R, 2003, UROLOGY, V61, P1156, DOI 10.1016/S0090-4295(03)00141-9
   Cho YH, 2002, INT J ANTIMICROB AG, V19, P576, DOI 10.1016/S0924-8579(02)00115-2
   Clemens JQ, 2007, J UROLOGY, V178, P1333, DOI 10.1016/j.juro.2007.05.140
   Clemens JQ, 2006, J UROLOGY, V176, P593, DOI 10.1016/j.juro.2006.03.089
   Collins MM, 1998, J UROLOGY, V159, P1224, DOI 10.1016/S0022-5347(01)63564-X
   CUNHA BA, 1983, B NEW YORK ACAD MED, V59, P443
   Daniels NA, 2005, UROLOGY, V66, P964, DOI 10.1016/j.urology.2005.05.034
   Drusano GL, 2000, ANTIMICROB AGENTS CH, V44, P2046, DOI 10.1128/AAC.44.8.2046-2051.2000
   Etienne M, 2008, BMC INFECT DIS, V8, P0, DOI 10.1186/1471-2334-8-12
   FitzGerald MP, 2009, J UROLOGY, V182, P570, DOI 10.1016/j.juro.2009.04.022
   GOURTSOYIANNIS N, 1990, AM J ROENTGENOL, V155, P541, DOI 10.2214/ajr.155.3.2117353
   KIRBY RS, 1982, BRIT J UROL, V54, P729, DOI 10.1111/j.1464-410X.1982.tb13635.x
   KRIEGER JN, 1984, SEX TRANSM DIS, V11, P100, DOI 10.1097/00007435-198404000-00011
   Krieger JN, 1999, JAMA-J AM MED ASSOC, V282, P236, DOI 10.1001/jama.282.3.236
   Krieger JN, 2008, INT J ANTIMICROB AG, V31, PS85, DOI 10.1016/j.ijantimicag.2007.08.028
   Le BV, 2009, UROL CLIN N AM, V36, P527, DOI 10.1016/j.ucl.2009.08.005
   Lee SH, 2009, UROLOGY, V73, P1036, DOI 10.1016/j.urology.2008.10.047
   Lipsky BA, 2010, CLIN INFECT DIS, V50, P1641, DOI 10.1086/652861
   Litwin MS, 1999, J UROLOGY, V162, P369, DOI 10.1016/S0022-5347(05)68562-X
   Litwin MS, 2002, UROLOGY, V60, P6
   Lugg J, 2008, J CHEMOTHERAPY, V20, P213, DOI 10.1179/joc.2008.20.2.213
   Mehik A, 2000, BJU INT, V86, P443, DOI 10.1046/j.1464-410X.2000.00836.x
   Mehik A, 2003, UROLOGY, V62, P425, DOI 10.1016/S0090-4295(03)00466-7
   MONTORSI F, 1995, J ENDOUROL, V9, P333, DOI 10.1089/end.1995.9.333
   Naber KG, 2008, INT J ANTIMICROB AG, V32, P145, DOI 10.1016/j.ijantimicag.2008.03.014
   Nadler RB, 2002, UROLOGY, V60, P42, DOI 10.1016/S0090-4295(02)02390-7
   Netter FH, 2010, ATLAS HUMAN ANATOMY, V0, P0
   Nickel J C, 1997, TECH UROL, V3, P38
   Nickel J Curtis, 2005, REV UROL, V7, P65
   Nickel JC, 2008, NEW ENGL J MED, V359, P2663, DOI 10.1056/NEJMoa0803240
   Nickel JC, 2004, BJU INT, V93, P991, DOI 10.1111/j.1464-410X.2003.04766.x
   Nickel JC, 2004, J UROLOGY, V171, P1594, DOI 10.1097/01.ju.0000117811.40279.19
   Nickel JC, 2003, J UROLOGY, V169, P1401, DOI 10.1097/01.ju.0000054983.45096.16
   Nickel JC, 1996, J UROLOGY, V155, P1950, DOI 10.1016/S0022-5347(01)66056-7
   Olyaei AJ, 2009, CLIN GERIATR MED, V25, P459, DOI 10.1016/j.cger.2009.04.004
   Özden E, 2009, UROLOGY, V74, P119, DOI 10.1016/j.urology.2008.12.067
   Persson BE, 1996, J UROLOGY, V155, P958, DOI 10.1016/S0022-5347(01)66357-2
   Pontari MA, 2007, J UROLOGY, V177, P2050, DOI 10.1016/j.juro.2007.01.128
   Potts Jeannette, 2007, CLEVE CLIN J MED, V74 Suppl 3, P0
   Propert KJ, 2006, QUAL LIFE RES, V15, P299, DOI 10.1007/s11136-005-1317-1
   Roberts RO, 2002, J UROLOGY, V168, P2467, DOI 10.1016/S0022-5347(05)64170-5
   ROSS DL, 1990, INT J PHARMACEUT, V63, P237, DOI 10.1016/0378-5173(90)90130-V
   Rowe E, 2005, J UROLOGY, V173, P2044, DOI 10.1097/01.ju.0000158445.68149.38
   Shoskes D A, 2001, CAN J UROL, V8 Suppl 1, P24
   Shoskes DA, 1999, UROLOGY, V54, P960, DOI 10.1016/S0090-4295(99)00358-1
   Shoskes DA, 2003, J UROLOGY, V169, P1406, DOI 10.1097/01.ju.0000055549.95490.3c
   Skerk V, 2003, INT J ANTIMICROB AG, V21, P457, DOI 10.1016/S0924-8579(03)00056-6
   Stahlmann R, 2010, DRUG AGING, V27, P193, DOI 10.2165/11531490-000000000-00000
   Taylor BC, 2008, AM J MED, V121, P444, DOI 10.1016/j.amjmed.2008.01.043
   THIN RNT, 1974, BRIT J VENER DIS, V50, P370
   Tugcu V, 2007, EUR UROL, V51, P1113, DOI 10.1016/j.eururo.2006.09.036
   Tunuguntla HSGR, 2002, PROSTATE CANCER P D, V5, P172, DOI 10.1038/sj.pcan.4500604
   Turner JA, 2004, J UROLOGY, V172, P538, DOI 10.1097/01.ju.0000132797.63480.44
   Vykhovanets EV, 2009, PROSTATE, V69, P633, DOI 10.1002/pros.20916
   Wagenlehner FME, 2006, J CHEMOTHERAPY, V18, P485, DOI 10.1179/joc.2006.18.5.485
   Wagenlehner FME, 2007, EXPERT OPIN PHARMACO, V8, P1667, DOI 10.1517/14656566.8.11.1667
   WISEMAN LR, 1994, DRUG AGING, V4, P145, DOI 10.2165/00002512-199404020-00007
   Yavasçaoglu I, 1999, INT J UROL, V6, P130, DOI 10.1046/j.1442-2042.1999.06338.x
   Ye ZQ, 2003, ASIAN J ANDROL, V5, P155
   Zhao WP, 2009, BRAZ J MED BIOL RES, V42, P963, DOI 10.1590/S0100-879X2009005000021
NR 67
TC 9
Z9 11
U1 0
U2 20
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1543-5946
EI 
J9 AM J GERIATR PHARMAC
JI Am. J. Geriatr. Pharmacother.
PD FEB 15
PY 2011
VL 9
IS 1
BP 37
EP 48
DI 10.1016/j.amjopharm.2011.02.005
PG 12
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 754PA
UT WOS:000289866600004
PM 21459307
DA 2026-01-16
ER

PT J
AU Induru, RR
   Lagman, RL
AF Induru, Raghava R.
   Lagman, Ruth L.
TI Managing cancer pain: Frequently asked questions
SO CLEVELAND CLINIC JOURNAL OF MEDICINE
LA English
DT Article
ID alternative medicine use; opioid therapy; complementary/alternative medicine; adjuvant analgesics; controlled-trial; primary-care; management; acupuncture; reliability; validity
AB For a variety of reasons, cancer pain is often undertreated, adversely affecting the quality of life for patients and caregivers. To manage cancer pain effectively, physicians need to understand its pathogenesis, how to assess it, how to treat it, and, in particular, how to optimize opioid treatment. We discuss common questions faced by physicians in everyday practice.
C1 [Induru, Raghava R.; Lagman, Ruth L.] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Lagman, RL (corresponding author), Cleveland Clin, Taussig Canc Ctr, R35,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM lagmanr@ccf.org
CR Adler SR, 1999, J FAM PRACTICE, V48, P453
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Berman B M, 1995, J AM BOARD FAM PRACT, V8, P361
   Chang HM, 1999, MED CLIN N AM, V83, P711, DOI 10.1016/S0025-7125(05)70131-0
   CHEEMA B, 2006, J CANC PAIN S PALLIA, V2, P39
   Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542
   Clarke SFJ, 2005, EMERG MED J, V22, P612, DOI 10.1136/emj.2003.009613
   Davis MP, 2007, ONCOLOGY-NY, V21, P1229
   Davis MP, 2005, SUPPORT CARE CANCER, V13, P878, DOI 10.1007/s00520-005-0849-9
   Davis MP, 2005, LANCET ONCOL, V6, P696, DOI 10.1016/S1470-2045(05)70317-X
   Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Ernst E, 1998, CANCER-AM CANCER SOC, V83, P777, DOI 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
   FISHBAIN DA, 1992, CLIN J PAIN, V8, P77, DOI 10.1097/00002508-199206000-00003
   Foley K, 2005, OXFORD TXB PALLIATIV, V0, P298
   Gallagher LM, 2006, SUPPORT CARE CANCER, V14, P859, DOI 10.1007/s00520-005-0013-6
   Goodwin PJ, 2001, NEW ENGL J MED, V345, P1719, DOI 10.1056/NEJMoa011871
   Grossman SA, 2000, ONCOLOGY-NY, V14, P135
   HARRIS JD, 2006, CANC PAIN PHARM INTE, V0, P207
   Harris JD, 2008, CLIN J PAIN, V24, PS8, DOI 10.1097/AJP.0b013e31816b58eb
   Jacobsen R, 2009, MEDICINA-LITHUANIA, V45, P427, DOI 10.3390/medicina45060055
   JENSEN MP, 1994, PAIN, V58, P387, DOI 10.1016/0304-3959(94)90133-3
   Jensen MP, 2003, J PAIN, V4, P2, DOI 10.1054/jpai.2003.1
   Johnson JR, 2010, J PAIN SYMPTOM MANAG, V39, P167, DOI 10.1016/j.jpainsymman.2009.06.008
   Katz NP, 2003, ANESTH ANALG, V97, P1097, DOI 10.1213/01.ANE.0000080159.83342.B5
   Klotz U, 2003, ARZNEIMITTELFORSCH, V53, P681
   Knotkova H, 2007, MED CLIN N AM, V91, P113, DOI 10.1016/j.mcna.2006.10.007
   Laird B, 2008, EUR J CANCER, V44, P1078, DOI 10.1016/j.ejca.2008.03.022
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lussier D, 2004, ONCOLOGIST, V9, P571, DOI 10.1634/theoncologist.9-5-571
   Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G
   Mercadante S, 2001, CANCER TREAT REV, V27, P51, DOI 10.1053/ctrv.2000.0192
   Muranyi Marianna, 2008, ORVOSI HETILAP, V149, P2363, DOI 10.1556/OH.2008.28449
   Newell S, 2000, MED J AUSTRALIA, V172, P110, DOI 10.5694/j.1326-5377.2000.tb127933.x
   Olaku O, 2011, EUR J CANCER, V47, P508, DOI 10.1016/j.ejca.2010.11.018
   Olson K, 2003, J PAIN SYMPTOM MANAG, V26, P990, DOI 10.1016/S0885-3924(03)00334-8
   Passik Steven D, 2005, J SUPPORT ONCOL, V3, P83
   Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9
   Peretti-Watel P, 2003, PALLIAT SUPPORT CARE, V1, P345
   Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0
   Post-White Janice, 2003, INTEGR CANCER THER, V2, P332, DOI 10.1177/1534735403259064
   Preston CC, 2000, ACTA PSYCHOL, V104, P1, DOI 10.1016/S0001-6918(99)00050-5
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Rome HP Jr, 2000, PAIN MED, V1, P7, DOI 10.1046/j.1526-4637.2000.99105.x
   SCHUG SA, 1992, J PAIN SYMPTOM MANAG, V7, P259, DOI 10.1016/0885-3924(92)90059-Q
   Shaheen PE, 2009, J PAIN SYMPTOM MANAG, V38, P409, DOI 10.1016/j.jpainsymman.2009.06.004
   Sloman R, 1994, CONTEMP NURSE, V3, P6
   Soden K, 2004, PALLIATIVE MED, V18, P87, DOI 10.1191/0269216304pm874oa
   SPIEGEL D, 1983, PSYCHOSOM MED, V45, P333, DOI 10.1097/00006842-198308000-00007
   Stannard C, 2003, CURR MED RES OPIN, V19, P703, DOI 10.1185/030079903125002478
   SYRJALA KL, 1995, PAIN, V63, P189, DOI 10.1016/0304-3959(95)00039-U
   Turk DC, 2008, CLIN J PAIN, V24, P497, DOI 10.1097/AJP.0b013e31816b1070
   Vadalouca Athina, 2008, J OPIOID MANAG, V4, P213, DOI 10.5055/jom.2008.0027
   VERHOEF MJ, 1995, SOC SCI MED, V41, P511, DOI 10.1016/0277-9536(94)00351-S
   Walsh D, 2000, SEMIN ONCOL, V27, P45
   Walsh Declan, 2004, SUPPORT CANCER THER, V1, P157, DOI 10.3816/SCT.2004.n.007
   Weinrich S P, 1990, APPL NURS RES, V3, P140, DOI 10.1016/S0897-1897(05)80135-1
   Wiedemer NL, 2007, PAIN MED, V8, P573, DOI 10.1111/j.1526-4637.2006.00254.x
   Wilkie D J, 2000, HOSP J, V15, P31
NR 63
TC 15
Z9 17
U1 1
U2 5
PU CLEVELAND CLINIC
PI CLEVELAND
PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA
SN 0891-1150
EI 1939-2869
J9 CLEV CLIN J MED
JI Clevel. Clin. J. Med.
PD JUL 15
PY 2011
VL 78
IS 7
BP 449
EP +
DI 10.3949/ccjm.78a.10054
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA 793XV
UT WOS:000292858100004
PM 21724928
DA 2026-01-16
ER

PT J
AU Kim, KH
   Lee, MS
   Choi, SM
AF Kim, Kun Hyung
   Lee, Myeong Soo
   Choi, Sun-Mi
TI Acupuncture for treating uremic pruritus in patients with end-stage renal
SO Journal of pain and symptom management
LA English
DT Journal Article
AB Uremic pruritus (UP) is a common and bothersome symptom in end-stage renal  disease (ESRD) that does not always respond to conventional care. Acupuncture is  frequently used for the treatment of a wide range of conditions, but its effects  on UP in ESRD patients are unclear. The objective of this review was to evaluate  the effectiveness of acupuncture for UP in patients with ESRD. We searched 16  electronic databases from their inception to November 2009. All prospective  clinical studies of needle acupuncture for UP in hemodialysis patients with ESRD  were included regardless of their design. Risk of bias of the included studies  was assessed using the Cochrane criteria. Three randomized controlled trials and  three uncontrolled observational studies were included. All of the included  trials reported beneficial effects of acupuncture. However, most of the studies  showed high risk of bias, which leaves their reports unconvincing. The current  evidence is insufficient to show that acupuncture is an effective treatment for  UP inpatients with ESRD because of suboptimal quality and lack of methodological  rigor of included studies. Future trials should overcome the limitations of the  currently available evidence. J Pain Symptom Manage 2010;40:117e125. 2010 U.S.  Cancer Pain Relief Committee.
C1 Acpuncture, Moxibustion, & Meridian Research Center, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
NR 0
TC 0
SN 1873-651
EI 
J9 J Pain Symptom Manage
PD JUL 29
PY 2011
VL 40
IS 1
BP 117
EP 25
DI 10.1016/j.jpainsymman.2009.11.325
PG -92
WC Acupuncture Therapy; methods; Bias; Electroacupuncture; methods; Humans; Kidney Failure, Chronic; complications; Pruritus; etiology; Randomized Controlled Trials as Topic; Uremia; complications
UT PubMed:21796811
PM 21796811
DA 2011-07-29
ER

PT J
AU Nagykálnai, T
   Landherr, L
   Mészáros, E
AF Nagykálnai, Tamás
   Landherr, László
   Mészáros, Edina
TI [Aromatase inhibitors and arthralgia].
SO Magyar onkologia
LA hun
DT Review
AB In several large adjuvant clinical trials it has been demonstrated that  substitution (eventually addition) of aromatase inhibitors (AIs) provides an  improved outcome of endocrine-sensitive breast cancer over tamoxifen alone.  Nevertheless, arthralgia induced by the AIs is one of the most frequent side  effects in hormonal therapy. It is characterized by tenosynovial changes and is  more frequent in patients in clinical practice than previously appreciated in  adjuvant clinical trials. AI-related arthralgia may be related to estrogen  deprivation, but estrogen replacement is not an option for these women. Therefore  standard painkillers, NSAIDs (COX2 inhibitors), week opioids and other  interventions (vitamin D, calcium, bisphosphonates, exercise, acupuncture,  complementary and alternative approaches, eventually switch to another endocrine  drug) are used for managing this treatment-related side effect, and improve  adherence and quality of life among breast cancer survivors.
C1 Budapest XV. ker. Onkológiai Gondozó, Budapest. nagykalnai.tamas@t-online.hu
NR 0
TC 0
SN 
EI 0025-024
J9 Magy Onkol
PD MAY 28
PY 2011
VL 55
IS 1
BP 32
EP 9
DI 
PG -23
WC Anastrozole; Androstadienes; adverse effects; Antineoplastic Agents, Hormonal; administration & dosage; Aromatase Inhibitors; administration & dosage; Arthralgia; chemically induced; Breast Neoplasms; drug therapy; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Medication Adherence; Neoplasms, Hormone-Dependent; drug therapy; Nitriles; adverse effects; Postmenopause; Quality of Life; Risk Factors; Triazoles; adverse effects
UT PubMed:21617789
PM 21617789
DA 2011-05-28
ER

PT J
AU Münstedt, K
   Thienel, J
   Hrogovic, I
   Hackethal, A
   Kalder, M
   Misselwitz, B
AF Muenstedt, Karsten
   Thienel, Janina
   Hrogovic, Igor
   Hackethal, Andreas
   Kalder, Matthias
   Misselwitz, Bjoern
TI Use of Acupuncture and Other CAM Methods in Obstetrics: An Analysis of 409,413 Deliveries from Hesse, Germany
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
ID nulliparous women; pain relief; labor; complementary; reduce
AB Objectives: This study was done to analyze the frequency of use of acupuncture and other complementary and alternative medicine (CAM) methods during labor and to investigate the different characteristics of women being treated with or without acupuncture and CAM methods, as well as try to analyze birth-related outcome measures. Study design: Data were analyzed from 409,413 deliveries, registered between 2001 and 2008 by the agency for quality assurance in Hesse (the Hessian Perinatal Registry [HEPE] survey), which made up more than 95% of all deliveries in this German state during the given time period. Results: Interest in the use of CAM seems to have decreased within the given time period. On average, acupuncture was used in 3.7% (15,345/409,295) of all deliveries and other CAM methods in 4.8% (19,507/409,295). The most important determinant for the use of one or both methods was the type of hospital. It was also found that German women with higher job qualifications were more likely to receive CAM treatment during delivery. Interestingly, application of CAM methods was associated with a higher use of analgesics during labor. The risk status of the pregnancy or the delivery was of minor importance. Conclusions: This analysis shows that the determinants of CAM use are similar to those in the field of oncology. In order to assess the efficacy of acupuncture or other CAM methods in the field of obstetrics, it seems necessary to extend the HEPE survey to cover these areas.
C1 [Muenstedt, Karsten; Hrogovic, Igor; Hackethal, Andreas] Univ Giessen, Dept Obstet & Gynaecol, D-35385 Giessen, Germany.
   [Thienel, Janina] Univ Munich, Munich, Germany.
   [Kalder, Matthias] Univ Marburg, Dept Gynaecol & Gynaecol Endocrinol & Oncol, Marburg, Germany.
   [Misselwitz, Bjoern] Inst Qual Assurance, Eschborn, Germany.
C3 Justus Liebig University Giessen; University of Munich; Philipps University Marburg
RP Münstedt, K (corresponding author), Univ Giessen, Dept Obstet & Gynaecol, Klinikstr 32, D-35385 Giessen, Germany.
EM karsten.muenstedt@gyn.med.uni-giessen.de
CR BISHOP FL, 2008, EVID BASED COMP 0313, V0, P0
   Boivin J, 2009, HUM REPROD, V24, P1626, DOI 10.1093/humrep/dep077
   Borup L, 2009, BIRTH-ISS PERINAT C, V36, P5, DOI 10.1111/j.1523-536X.2008.00290.x
   Goerke K, 2000, GYNAKOLOGE, V33, P220, DOI 10.1007/s001290050538
   Hantoushzadeh S, 2007, AUST NZ J OBSTET GYN, V47, P26, DOI 10.1111/j.1479-828X.2006.00674.x
   Koog YH, 2009, J ALTERN COMPLEM MED, V15, P1107, DOI 10.1089/acm.2009.0132
   KUBISTA E, 1973, WIEN KLIN WOCHENSCHR, V85, P628
   KUNZEL W, 1994, EUR J OBSTET GYN R B, V54, P13, DOI 10.1016/0028-2243(94)90075-2
   Lee H, 2004, AM J OBSTET GYNECOL, V191, P1573, DOI 10.1016/j.ajog.2004.05.027
   Mårtensson L, 2011, MIDWIFERY, V27, P93, DOI 10.1016/j.midw.2010.08.011
   MESTLER G E, 1954, BULL MED LIBR ASSOC, V42, P468
   Münstedt K, 2009, EUR J OBSTET GYN R B, V146, P50, DOI 10.1016/j.ejogrb.2009.05.013
   Münstedt K, 2009, FORSCH KOMPLEMENTMED, V16, P111, DOI 10.1159/000208918
   Nesheim BI, 2003, CLIN J PAIN, V19, P187, DOI 10.1097/00002508-200305000-00006
   Peuker E, 2001, ACUPUNCT MED, V19, P103
   Selmer-Olsen T, 2007, ACTA OBSTET GYN SCAN, V86, P1447, DOI 10.1080/00016340701645287
   Smith CA, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003521.pub2
   SMITH CA, 2001, COCHRANE DB SYST REV, V1, P0
   Smith CA, 2009, BIRTH-ISS PERINAT C, V36, P246, DOI 10.1111/j.1523-536X.2009.00329.x
   So EWS, 2009, HUM REPROD, V24, P341, DOI 10.1093/humrep/den380
   Tournaire M, 2007, EVID-BASED COMPL ALT, V4, P409, DOI 10.1093/ecam/nem012
NR 21
TC 11
Z9 16
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD MAY 15
PY 2011
VL 17
IS 5
BP 421
EP 426
DI 10.1089/acm.2010.0145
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 766LP
UT WOS:000290784100007
PM 21554127
DA 2026-01-16
ER

PT J
AU Deng, G
   Cassileth, B
AF Deng, Gary
   Cassileth, Barrie
TI Acupuncture in cancer care.
SO Oncology (Williston Park, N.Y.)
LA English
DT Journal Article
NR 0
TC 0
SN 
EI 0890-909
J9 Oncology (Williston Park)
PD JUL 1
PY 2011
VL 25
IS 7 Suppl Nurse Ed
BP 
EP 
DI 
PG 0
WC Acupuncture Therapy; Hot Flashes; etiology; Humans; Nausea; etiology; Neoplasms; complications; Oncology Nursing; methods; Pain; etiology; Practice Guidelines as Topic; Risk Factors; Vomiting; etiology; Xerostomia; etiology
UT PubMed:25373274
PM 25373274
DA 2011-07-01
ER

PT J
AU Paley, CA
   Johnson, MI
   Bennett, MI
AF Paley, Carole A.
   Johnson, Mark I.
   Bennett, Michael I.
TI Should physiotherapists use acupuncture for treating patients with cancer-induced bone pain? A discussion paper
SO PHYSIOTHERAPY
LA English
DT Editorial Material
DE Acupuncture; Pain; Cancer; Metastases; Bone
ID rat model; complementary/alternative medicine; stimulation; morphine; brain; electroacupuncture; interleukin-1-beta; mechanisms; expression; analgesia
AB Background Patients suffering from pain due to bony metastases in cancer represent a challenge to the physiotherapist as part of the multidisciplinary team. Adequate pain relief improves quality of life and functional status, yet conventional analgesia often has undesirable side-effects and non-pharmacological treatments (e. g. some electrotherapies) may be contraindicated in cancer. Acupuncture is a potential treatment for cancer-induced bone pain (CIBP) as it has few side effects and is relatively easy to administer. There is a dearth of research on the use of acupuncture in treating CIBP and some practitioners express fears about treating cancer patients with acupuncture. Objectives To discuss the use of acupuncture for CIBP by reviewing the physiological rationale for using acupuncture to treat CIBP and the risks and benefits of using acupuncture in clinical practice. Data Sources Evidence was identified by searching seven major databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, PsycINFO, AMED and SPORTDiscus. Evidence was synthesised by the authors to raise issues and discussion points within a narrative review framework. Findings Available physiological evidence supports potentially efficacious effects of acupuncture for reduction of CIBP. Clinical literature suggests that acupuncture may be effective as an adjunctive treatment for CIBP and that risks are manageable. However, there is a need for well-designed randomised controlled trials to investigate efficacy and effectiveness in patients. Conclusions Acupuncture has the potential to provide sustained background analgesia and/or rapid onset analgesia for breakthrough pain if the appropriate points and techniques are used. (C) 2010 Chartered Society of Physiotherapy. Published by Elsevier Ltd. All rights reserved.
C1 [Paley, Carole A.] Airedale NHS Fdn Trust, Steeton BD20 6TD, Keighley, England.
   [Paley, Carole A.; Johnson, Mark I.] Leeds Metropolitan Univ, Fac Hlth, Leeds LS1 3HE, W Yorkshire, England.
   [Bennett, Michael I.] Univ Lancaster, Sch Hlth & Med, Int Observ End Life Care, Lancaster, England.
C3 Leeds Beckett University; Lancaster University
RP Paley, CA (corresponding author), Airedale NHS Fdn Trust, Skipton Rd, Steeton BD20 6TD, Keighley, England.
EM biodynamics.physiotherapy@tesco.net
CR Acupuncture Association of Chartered Physiotherapists, 2007, AACP GUID SAF PRACT, V0, P0
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2004, IMPR SUPP PALL CAR A, V0, P0
   Association of Chartered Physiotherapists in Oncology and Palliative Care, 2009, ROL PHYS ONC PALL CA, V0, P0
   Benham A, 2009, ACUPUNCT MED, V27, P65, DOI 10.1136/aim.2008.000174
   Bennett MI, 2010, J PAIN, V11, P351, DOI 10.1016/j.jpain.2009.08.002
   Bowsher D, 1987, ACUPUNCT MED, V4, P12
   CAMPBELL A, 1999, ACUPUNCT MED, V17, P124, DOI 10.1136/AIM.17.2.124
   Campbell A, 1999, ACUPUNCT MED, V17, P113, DOI 10.1136/AIM.17.2.113
   Campbell Anthony, 2006, ACUPUNCT MED, V24, P118
   Campbell Anthony, 2006, ACUPUNCT MED, V24, P169
   Carlsson Christer, 2002, ACUPUNCT MED, V20, P82
   Ceccherelli F, 2002, J ALTERN COMPLEM MED, V8, P341, DOI 10.1089/10755530260128032
   Chan Gunn C, 1989, ACUPUNCTURE IN MEDICINE, V6, P50
   CLEMENTJONES V, 1980, LANCET, V2, P946
   Clohisy DR, 2003, CANCER-AM CANCER SOC, V97, P866, DOI 10.1002/cncr.11144
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2006, CLIN CANCER RES, V12, P6243S, DOI 10.1158/1078-0432.CCR-06-0931
   Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9
   Colvin L, 2008, EUR J CANCER, V44, P1083, DOI 10.1016/j.ejca.2008.03.001
   Cummings M, 2007, BEST PRACT RES CL RH, V21, P367, DOI 10.1016/j.berh.2006.12.006
   Cummings TM, 2001, ARCH PHYS MED REHAB, V82, P986, DOI 10.1053/apmr.2001.24023
   Diel IJ, 2006, EJC SUPPL, V4, P1, DOI 10.1016/j.ejcsup.2006.07.001
   Dillon M, 1999, PALLIATIVE MED, V13, P253, DOI 10.1191/026921699667999073
   Donovan-Rodriguez T, 2005, ANESTHESIOLOGY, V102, P132, DOI 10.1097/00000542-200501000-00022
   Ernst E, 1997, PAIN, V71, P123, DOI 10.1016/S0304-3959(97)03368-X
   Ernst E, 2007, SUPPORT CARE CANCER, V15, P565, DOI 10.1007/s00520-006-0174-y
   Ernst E, 2003, EUR J CANCER, V39, P2273, DOI 10.1016/S0959-8049(03)00604-X
   Eustachi A, 2009, INTEGR CANCER THER, V8, P56, DOI 10.1177/1534735408327996
   Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583
   Filshie J, 2005, EJC SUPPL, V3, P107, DOI 10.1016/S1359-6349(05)80267-8
   Filshie J, 2001, ACUPUNCT MED, V19, P117
   FILSHIE J, 1990, ACUPUNCT MED, V8, P38
   Filshie Jacqueline, 2005, ACUPUNCT MED, V23, P171
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Freeman M, 2009, J BRACH PLEXUS PERIP, V0, P1
   Goblirsch MJ, 2005, J CELL BIOCHEM, V96, P682, DOI 10.1002/jcb.20589
   Guo HF, 1996, MOL BRAIN RES, V43, P157, DOI 10.1016/S0169-328X(96)00170-2
   HAN JS, 1986, ASIA PAC J PHARMACOL, V1, P17
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   HAN JS, 1982, ANNU REV PHARMACOL, V22, P193, DOI 10.1146/annurev.pa.22.040182.001205
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hopwood V, 2004, POSSIBLE ACUPUNCTURE, V0, P198
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F
   Johnson MI, 2010, EVIDENCE BASED CHRON, V0, P348
   Johnson Mark, 2007, REV PAIN, V1, P7, DOI 10.1177/204946370700100103
   Kerr DP, 2001, COMPLEMENT THER MED, V9, P21, DOI 10.1054/ctim.2000.0422
   Lai J, 2001, MOL INTERV, V1, P160
   Langevin HM, 2007, J ALTERN COMPLEM MED, V13, P355, DOI 10.1089/acm.2007.6351
   Langevin HM, 2006, HISTOCHEM CELL BIOL, V125, P487, DOI 10.1007/s00418-005-0138-1
   Le Bars D, 1991, ACUPUNCT MED, V9, P47, DOI 10.1136/AIM.9.2.47
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Leng G, 1999, PALLIATIVE MED, V13, P163, DOI 10.1191/026921699676243035
   Lipton Allan, 2004, J SUPPORT ONCOL, V2, P205
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304-3959(02)00102-1
   Lund I, 2002, EUR J NEUROSCI, V16, P330, DOI 10.1046/j.1460-9568.2002.02087.x
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   *MACM CANC REL, 2002, DIR COMPL THER SERV, V0, P0
   MacPherson H, 2001, ACUPUNCT MED, V19, P93
   MacPherson H, 2008, NEUROSCI LETT, V434, P144, DOI 10.1016/j.neulet.2008.01.058
   Mann F, 2000, REINVENTING ACUPUNCT, V0, P41
   Mantyh P, 2006, EJC SUPPL, V4, P4, DOI 10.1016/j.ejcsup.2006.07.003
   MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5
   Mcquay HJ, 2013, COCHRANE DATABASE SYST REV., V0, P0, DOI DOI 10.1002/14651858.CD001793.PUB2
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304-3959(96)03267-8
   Paley CA, 2009, COCHRANE DATABASE SY, V0, P0
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0
   Qaseem A, 2009, ANN INTERN MED, V150, P148
   RAMPES H, 1999, ACUPUNCTURE SCI APPR, V0, P128
   Ren K, 2009, BRAIN RES REV, V60, P57, DOI 10.1016/j.brainresrev.2008.12.020
   Robb KA, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub2
   Robertson VJ, 2006, ELECTROTHERAPY EXPLA, V0, P0
   Sandkuhler J, 1997, J NEUROSCI, V17, P6483
   Sandkühler J, 2000, PAIN, V88, P113, DOI 10.1016/S0304-3959(00)00424-3
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Speed CA, 2001, RHEUMATOLOGY, V40, P1331, DOI 10.1093/rheumatology/40.12.1331
   Suzuki R, 2005, NEUROSIGNALS, V14, P175, DOI 10.1159/000087656
   Theobald Dale E, 2004, CLIN CORNERSTONE, V6 Suppl 1D, PS15, DOI 10.1016/S1098-3597(05)80003-1
   Thompson JW, 2005, OXFORD TXB PALLIATIV, V0, P421
   TWYCROSS RG, 1995, CLIN ORTHOP RELAT R, V0, P187
   Urch CE, 2005, J PAIN, V6, P837, DOI 10.1016/j.jpain.2005.08.005
   Urch CE, 2003, PAIN, V106, P347, DOI 10.1016/j.pain.2003.08.002
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   White A, 2001, ACUPUNCT MED, V19, P84
   White A, 1999, ACUPUNCTURE - A SCIENTIFIC APPRAISAL, V0, P60
   White A, 2008, AN INTRODUCTION TO WESTERN MEDICAL ACUPUNCTURE, V0, P0
   White A, 2009, PREPARATION TREATMEN, V0, P127
   White A, 2008, NEUROLOGICAL MECH, V0, P51
   WILLER JC, 1989, J NEUROPHYSIOL, V62, P1028, DOI 10.1152/jn.1989.62.5.1028
   Wu MT, 1999, RADIOLOGY, V212, P133, DOI 10.1148/radiology.212.1.r99jl04133
   Zhang RX, 2008, NEUROSCIENCE, V154, P1533, DOI 10.1016/j.neuroscience.2008.04.072
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   ZHOU ZF, 1981, SCI SINICA, V24, P1166
NR 99
TC 6
Z9 9
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0031-9406
EI 1873-1465
J9 PHYSIOTHERAPY
JI Physiotherapy
PD SEP 15
PY 2011
VL 97
IS 3
BP 256
EP 263
DI 10.1016/j.physio.2010.08.008
PG 8
WC Rehabilitation
SC Rehabilitation
GA 803GF
UT WOS:000293569100012
PM 21820545
DA 2026-01-16
ER

PT J
AU Park, JW
   Jeon, JH
   Yoon, J
   Jung, TY
   Kwon, KR
   Cho, CK
   Lee, YW
   Sagar, S
   Wong, R
   Yoo, HS
AF Park, Jae-Woo
   Jeon, Ju-Hyun
   Yoon, Jeungwon
   Jung, Tae-Young
   Kwon, Ki-Rok
   Cho, Chong-Kwan
   Lee, Yeon-Weol
   Sagar, Stephen
   Wong, Raimond
   Yoo, Hwa-Seung
TI Effects of sweet bee venom pharmacopuncture treatment for chemotherapy-induced
SO Integrative cancer therapies
LA English
DT Journal Article
AB OBJECTIVE: This is a case series reporting safety and degree of response to 1  dose level of sweet bee venom pharmacopuncture (SBVP) or melittin as a  symptom-control therapy for chemotherapy-induced peripheral neuropathy (CIPN).  SETTING: All treatments were conducted at the East West Cancer Center (EWCC),  Dunsan Oriental Hospital, Daejeon University, Republic of Korea, an institution  that uses complementary therapies for cancer patients. METHODS: Five consecutive  patients with CIPN were referred to the EWCC from March 20, 2010, to April 10,  2010. Patients with World Health Organization Chemotherapy-Induced Peripheral  Neuropathy (WHO CIPN) grade 2 or more were treated with SBVP for 3 treatment  sessions over a 1-week period. Measures of efficacy and safety. Validated Visual  Analog System (VAS) pain scale, WHO CIPN grade, and Functional Assessment of  Cancer Therapy-General (FACT-G) were compared before and after the 1-week course  of treatment. To ensure the safety of SBVP, pretreatment skin response tests were  given to patients to avoid any potential anaphylactic adverse effects. All  patients were closely examined for any allergenic responses following each  treatment session. RESULTS: One patient discontinued treatment after the first  session, and 4 patients completed all treatment sessions. Using each patient as  their own comparator, marked improvements of VAS, WHO CIPN grade, and physical  section scores of FACT-G were seen in 3 patients. Most important, there were no  related adverse side effects found. CONCLUSION: This safety results of the SBVP  therapy merits further investigations in a larger size trial for it to develop  into a potential intervention for managing CIPN symptoms. This study will be  extended to a dose-response evaluation to further establish safety and response,  prior to a randomized trial.
C1 Daejeon University, Daejeon, Korea.
NR 0
TC 0
SN 1552-695
EI 
J9 Integr Cancer Ther
PD JUL 1
PY 2011
VL 11
IS 2
BP 166
EP 71
DI 10.1177/1534735411413265
PG -95
WC Acupuncture Therapy; adverse effects; Antineoplastic Agents; adverse effects; Bee Venoms; administration & dosage; Female; Humans; Melitten; administration & dosage; Middle Aged; Neoplasms; drug therapy; Pain Measurement; methods; Peripheral Nervous System Diseases; chemically induced; Prospective Studies; Republic of Korea
UT PubMed:21715371
PM 21715371
DA 2011-07-01
ER

PT J
AU Donald, GK
   Tobin, I
   Stringer, J
AF Donald, Graeme K
   Tobin, Irene
   Stringer, Jacqui
TI Evaluation of acupuncture in the management of chemotherapy-induced peripheral
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
AB AIM: To clinically evaluate the effectiveness of acupuncture when used in the  management of chemotherapy-induced peripheral neuropathy (PN). BACKGROUND: During  cancer treatment, certain chemotherapies can cause varying degrees of PN.  Patients' quality of life can be seriously impaired through loss of sensation,  pain or mobility problems. Conventional medications routinely used to manage  neuropathic symptoms have poor side-effect profiles and there is little or no  evidence justifying their use to treat chemotherapy-related neurotoxicities.  There are studies suggesting that acupuncture may be an effective therapy in  treating PN across a number of different aetiologies. Design A retrospective  service evaluation. METHOD: Patients (n=18) were referred for acupuncture by the  medical staff and/ornurse specialists or they self-referred for treatment. A  course of six weekly acupuncture sessions was offered to them, and their details  were recorded on an evaluation form prior to session one. Points were selected by  acupuncturists, based on patient presentation, and needles remained in situ for  30-45 min. Treatments took place in outpatient clinics, chemotherapy day case  ward or a drop-in clinic based in a physiotherapy gym. The evaluation form was  completed at the end of session 6 by a therapist who had not been involved in  patient care. RESULTS: 82% (n=14) of patients reported an improvement in symptoms  following their course of acupuncture; one patient with advanced disease died  during the 6 weeks. Some patients derived additional benefits from the treatment  including a reduction in analgesic use and improved sleeping patterns. The most  common acupoints used were SP6 (n=18), ST36 (n=18) and LV3 (n=14). CONCLUSION:  Although these results are encouraging, they are uncontrolled. They suggest that  acupuncture could be an option for these patients and controlled trials using  validated patient-reported outcome measures are justified.
C1 Complementary Therapy Service, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. graeme.donald@christie.nhs.uk
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD AUG 31
PY 2011
VL 29
IS 3
BP 230
EP 3
DI 10.1136/acupmed.2011.010025
PG -227
WC Acupuncture Therapy; Adult; Aged; Antineoplastic Agents; adverse effects; Female; Humans; Male; Middle Aged; Neoplasms; complications; Peripheral Nervous System Diseases; etiology
UT PubMed:21875929
PM 21875929
DA 2011-08-31
ER

PT J
AU Dobos, G
   Tao, I
AF Dobos, Gustav
   Tao, Iven
TI The Model of Western Integrative Medicine: The Role of Chinese Medicine
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE integrative medicine; complementary and alternative medicine; traditional Chinese medicine; integrative oncology; evidence-based medicine; Chinese herbal medicine; acupuncture
ID rheumatoid-arthritis; controlled-trials; vegetarian diet; research design; leech therapy; tai chi; acupuncture; cancer; osteoarthritis; metaanalysis
AB The basic concept of integrative medicine (IM) is that by combining mainstream (biomedicine) with complementary and alternative medicine (CAM), synergistic therapeutic effects can be attained. When the methods of mind/body medicine (MBM) are added to this combination, as in Western countries, a new concept emerges that drastically changes the approach toward illness. It is interesting to note that the joining of traditional Chinese medicine and Western medicine in the early days of the Peoples' Republic of China preceded the Western model of IM by almost 50 years. Several elements that make up the key components of IM as practiced today in the West were already present in the Chinese version of IM, and Chinese medicine has played and continues to play an important role in advancing IM. However, one of the major differences between the Chinese and the Western models of IM today, besides MBM and some other treatment options, is that Western integrative medicine (WIM) strictly requires its CAM methods to be supported by scientific evidence. The therapeutic methods of IM and their applications are many and varied. However, they are most frequently employed to treat chronic medical conditions, e.g., bronchial asthma, rheumatic disease, chronic inflammatory bowel disorder and chronic pain. Other fields in which IM may be applied are internal medicine (inflammatory bowel diseases and cardiovascular diseases), musculoskeletal disorders, oncology (chemotherapy-induced side effects), obstetrics and gynecology (dysmenorrhea, endometriosis, infertility and menopausal complaints), pediatrics, geriatrics, neurology (migraine and chronic headache), and psychiatry (anxiety and depression). The concept of WIM is discussed here in detail by reviewing its scope and implications for the practice of medicine and focusing on the role of Chinese medicine in WIM.
C1 [Dobos, Gustav; Tao, Iven] Univ Duisburg Essen, Dept Complementary & Integrat Med, Kliniken Essen Mitte, Knappschafts Krankenhaus, D-45276 Essen, Germany.
C3 Kliniken Essen-Mitte; University of Duisburg Essen
RP Dobos, G (corresponding author), Univ Duisburg Essen, Dept Complementary & Integrat Med, Kliniken Essen Mitte, Knappschafts Krankenhaus, Deimelsberg 34A, D-45276 Essen, Germany.
EM gustav.dobos@uni-duisburg-essen.de
CR Allensbach Poll (Umfrage), 2005, INT MED TRAD CHIN ME, V0, P0
   Unknown -, 2004, **DROPPED REF**, V0, P0
   Unknown -, 1900, DOI 10.1002/14651858.CD001929.PUB2, V0, P0
   Unknown -, 2005, COCHRANE DB SYST REV, V0, P0
   Antonovsky A, 1987, UNRAVELING THE MYSTERY OF HEALTH, V0, P0
   Astin JA, 2003, J AM BOARD FAM PRACT, V16, P131, DOI 10.3122/jabfm.16.2.131
   Benson H, 2000, RELAXATION RESPONSE, V0, P0
   Benson H, 1993, THE WELLNESS BOOK: THE COMPREHENSIVE GUIDE TO MAINTAINING HEALTH AND TREATING STRESSRELATED ILLNESS, V0, P0
   Berman BM, 2010, NEW ENGL J MED, V363, P454, DOI 10.1056/NEJMct0806114
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Cheong YC, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006920.pub2
   Cramp F, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006145.pub2
   Cutolo M, 2006, NEUROIMMUNOMODULAT, V13, P277, DOI 10.1159/000104855
   Diener HC, 2006, LANCET NEUROL, V5, P310, DOI 10.1016/S1474-4422(06)70382-9
   Dieterle S, 2009, FERTIL STERIL, V92, P1340, DOI 10.1016/j.fertnstert.2009.02.041
   Dobos G, 2006, BUNDESGESUNDHEITSBLATT GESUNDHEITSFORSCHUNG GESUNDHEITSSCHUTZ, V49, P723, DOI 10.1007/s00103-006-0001-0
   Dobos G, 2006, TREATING CHRONIC DIS, V0, P0
   Dobos G, 2010, ESS CONS C 2009 FUT, V0, P0
   Dobos G, 2009, EUR J INTEGR MED, V1, P109, DOI 10.1016/j.eujim.2009.08.001
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Ernst E, 1997, AM J CHINESE MED, V25, P3, DOI 10.1142/S0192415X97000032
   Gatenby RA, 2009, CANCER RES, V69, P4894, DOI 10.1158/0008-5472.CAN-08-3658
   Gillespie LD, 2009, COCHRANE DB SYST REV, V2, P0
   Goldberg RJ, 2007, PAIN, V129, P210, DOI 10.1016/j.pain.2007.01.020
   HOFFMAN JW, 1982, SCIENCE, V215, P190, DOI 10.1126/science.7031901
   Kabat-Zin Jon, 1990, FULL CATASTROPHE LIV, V0, P0
   Kabat-Zinn J, 1987, CLINICAL JOURNAL OF PAIN, V2, P159, DOI 10.1097/00002508-198602030-00004
   KJELDSENKRAGH J, 1991, LANCET, V338, P899, DOI 10.1016/0140-6736(91)91770-U
   Klose P, 2009, EUR J INTEGR MED, V1, P247
   Koller M, 2006, MMW FORTSCHR MED, V148, P51
   Kuhn ThomasS, 1964, THE STRUCTURE OF SCIENTIFIC REVOLUTIONS, V0, P0
   Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200
   Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795
   Lu AP, 2008, CHIN J INTEGR MED, V14, P234, DOI 10.1007/s11655-008-240-z
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Matthiessen PF, 2008, FORSCH KOMPLEMENTMED, V15, P248, DOI 10.1159/000154039
   McCulloch M, 2006, J CLIN ONCOL, V24, P419, DOI 10.1200/JCO.2005.03.6392
   McIntosh H, 2000, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD000527
   Melchart D, 2006, HEADACHE, V46, P632, DOI 10.1111/j.1526-4610.2006.00365.x
   Melchart D, 2007, NATUROPATHIC TREATME, V0, P0
   Melchart D, 2008, FORSCH KOMPLEMENTMED, V15, P308, DOI 10.1159/000166749
   Michalsen A, 2003, ANN INTERN MED, V139, P724, DOI 10.7326/0003-4819-139-9-200311040-00006
   Michalsen A, 2008, PAIN, V137, P452, DOI 10.1016/j.pain.2008.03.012
   Michalsen A, 2009, J PAIN, V10, P601, DOI 10.1016/j.jpain.2008.12.013
   MOBUS S, 2006, CHRONISCHE ERKRANKUN, V0, P0
   Müller H, 2001, SCAND J RHEUMATOL, V30, P1, DOI 10.1080/030097401750065256
   Pradhan EK, 2007, ARTHRIT RHEUM-ARTHR, V57, P1134, DOI 10.1002/art.23010
   Rakel D, 2007, INTEGRATIVE MED, V0, P5
   REILLY RP, 1989, AM J PHYS MED REHAB, V68, P196, DOI 10.1097/00002060-198908000-00009
   Sackett DL, 1997, BRIT MED J, V315, P1636, DOI 10.1136/bmj.315.7123.1636
   Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71
   Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005
   Schwickert M, 2006, FORSCH KOMP KLAS NAT, V13, P184, DOI 10.1159/000093449
   Shang AJ, 2007, INT J EPIDEMIOL, V36, P1086, DOI 10.1093/ije/dym119
   Sobel DS, 2000, JAMA-J AM MED ASSOC, V284, P1705, DOI 10.1001/jama.284.13.1705
   Song Juan-juan, 2006, CHIN J INTEGR MED, V12, P312, DOI 10.1007/s11655-001-0312-9
   Tang JL, 1999, BMJ-BRIT MED J, V319, P160, DOI 10.1136/bmj.319.7203.160
   Taylor K, 2000, THESIS U CAMBRIDGE, V0, P0
   Thomas R, 2008, CHIN J INTEGR MED, V14, P194, DOI 10.1007/s11655-008-0194-1
   Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5
   Wang CC, 2010, NEW ENGL J MED, V363, P743, DOI 10.1056/NEJMoa0912611
   Wang CZ, 2007, CANCER CHEMOTH PHARM, V60, P69, DOI 10.1007/s00280-006-0350-2
   Wang QA, 1998, JAMA-J AM MED ASSOC, V280, P283, DOI 10.1001/jama.280.3.283
   Wesa K, 2008, HEMATOL ONCOL CLIN N, V22, P343, DOI 10.1016/j.hoc.2008.02.002
   WILLICH S, 2009, NATURA MED, V1, P22
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Xu H, 2008, J ALTERN COMPLEM MED, V14, P3, DOI 10.1089/acm.2006.6329
   Zhang ZT, 1990, SELECTED MED HLTH RE, V0, P0
   Zhao YT, 2009, ANN MED, V41, P301, DOI 10.1080/07853890802698834
   Zuger A, 2004, NEW ENGL J MED, V350, P69, DOI 10.1056/NEJMsr031703
NR 70
TC 65
Z9 86
U1 1
U2 114
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD JAN 15
PY 2011
VL 17
IS 1
BP 11
EP 20
DI 10.1007/s11655-011-0601-x
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 705ID
UT WOS:000286121200003
PM 21258891
DA 2026-01-16
ER

PT J
AU Kim, HS
   Park, IH
   Seo, SH
   Han, I
   Cho, HS
AF Kim, Han-Soo
   Park, Il Hyung
   Seo, Sung Hwa
   Han, Ilkyu
   Cho, Hwan Seong
TI Multifocal Infection of Mycobacterium Other Than Tuberculosis Mimicking a Soft Tissue Tumor of the Extremity
SO ORTHOPEDICS
LA English
DT Article
AB Mycobacterium other than tuberculosis infections rarely develop in healthy individuals, but direct inoculation such as contaminated acupuncture can cause mycobacteriosis even in an immunocompetent host. A 56-year-old woman gradually developed pain on the anterior aspect of the left knee and the distal thigh after hiking without trauma. She received acupuncture for 3 consecutive days on the bilateral knees at the suprapatellar and infrapopliteal areas. After acupuncture, mild localized heat and painful swelling developed around the knees bilaterally. Magnetic resonance imaging (MRI) demonstrated soft tissue masses with a lobulated contour at the prefemoral fat between the suprapatellar pouch and the distal femur and at the proximal tibia behind the knee joint capsule. Fibromatosis, pigmented villonodular synovitis, and soft tissue sarcoma were considered. On pathologic examination, multiple granulomas with lymphoplasmatic infiltration were evident, and acid-fast bacteria staining revealed acid-fast bacilli. A mycobacterial culture confirmed Mycobacterium other than tuberculosis infection, and a polymerase chain reaction-fragment length polymorphism assay identified the isolates as Mycobacterium abscessus. After treatment with appropriate antibiotics, the patient had no evidence of disease and reported no pain during activities of daily living. Acupuncture is growing in prominence in Europe and the United States, and the number of reports on complications increases with its widespread use. Although the risk to an individual patient is difficult to determine, acupuncture may cause serious complications in patients with coagulopathy, heart valve disease, and immune deficiency. In addition, direct inoculation such as contaminated acupuncture can cause mycobacteriosis even in an immunocompetent host.
C1 [Kim, Han-Soo; Han, Ilkyu; Cho, Hwan Seong] Seoul Natl Univ, Coll Med, Dept Orthoped Surgety, Seoul, South Korea.
   [Park, Il Hyung] Kyungpook Natl Univ, Sch Med, Dept Orthoped Surgery, Taegu, South Korea.
   [Seo, Sung Hwa] Kyungpook Natl Univ, Dept Biomed Sci, Taegu, South Korea.
C3 Seoul National University (SNU); Kyungpook National University (KNU); Kyungpook National University (KNU)
RP Cho, HS (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Orthoped Surg, 166 Gumi Ro Bundang Gu, Songnam 463707, Gyeonggi Do, South Korea.
EM mdchs111@snu.ac.kr
NR 0
TC 5
Z9 7
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0147-7447
EI 
J9 ORTHOPEDICS
JI Orthopedics
PD DEC 15
PY 2011
VL 34
IS 12
BP 1007
EP 1007
DI 10.3928/01477447-20111021-31
PG 1
WC Orthopedics
SC Orthopedics
GA 864AJ
UT WOS:000298209100040
DA 2026-01-16
ER

PT J
AU Paley, CA
   Tashani, OA
   Bagnall, AM
   Johnson, MI
AF Paley, Carole A
   Tashani, Osama A
   Bagnall, Anne-Marie
   Johnson, Mark I
TI A Cochrane systematic review of acupuncture for cancer pain in adults.
SO BMJ supportive & palliative care
LA English
DT Journal Article
AB BACKGROUND: Cancer-related pain is a significant and debilitating problem.  Non-pharmacological treatments such as acupuncture may have an adjunctive role in  controlling pain without the undesirable side effects of drug regimens and yet  the evidence base remains limited. OBJECTIVES: The main objective of this  systematic review was to evaluate the effectiveness of acupuncture in the  management of cancer-related pain in adults. Subgroup analyses were planned for  acupuncture dose and for the outcome of studies investigating acupuncture for  cancer-induced bone pain. METHODS: Six electronic databases were searched,  including the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE,  PsycINFO, AMED and SPORTDiscus. Studies included in the review were randomised  controlled trials investigating the use of acupuncture for cancer pain using pain  as a primary outcome measure. In total, 253 published references were identified  but only three studies met the inclusion criteria and were included in the final  review. RESULTS: Of the three included studies, only one was judged to be of high  methodological quality and showed auricular acupuncture to be superior to placebo  acupuncture and ear seeds at placebo points. However, the study was relatively  small and blinding was compromised. The two low-quality studies gave positive  results in favour of acupuncture for cancer pain, but these results should be  viewed with caution due to methodological limitations, small sample sizes, poor  reporting and inadequate analysis. CONCLUSION: There is insufficient evidence to  judge whether acupuncture is effective in treating cancer pain in adults.
C1 Research & Effectiveness Department, Airedale NHS Foundation Trust, Steeton, Keighley, UK.
NR 0
TC 0
SN 2045-436
EI 
J9 BMJ Support Palliat Care
PD JUN 1
PY 2011
VL 1
IS 1
BP 51
EP 5
DI 10.1136/bmjspcare-2011-000022
PG -46
WC Acupuncture Therapy; methods; Acupuncture, Ear; methods; Adult; Humans; Neoplasms; complications; Pain; etiology; Pain Management; methods; Treatment Outcome
UT PubMed:24653050
PM 24653050
DA 2011-06-01
ER

PT J
AU González-Escalada, JR
   Camba, A
   Casas, A
   Gascón, P
   Herruzo, I
   Núñez-Olarte, JM
   Ramos-Aguerri, A
   Trelis, J
   Torres, LM
AF Ramon Gonzalez-Escalada, Jose
   Camba, Alberto
   Casas, Ana
   Gascon, Pere
   Herruzo, Ismael
   Manuel Nunez-Olarte, Juan
   Ramos-Aguerri, Alfredo
   Trelis, Jordi
   Miguel Torres, Luis
TI Good clinical practice guide for control of oncological pain
SO MEDICINA PALIATIVA
LA Spanish
DT Article
DE Oncological pain; Breakthrough pain; Cancer; Opioids; Fentanyl
ID quality-of-care; cancer pain; breakthrough pain; intrathecal ziconotide; analgesic ladder; randomized-trial; management; morphine; therapy; opioids
AB Patients with cancer often do not mention their pain as they are afraid that the doctor will be distracted towards this symptom instead of focusing on the treatment of their primary disease. However, should know that the treatment of their pain not only does it not interfere with their remedial therapy, but also contributes to it. It is usual, among patients, to be afraid that the advance of the disease may lead to situations of unsustainable suffering which may exceed all the medical possibilities, but it is our duty to help them to be aware that medicine offers a wide range of treatments to relieve their pain and prevent them suffering. This knowledge is essential to increase their confidence in the treatment and to improve the doctor-patient relationship. Faced with this challenge, the Spanish Society of Palliative Care, the Spanish Pain Society, the Spanish Medical Oncology Society, and the Spanish Society of Radiotherapeutic Oncology, have joined forces and created ALIADO (Alliance Against Oncological Pain), a multidisciplinary working group which was founded with the purpose of raising the awareness and involving all medical groups in the need to improve the quality of life of the patient with oncological pain. The first initiative of ALIADO in this direction, is the preparation of a good practice code for the treatment of oncological pain, which attempts to contribute to the advance of knowledge and treatment of these patients. (C) 2011 Sociedad Espanola de Cuidados Paliativos. Published by Elsevier Espana, S.L. All rights reserved.
C1 [Miguel Torres, Luis] Hosp Univ Puerto del Mar, Serv Anestesia Reanimac & Tratamiento Dolor, Cadiz, Spain.
   [Trelis, Jordi] Hosp Badalona Germans Trias & Pujol, Inst Catalan Oncol, Serv Soporte Integral & Cuidados Paliat, Badalona, Spain.
   [Ramos-Aguerri, Alfredo] Hosp Ramon & Cajal, Serv Oncol Radioterap, E-28034 Madrid, Spain.
   [Manuel Nunez-Olarte, Juan] Hosp Gen Univ Gregorio Maranon, Unidad Cuidados Paliat, Madrid, Spain.
   [Gascon, Pere] Hosp Clin Barcelona, Med Oncol Serv, Barcelona, Spain.
   [Casas, Ana] Hosp Virgen del Rocio, Serv Oncol, Seville, Spain.
   [Camba, Alberto] CHA Marcide, Serv Anestesiol Reanimac & Tratamiento Dolor, La Coruna, Spain.
   [Camba, Alberto] SED, La Coruna, Spain.
   [Ramon Gonzalez-Escalada, Jose] Hosp Ramon & Cajal, Unidad Dolor, E-28034 Madrid, Spain.
   [Herruzo, Ismael] Hosp Carlos Haya, Serv Oncol Radioterap, Malaga, Spain.
   [Herruzo, Ismael] SEOR, Malaga, Spain.
C3 Universidad de Cadiz; Hospital Universitario Puerta del Mar; Hospital Germans Trias i Pujol; Institut Catala d'Oncologia; Hospital Universitario Ramon y Cajal; General University Gregorio Maranon Hospital; University of Barcelona; Hospital Clinic de Barcelona; Virgen del Rocio University Hospital; Hospital Universitario Ramon y Cajal; Hospital Regional Universitario de Malaga
RP Torres, LM (corresponding author), Hosp Univ Puerto del Mar, Serv Anestesia Reanimac & Tratamiento Dolor, Cadiz, Spain.
EM lmtorres@arrakis.es
CR Unknown -, 1999, RADIOTHER ONCOL, V52, P111, DOI 10.1016/S0167-8140(99)00097-3
   Unknown -, 1986, CANC PAIN REL, V0, P0
   Unknown -, 2005, REC REC 2003 24 COM, V0, P0
   Unknown -, 2007, ESTR NAC SAL CUID PA, V0, P35
   Unknown -, 2006, SEMFYC, V38, P1
   Unknown -, 2003, IJRBOP, V55, P594
   Apolone G, 2009, BRIT J CANCER, V100, P1566, DOI 10.1038/sj.bjc.6605053
   Appelgren L, 1997, J PAIN SYMPTOM MANAG, V13, P25, DOI 10.1016/S0885-3924(96)00203-5
   Bernhard J, 2008, J CLIN ONCOL, V26, P3695, DOI 10.1200/JCO.2007.15.6240
   Bilbeny N, 1990, ASPECTOS BASICOS CLI, V0, P87
   BREITBART W, 1989, CANCER, V63, P2336, DOI 10.1002/1097-0142(19890601)63:11<2336::AID-CNCR2820631144>3.0.CO;2-7
   Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55
   Bruera E, 2003, JAMA-J AM MED ASSOC, V290, P2476, DOI 10.1001/jama.290.18.2476
   BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z
   Bugedo G, 1989, REV CHIL ANESTESIA, V18, P132
   Burton AW, 2007, PAIN MED, V8, P189, DOI 10.1111/j.1526-4637.2006.00220.x
   Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa
   Casinello J, 2005, GUIA RAPIDA TRATAMIE, V0, P0
   Cassell EJ, 2008, PALLIATIVE MED, V0, P46
   CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9
   Chen ML, 2004, PALLIATIVE MED, V18, P712, DOI 10.1191/0269216304pm950oa
   Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542
   CHERNY NI, 1994, CA-CANCER J CLIN, V44, P262, DOI 10.3322/canjclin.44.5.263
   Cleeland CS, 2000, INT J RADIAT ONCOL, V47, P203, DOI 10.1016/S0360-3016(99)00276-X
   Collado A, 2004, REV SOC ESPAR IOLA D, V11, P203
   Cormie P J, 2008, BMJ: BRITISH MEDICAL JOURNAL, V337, P1106
   Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   Fainsinger RL, 2009, J CLIN ONCOL, V27, P585, DOI 10.1200/JCO.2008.17.1660
   Fisch MJ, 2007, CANC PAIN MANAGEMENT, V0, P0
   Foley K, 2004, OXFORD TEXTBOOK OF PALLIATIVE MEDICINE, V0, P298
   Foley K, 2003, OXFORD TXB PALLIATIV, V0, P0
   Forbes Karen, 2006, J PAIN PALLIAT CARE PHARMACOTHER, V20, P33, DOI 10.1300/J354v20n03_08
   Fuentes, 2003, TRATAMIENTO SOPORTE, V0, P0
   Geppetti P, 2009, CLIN DRUG INVEST, V29, P3, DOI 10.2165/0044011-200929001-00002
   Given B, 2008, J PAIN SYMPTOM MANAG, V35, P126, DOI 10.1016/j.jpainsymman.2007.03.012
   Glare P, 2008, PALLIATIVE MED, V0, P657
   Gómez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9
   Gordon DB, 2005, ARCH INTERN MED, V165, P1574, DOI 10.1001/archinte.165.14.1574
   Grande LA, 2008, ANESTH ANALG, V107, P1380, DOI 10.1213/ane.0b013e3181733ddd
   Grossman SA, 2008, ABELOFFS CLIN ONCOLO, V0, P565
   Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680
   Hartsell WF, 2005, JNCI-J NATL CANCER I, V97, P798, DOI 10.1093/jnci/dji139
   Hassenbusch SJ, 2000, J PAIN SYMPTOM MANAG, V20, PS4, DOI 10.1016/S0885-3924(00)00203-7
   Hauser K, 2008, PALLIATIVE MED, V0, P325
   Higginson I, 2008, CLIN PAIN MANAGEMENT, V0, P13
   Ho ST, 2002, ANESTH ANALG, V95, P948, DOI 10.1097/00000539-200210000-00029
   Hojsted J, 2007, EUR J PAIN, V11, P490, DOI 10.1016/j.ejpain.2006.08.004
   HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8
   Huskisson EC, 1983, PAIN MEASUREMENT ASS, V0, P33
   JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870
   KATZ J, 1992, ANESTHESIOL CLIN N A, V10, P229
   Shahi PK, 2007, AN MED INTERN, V24, P554
   Levy MH, 2005, SEMIN ONCOL, V32, P179, DOI 10.1053/j.seminoncol.2005.02.004
   Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507
   Lichtental WG, 2008, PALLIATIVE MED, V0, P55
   Maltoni M, 2005, SUPPORT CARE CANCER, V13, P888, DOI 10.1007/s00520-005-0807-6
   Martinez Martinez B, 2003, TRATAMIENTOS CON EFE, V0, P296
   MCQUAY HJ, 2002, COCHRANE LIB, V0, P0
   Mercadante S, 2006, EUR J PAIN, V10, P153, DOI 10.1016/j.ejpain.2005.02.006
   Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249
   Mercadante S, 2008, PALLIATIVE MED, V0, P1425
   Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001
   Minguez Marti A, 1999, FARM HOSP, V23, P313
   Ministerio de Sanidad y Consumo SECPAL, 2002, GUI CRIT CAL CUID PA, V0, P0
   Monsalve V, 2006, PSICOONCOLOGIA, V3, P139
   Newsome S, 2008, CURR PAIN HEADACHE R, V12, P249, DOI 10.1007/s11916-008-0043-0
   Novy D, 2005, J PAIN SYMPTOM MANAG, V29, P603, DOI 10.1016/j.jpainsymman.2004.09.005
   Ohnhanus E, 1975, PAIN, V1, P374
   Olsen AK, 1996, EUR J PALLIAT CARE, V3, P139
   Polati E, 2008, TRANSPL P, V40, P1200, DOI 10.1016/j.transproceed.2008.03.115
   PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W
   PORTENOY RK, 1992, CANCER-AM CANCER SOC, V70, P1616, DOI 10.1002/1097-0142(19920915)70:6<1616::AID-CNCR2820700630>3.0.CO;2-7
   Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0
   Portenoy RK, 2008, PALLIATIVE MED, V0, P438
   Pu L, 2002, J NEUROSCI, V22, P1914, DOI 10.1523/JNEUROSCI.22-05-01914.2002
   Rainone F, 2004, J AM BOARD FAM PRACT, V17, PS48, DOI 10.3122/jabfm.17.suppl_1.S48
   Randall F, 2008, CLIN PAIN MANAGEMENT, V0, P93
   Ratanatharathorn, 1999, METAANALISIS IJRBOP, V44, P1
   Reich M, 2008, CURR OPIN ONCOL, V20, P353, DOI 10.1097/CCO.0b013e3282fc734b
   Rose, 1998, IJRBOP, V40, P117
   Roth Andrew J, 2007, CURR OPIN SUPPORT PALLIAT CARE, V1, P50, DOI 10.1097/SPC.0b013e32813aeb23
   SCHUG SA, 1992, J PAIN SYMPTOM MANAG, V7, P259, DOI 10.1016/0885-3924(92)90059-Q
   SEES KL, 1993, J PAIN SYMPTOM MANAG, V8, P257, DOI 10.1016/0885-3924(93)90154-N
   Sepúlveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2
   SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H
   Sharpe M, 2004, BRIT J CANCER, V90, P314, DOI 10.1038/sj.bjc.6601578
   Smith WB, 1998, PAIN, V78, P123, DOI 10.1016/S0304-3959(98)00122-5
   Staats PS, 2001, NEUROMODULATION, V4, P121, DOI 10.1046/j.1525-1403.2001.00121.x
   Staats PS, 2004, JAMA-J AM MED ASSOC, V291, P63, DOI 10.1001/jama.291.1.63
   Stark D, 2002, J CLIN ONCOL, V20, P3137, DOI 10.1200/JCO.2002.08.549
   Steenland E, 1999, RADIOTHER ONCOL, V52, P101, DOI 10.1016/S0167-8140(99)00110-3
   Steinman R, 2009, IASP, V17, P0
   Stjernsward J, 2008, PALLIATIVE MED, V0, P2
   Strong V, 2008, LANCET, V5, P8
   Thomas JR, 2003, CNS DRUGS, V17, P621, DOI 10.2165/00023210-200317090-00002
   Trelis J, 2004, REV SOC ESP DOLOR, V11, P184
   Uchida K, 2009, PAIN PHYSICIAN, V12, P0
   VENTAFRIDDA V, 1987, CANCER-AM CANCER SOC, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1
   von Moos R, 2008, SUPPORT CARE CANCER, V16, P1105, DOI 10.1007/s00520-008-0487-0
   Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa
   Walker J, 2009, TRIALS, V10, P0, DOI 10.1186/1745-6215-10-18
   Walker SM, 2002, ANESTH ANALG, V95, P674, DOI 10.1213/01.ANE.0000023209.14008.5B
   WALLER A, 1996, HDB PALLIATIVE CARE, V0, P0
   Wandler E, 2005, AM J ROENTGENOL, V185, P797, DOI 10.2214/ajr.185.3.01850797
   Whitecar PS, 2000, AM FAM PHYSICIAN, V61, P755
   William L, 2008, DRUGS, V68, P913, DOI 10.2165/00003495-200868070-00003
   Zech DF, 2005, PAIN, V63, P65
   ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M
   Zeppetella G, 2009, CURR OPIN SUPPORT PA, V0, P31
   ZHUKOVSKY DS, 1995, J PAIN SYMPTOM MANAG, V10, P113, DOI 10.1016/0885-3924(94)00072-S
NR 114
TC 1
Z9 1
U1 0
U2 1
PU ARAN EDICIONES, S A
PI MADRID
PA CASTELLO, 128, 28006 MADRID, SPAIN
SN 1134-248X
EI 
J9 MED PALIATIVA
JI Med. Paliativa.
PD APR-JUN 15
PY 2011
VL 18
IS 2
BP 63
EP 79
DI 
PG 17
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 871BM
UT WOS:000298712600005
DA 2026-01-16
ER

PT J
AU Brulé, S
AF Brulé, Sabine
TI [Auriculotherapy, an anodyne technique in oncology].
SO Soins; la revue de reference infirmiere
LA fre
DT Journal Article
AB Auriculotherapy is a complementary therapy recommended for the treatment of  chronic pain. Effectively, the whole of the body's innervation territory is  mapped out on the ear auricles, "connected" on the level of the brainstem, the  relay station of all the body's sensory information. The therapy consists in  inserting semi-permanent needles or localised stimulations in the auricles. The  ear point is determined on the basis of neurophysiological reasoning.
C1 Centre anticancéreux de l'Institut Gustave Roussy, Villejuif. sabine.brule@wanadoo.fr
NR 0
TC 0
SN 
EI 0038-081
J9 Soins
PD OCT 19
PY 2011
VL 0
IS 758
BP 45
EP 6
DI 
PG -39
WC Acupuncture Points; Acupuncture, Ear; nursing; Auriculotherapy; nursing; Chronic Pain; nursing; Ear, External; innervation; France; Neoplasms; nursing; Neuralgia; nursing; Reflexotherapy; nursing; Treatment Outcome
UT PubMed:22003795
PM 22003795
DA 2011-10-19
ER

PT J
AU Paloni, EDMP
   Alves, FB
   Morais, AD
   Pereira, ML
   Bahmdouni, L
AF Paloni, E. D. M. P.
   Bonachela Alves, F.
   Morais, A. D.
   Pereira, M. L.
   Bahmdouni, L.
TI THE COST OF STRONG OPIOID TREATMENT OF ONCOLOGICAL PAIN IN THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Paloni, E. D. M. P.; Bonachela Alves, F.] ORIZON Companhia Brasileira Gestao Serv, Sao Paulo, Brazil.
   [Morais, A. D.; Pereira, M. L.; Bahmdouni, L.] Janssen Cilag Farmaceut, Sao Paulo, Brazil.
C3 Johnson & Johnson; Johnson & Johnson Brazil
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 
J9 VALUE HEALTH
JI Value Health
PD NOV 15
PY 2011
VL 14
IS 7
BP A444
EP A444
DI 10.1016/j.jval.2011.08.1159
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 876KT
UT WOS:000299107101232
DA 2026-01-16
ER

PT J
AU Gim, GT
   Lee, JH
   Park, E
   Sung, YH
   Kim, CJ
   Hwang, WW
   Chu, JP
   Min, BI
AF Gim, Gyeong-Taek
   Lee, Ji-hye
   Park, Eunkuk
   Sung, Yun-Hee
   Kim, Chang-Ju
   Hwang, Wei-wan
   Chu, Jong-Phil
   Min, Byung-Il
TI Electroacupuncture attenuates mechanical and warm allodynia through suppression of spinal glial activation in a rat model of neuropathic pain
SO BRAIN RESEARCH BULLETIN
LA English
DT Article
DE Neuropathic pain; Glial activation; Electroacupuncture; Matrix metalloproteinase; Proinflammatory cytokine
ID caudal trunk injury; matrix metalloproteinases; serotonergic receptors; electrical-stimulation; microglial activation; cytokine expression; inflammatory pain; inhibitory system; nmda receptors; fos expression
AB Neuropathic pain remains one of the most difficult clinical pain syndromes to treat. It is traditionally viewed as being mediated solely by neurons; however, glial cells have recently been implicated as powerful modulators of pain. It is known that the analgesic effects of electroacupuncture (EA) are mediated by descending pain inhibitory systems, which mainly involve spinal opioid, adrenergic, dopaminergic, serotonergic, and cholinergic receptors. However, studies investigating the suppressive effects of EA on spinal glial activation are rare. In the present study, we assessed the cumulative analgesic effects of EA on mechanical and warm allodynia in a rat model of neuropathic pain. We investigated the clinical efficacy of EA as long-term therapy and examined its effects on spinal glia, matrix metalloproteinase (MMP)-9/MMP-2, proinflammatory cytokines and serum immunoglobulin G (IgG) concentration. Rats were randomly divided into four groups as follows: the operation group (OP), operation with EA-non acupoint (EA-NA), operation with EA-ST36 acupoint (EA-ST36), and sham operation (shamOP). Following neuropathic or sham surgery, repeated EA was performed every other day after the behavioral test. On day 53 after the behavioral test, rats were perfused for immunohistochemistry and Western blot analysis to observe quantitative changes in spinal glial markers such as OX-42, astrocytic glial fibrillary acidic protein (GFAP), MMP-9/MMP-2, and proinflammatory cytokines. Allodynia and OX-42/GFAP/MMP-9/MMP-2/tumor necrosis factor (TNF)-alpha/interleukin (IL)-1 beta activity in the EA-ST36 group was significantly reduced, compared to the OP and EA-NA groups, and IgG in EA-ST36 rats significantly increased. Our results suggest that the analgesic effect of EA may be partly mediated via inhibition of inflammation and glial activation and repeated EA stimulation may be useful for treating chronic pain clinically. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Sung, Yun-Hee; Kim, Chang-Ju; Min, Byung-Il] Kyung Hee Univ, Coll Med, Dept Physiol, Seoul 130701, South Korea.
   [Gim, Gyeong-Taek; Lee, Ji-hye; Min, Byung-Il] Kyung Hee Univ, Grad Sch, Dept EW Med, Seoul 130701, South Korea.
   [Park, Eunkuk; Chu, Jong-Phil] Kyung Hee Univ, Coll Med, Dept Med Zool, Seoul 130701, South Korea.
   [Hwang, Wei-wan] Kyung Hee Univ, Med Ctr, Hosp Korean Med, Dept Neuropsychiat, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University Hospital
RP Min, BI (corresponding author), Kyung Hee Univ, Coll Med, Dept Physiol, 1 Hoegi Dong, Seoul 130701, South Korea.
EM mbi@khu.ac.kr
FU Kyung Hee University [KHU-20100654]
CR Baek YH, 2005, BRAIN RES, V1057, P181, DOI 10.1016/j.brainres.2005.07.014
   Bridges D, 2001, BRIT J ANAESTH, V87, P12, DOI 10.1093/bja/87.1.12
   Butera JA, 2007, J MED CHEM, V50, P2543, DOI 10.1021/jm061015w
   Chang FC, 2004, J BIOMED SCI, V11, P179, DOI 10.1159/000076030
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen Yun-Fei, 2008, ZHONGGUO ZHEN JIU, V28, P675
   Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011
   Choi DC, 2010, NEUROBIOL DIS, V39, P272, DOI 10.1016/j.nbd.2010.04.003
   Cobacho N, 2010, BRAIN RES BULL, V83, P304, DOI 10.1016/j.brainresbull.2010.08.012
   Dai Y, 2001, J PAIN, V2, P151, DOI 10.1054/jpai.2001.19964
   DeLeo JA, 2001, PAIN, V90, P1, DOI 10.1016/S0304-3959(00)00490-5
   DeLeo JA, 2004, NEUROSCIENTIST, V10, P40, DOI 10.1177/1073858403259950
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Dong H, 2009, NEUROL RES, V31, P853, DOI 10.1179/174313209X393960
   Dong ZQ, 2006, BRAIN RES BULL, V69, P30, DOI 10.1016/j.brainresbull.2005.08.027
   Eisenach JC, 1999, LIFE SCI, V64, P549, DOI 10.1016/S0024-3205(98)00600-6
   Gao X, 1998, SHENG LI XUE BAO, V50, P43
   GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3
   Gok B, 2009, J CLIN NEUROSCI, V16, P549, DOI 10.1016/j.jocn.2008.04.024
   Guan Z, 1995, J TRADIT CHIN MED, V15, P102
   Han J S, 1987, THE NEUROCHEMICAL BASIS OF PAIN RELIEF BY ACUPUNCTURE, V0, P0
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   He TF, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/290489
   Huang C, 2004, NEUROSCI LETT, V368, P327, DOI 10.1016/j.neulet.2004.07.073
   Hwang BG, 2002, NEUROSCI LETT, V320, P49, DOI 10.1016/S0304-3940(02)00027-7
   Kang JM, 2007, BRAIN RES, V1131, P211, DOI 10.1016/j.brainres.2006.10.089
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kavoussi B, 2007, INTEGR CANCER THER, V6, P251, DOI 10.1177/1534735407305892
   Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723
   Kim HY, 2009, PAIN, V145, P332, DOI 10.1016/j.pain.2009.06.035
   Kim JH, 2004, BRAIN RES, V998, P230, DOI 10.1016/j.brainres.2003.11.045
   Kim JH, 2000, NEUROSCI LETT, V279, P149, DOI 10.1016/S0304-3940(99)00994-5
   Kim SK, 2005, EXP NEUROL, V195, P430, DOI 10.1016/j.expneurol.2005.06.018
   Kim SK, 2010, AUTON NEUROSCI-BASIC, V157, P38, DOI 10.1016/j.autneu.2010.03.010
   Kim YI, 1997, NEUROREPORT, V8, P2149, DOI 10.1097/00001756-199707070-00011
   Ledeboer A, 2005, PAIN, V115, P71, DOI 10.1016/j.pain.2005.02.009
   Li A, 2007, BRAIN RES, V1186, P171, DOI 10.1016/j.brainres.2007.10.022
   MALMBERG AB, 1995, BRIT J PHARMACOL, V114, P1069, DOI 10.1111/j.1476-5381.1995.tb13315.x
   Mika J, 2009, EUR J PHARMACOL, V623, P65, DOI 10.1016/j.ejphar.2009.09.030
   Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6
   Milligan ED, 2003, J NEUROSCI, V23, P1026
   Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189
   NA HS, 1994, NEUROSCI LETT, V177, P50, DOI 10.1016/0304-3940(94)90042-6
   Namaka M, 2004, CLIN THER, V26, P951, DOI 10.1016/S0149-2918(04)90171-3
   Park JH, 2009, J PHYSIOL SCI, V59, P291, DOI 10.1007/s12576-009-0035-9
   Park JH, 2010, BRAIN RES, V1322, P24, DOI 10.1016/j.brainres.2010.02.001
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   Raghavendra V, 2003, J PHARMACOL EXP THER, V306, P624, DOI 10.1124/jpet.103.052407
   Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108
   Shan S, 2007, NEUROBIOL DIS, V26, P558, DOI 10.1016/j.nbd.2007.02.007
   Shapiro S, 2002, CANCER, V95, P2032, DOI 10.1002/cncr.10905
   Sommer C, 1997, NEUROSCI LETT, V237, P45, DOI 10.1016/S0304-3940(97)00813-6
   Sun RQ, 2004, EXP NEUROL, V187, P23, DOI 10.1016/j.expneurol.2003.12.011
   Sun S, 2008, BRAIN RES BULL, V75, P83, DOI 10.1016/j.brainresbull.2007.07.027
   Sweitzer SM, 2001, J PHARMACOL EXP THER, V297, P1210
   TAKESHIGE C, 1992, BRAIN RES BULL, V29, P617, DOI 10.1016/0361-9230(92)90131-G
   Talhouk RS, 2000, PAIN, V84, P397, DOI 10.1016/S0304-3959(99)00238-9
   Tawfik VL, 2007, BRAIN BEHAV IMMUN, V21, P238, DOI 10.1016/j.bbi.2006.07.001
   Vallejo R, 2010, PAIN PRACT, V10, P167, DOI 10.1111/j.1533-2500.2010.00367.x
   Wang J, 2009, BRAIN RES BULL, V80, P89, DOI 10.1016/j.brainresbull.2009.04.020
   Wang LN, 2006, BRAIN RES, V1120, P46, DOI 10.1016/j.brainres.2006.08.077
   Watkins LR, 2005, TRENDS NEUROSCI, V28, P661, DOI 10.1016/j.tins.2005.10.001
   Watkins LR, 2003, NAT REV DRUG DISCOV, V2, P973, DOI 10.1038/nrd1251
   Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3
   XIONG W, 2007, CHIN J REHABIL, V0, P0
   YANG MMP, 1989, AM J CHINESE MED, V17, P89, DOI 10.1142/S0192415X89000152
   Yim YK, 2007, EVID-BASED COMPL ALT, V4, P51, DOI 10.1093/ecam/nel054
   Zhuang ZY, 2005, PAIN, V114, P149, DOI 10.1016/j.pain.2004.12.022
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 69
TC 54
Z9 68
U1 0
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-9230
EI 1873-2747
J9 BRAIN RES BULL
JI Brain Res. Bull.
PD NOV 25
PY 2011
VL 86
IS 5-6
BP 403
EP 411
DI 10.1016/j.brainresbull.2011.09.010
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 871AZ
UT WOS:000298711300017
PM 21958939
DA 2026-01-16
ER

PT J
AU Ouyang, BS
   Gao, J
   Che, JL
   Zhang, Y
   Li, J
   Yang, HZ
   Hu, TY
   Yang, M
   Wu, YJ
   Ji, LL
AF Ouyang, Ba-Si
   Gao, Jie
   Che, Jian-Li
   Zhang, Yin
   Li, Jun
   Yang, Hai-Zhou
   Hu, Tian-Yan
   Yang, Man
   Wu, Yuan-Jian
   Ji, Ling-Ling
TI Effect of electro-acupuncture on tumor necrosis factor-α and vascular endothelial
SO Chinese journal of integrative medicine
LA English
DT Journal Article
AB OBJECTIVE: To observe the effect of electro-acupuncture (EA) on tumor necrosis  factor-α (TNF-α) and vascular endothelial growth factor (VEGF) in peripheral  blood and joint synovia in patients with rheumatoid arthritis (RA) to verify the  clinical efficacy of EA. METHODS: Adopting randomized controlled principle, the  63 RA patients enrolled were assigned to two groups, the 32 patients in the EA  group were treated with EA, and the 31 patients in the simple needling (SN) group  treated with simple needling. According to the integral-local combining method,  the acupoints were selected mainly from yang-meridian and local Ashi points  (pain-point). EA or SN was applied every other day, 10 times as a course, and  each patient received a total of 3 courses of treatment. RESULTS: Blood and  synovial levels of TNF-α and VEGF were reduced significantly after treatment in  both groups. The lowering (absolute value and difference value) of TNF-α as well  as the absolute value of VEGF, either in blood or in synovia, were similar in the  two groups (P>0.05); but the lowering of VEGF after treatment was more  significant in the EA group than that in the SN group (P<0.05). CONCLUSION: EA  could effectively lower the contents of TNF-α and VEGF in peripheral blood and  joint synovia to improve the internal environment for genesis and development of  RA, so as to enhance the clinical therapeutic effectiveness.
C1 Suzhou Hospital of Traditional Chinese Medicine, Suzhou, Jiangsu Province 215003, China. oybasi@163.com
NR 0
TC 0
SN 1993-040
EI 
J9 Chin J Integr Med
PD JUL 5
PY 2011
VL 17
IS 7
BP 505
EP 9
DI 10.1007/s11655-011-0783-2
PG -496
WC Adolescent; Adult; Aged; Arthritis, Rheumatoid; blood; Electroacupuncture; adverse effects; Female; Humans; Joints; pathology; Male; Synovial Fluid; metabolism; Treatment Outcome; Tumor Necrosis Factor-alpha; blood; Vascular Endothelial Growth Factor A; blood; Young Adult
UT PubMed:21725875
PM 21725875
DA 2011-07-05
ER

PT J
AU Lee, EJ
   Frazier, SK
AF Lee, Eun Jin
   Frazier, Susan K.
TI The Efficacy of Acupressure for Symptom Management: A Systematic Review
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Review
DE Acupressure; pain; dyspnea; fatigue; nausea; review
ID stage renal-disease; quality-of-life; postoperative nausea; p6 acupressure; prehospital analgesia; spinal-anesthesia; relieve nausea; double-blind; pregnancy; therapy
AB Context. Acupressure is a noninvasive strategy used to manage various symptoms. Objectives. The purpose of this article was to review randomized controlled trials that investigated the efficacy of acupressure for the management of symptoms. Methods. A literature search was conducted in the Cumulative Index to Nursing and Allied Health Literature, Medline, and PubMed using the key words acupressure, clinical trial, human, and/or randomized. Randomized clinical trials published between January 1, 2000 and January 31, 2010, which used acupressure as the sole intervention for one group, were included when they were written in English and when there were four or more studies of the efficacy of acupressure for that particular symptom. Results. Forty-three studies were included in this review. Investigators in 16 of 23 studies concluded acupressure was effective, primarily for the management of nausea and vomiting in patients during pregnancy and during chemotherapy. Investigators in nine of 10 studies concluded that acupressure was effective for pain in patients with dysmenorrhea, during labor and after trauma. Investigators of four studies concluded that acupressure was effective in the management of dyspnea and investigators in six studies concluded that acupressure was effective in improving fatigue and reducing insomnia in a variety of populations. However, evaluation of the randomized controlled trial reports indicated a significant likelihood of bias. Conclusion. Acupressure may be a useful strategy for the management of multiple symptoms in a variety of patient populations, but rigorous trials are needed. Inclusion of acupressure as an intervention may improve patient outcomes. J Pain Symptom Manage 2011;42:589-603. (C) 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Lee, Eun Jin] Cent Baptist Hosp, Lexington, KY USA.
   [Frazier, Susan K.] Univ Kentucky, Coll Nursing, Lexington, KY USA.
C3 Central Baptist Hospital; University of Kentucky
RP Lee, EJ (corresponding author), Fayetteville State Univ, 1200 Murchison Rd,Nursing Bldg 311, Fayetteville, NC 28301 USA.
EM peace-peace@hanmail.net
FU National Institutes of Health's National Institute of Nursing Research [1P20NR010679]
CR Agarwal A, 2000, CAN J ANAESTH, V47, P319, DOI 10.1007/BF03020945
   Agarwal A, 2002, CAN J ANAESTH, V49, P554, DOI 10.1007/BF03017380
   Alkaissi A, 2005, CAN J ANAESTH, V52, P703, DOI 10.1007/BF03016557
   Alkaissi A, 2002, CAN J ANAESTH, V49, P1034, DOI 10.1007/BF03017897
   American Pain Society, 2006, APS B, V16, P0
   Barford KL, 2008, CURR TREAT OPTION ON, V9, P204, DOI 10.1007/s11864-008-0062-4
   Carlson LE, 2008, CURR TREAT OPTION ON, V9, P127, DOI 10.1007/s11864-008-0064-2
   Chen HM, 2004, J ADV NURS, V48, P380, DOI 10.1111/j.1365-2648.2004.03236.x
   Cho Yi-Ching, 2004, J NURS RES, V12, P51
   Chung Ue-Lin, 2003, J NURS RES, V11, P251
   Dent HE, 2003, COMPLEMENT THER MED, V11, P72, DOI 10.1016/S0965-2299(03)00058-X
   Dibble S L, 2000, ONCOL NURS FORUM, V27, P41
   Dodd M, 2001, J ADV NURS, V33, P668, DOI 10.1046/j.1365-2648.2001.01697.x
   Durham University, 2010, EFF SIZ CALC, V0, P0
   Habek D, 2004, FORSCH KOMP KLAS NAT, V11, P20, DOI 10.1159/000077192
   Harmon D, 2000, BRIT J ANAESTH, V84, P463
   Harris RE, 2005, J ALTERN COMPLEM MED, V11, P673, DOI 10.1089/acm.2005.11.673
   Hassett AL, 2009, RHEUM DIS CLIN N AM, V35, P393, DOI 10.1016/j.rdc.2009.05.003
   Heazell A, 2006, AM J OBSTET GYNECOL, V194, P815, DOI 10.1016/j.ajog.2005.08.042
   Ho CM, 2006, ANESTH ANALG, V102, P900, DOI 10.1213/01.ane.0000195553.82409.00
   Hsieh LLC, 2006, BMJ-BRIT MED J, V332, P696, DOI 10.1136/bmj.38744.672616.AE
   Hsieh LLC, 2004, PREV MED, V39, P168, DOI 10.1016/j.ypmed.2004.01.036
   Jamigorn Mattawan, 2007, ARCHIVES OF GYNECOLOGY AND OBSTETRICS, V276, P245, DOI 10.1007/s00404-007-0336-2
   Jones Emily, 2008, J SOC INTEGR ONCOL, V6, P141
   Klein AA, 2004, J CARDIOTHOR VASC AN, V18, P68, DOI 10.1053/j.jvca.2003.10.014
   Kober A, 2002, ANESTH ANALG, V95, P723, DOI 10.1097/00000539-200209000-00035
   Kromer TO, 2009, J REHABIL MED, V41, P870, DOI 10.2340/16501977-0453
   Lang T, 2007, AM J EMERG MED, V25, P887, DOI 10.1016/j.ajem.2007.01.016
   Lee MK, 2004, J ALTERN COMPLEM MED, V10, P959
   LEONARD R, 2008, J PHARM PRACT, V21, P165, DOI 10.1177/0897190008316473
   Maa SH, 2003, J ALTERN COMPLEM MED, V9, P659, DOI 10.1089/107555303322524517
   Maa SH, 2007, J CLIN NURS, V16, P794, DOI 10.1111/j.1365-2702.2005.01515.x
   Mans J, 2009, IMMUNOL RES, V43, P264, DOI 10.1007/s12026-008-8081-6
   Mansky PJ, 2006, CANCER J, V12, P425, DOI 10.1097/00130404-200609000-00011
   Ming JL, 2002, J ADV NURS, V39, P343, DOI 10.1046/j.1365-2648.2002.02295.x
   Moher D, 2001, J AM PODIAT MED ASSN, V91, P437, DOI 10.7547/87507315-91-8-437
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   National Cancer Institute, 2007, AC, V0, P0
   Nordio M, 2008, MINERVA MED, V99, P539
   Norheim AJ, 2001, SCAND J PRIM HEALTH, V19, P43, DOI 10.1080/028134301300034666
   Pouresmail Zahra, 2002, J TRADIT CHIN MED, V22, P205
   Roscoe JA, 2003, J PAIN SYMPTOM MANAG, V26, P731, DOI 10.1016/S0885-3924(03)00254-9
   Roscoe Joseph A, 2006, J SOC INTEGR ONCOL, V4, P16
   Roscoe JA, 2009, J PAIN SYMPTOM MANAG, V38, P381, DOI 10.1016/j.jpainsymman.2008.09.006
   Rosenberg EI, 2008, PAIN MED, V9, P1065, DOI 10.1111/j.1526-4637.2008.00477.x
   Sadighha A, 2008, ANN SAUDI MED, V28, P287
   Sakurai M, 2003, ANESTH ANALG, V96, P493, DOI 10.1097/00000539-200302000-00036
   Samad K, 2003, J PAK MED ASSOC, V53, P68
   Schultz AA, 2003, APPL NURS RES, V16, P256, DOI 10.1016/S0897-1897(03)00057-0
   Shapiro AP, 2004, BRIT J PSYCHIAT, V185, P140, DOI 10.1192/bjp.185.2.140
   Shin BC, 2007, J ALTERN COMPLEM MED, V13, P247, DOI 10.1089/acm.2006.6189
   Shin HS, 2007, J ADV NURS, V59, P510, DOI 10.1111/j.1365-2648.2007.04342.x
   Taylor D, 2002, J ALTERN COMPLEM MED, V8, P357, DOI 10.1089/10755530260128050
   Tsay SL, 2005, J ADV NURS, V52, P142, DOI 10.1111/j.1365-2648.2005.03576.x
   Tsay SL, 2004, AM J CHINESE MED, V32, P407, DOI 10.1142/S0192415X04002065
   Tsay SL, 2004, INT J NURS STUD, V41, P99, DOI 10.1016/S0020-7489(03)00079-8
   Tsay SL, 2003, J ADV NURS, V42, P134, DOI 10.1046/j.1365-2648.2003.02596.x
   Tsay SL, 2003, INT J NURS STUD, V40, P1, DOI 10.1016/S0020-7489(02)00019-6
   Turgut S, 2007, EUR J ANAESTH, V24, P87, DOI 10.1017/S0265021506001190
   Werntoft E, 2001, J REPROD MED, V46, P835
   Wu HS, 2004, J ADV NURS, V45, P252, DOI 10.1046/j.1365-2648.2003.02886.x
   Wu HS, 2007, J ALTERN COMPLEM MED, V13, P253, DOI 10.1089/acm.2006.5342
NR 64
TC 119
Z9 144
U1 0
U2 33
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD OCT 15
PY 2011
VL 42
IS 4
BP 589
EP 603
DI 10.1016/j.jpainsymman.2011.01.007
PG 15
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA 836VO
UT WOS:000296144300014
PM 21531533
DA 2026-01-16
ER

PT J
AU Paley, CA
   Johnson, MI
AF Paley, Carole A.
   Johnson, Mark I.
TI Acupuncture for cancer-induced bone pain: a pilot study
SO ACUPUNCTURE IN MEDICINE
LA English
DT Letter
ID rat model; pathophysiology; interventions; mechanisms; behavior; neurons
C1 [Paley, Carole A.] Airedale NHS Fdn Trust, Res Off, Steeton BD20 6TD, Keighley, England.
   [Paley, Carole A.; Johnson, Mark I.] Leeds Metropolitan Univ, Leeds LS1 3HE, W Yorkshire, England.
C3 Leeds Beckett University
RP Paley, CA (corresponding author), Airedale NHS Fdn Trust, Res Off, Skipton Rd, Steeton BD20 6TD, Keighley, England.
EM biodynamics.physiotherapy@tesco.net
CR Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005
   Bennett MI, 2010, J PAIN, V11, P351, DOI 10.1016/j.jpain.2009.08.002
   Briggs M, 1999, J PAIN SYMPTOM MANAG, V18, P438, DOI 10.1016/S0885-3924(99)00092-5
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Donovan-Rodriguez T, 2005, ANESTHESIOLOGY, V102, P132, DOI 10.1097/00000542-200501000-00022
   Evans CJ, 2004, PAIN, V112, P254, DOI 10.1016/j.pain.2004.09.005
   FILSHIE J, 1990, ACUPUNCT MED, V8, P38
   Gralow J, 2007, J PAIN SYMPTOM MANAG, V33, P462, DOI 10.1016/j.jpainsymman.2007.01.001
   HAN JS, 1986, ASIAN PACIFIC J PHAR, V1, P7
   Kawakita K, 2006, ACUPUNCTURE IN MEDICINE, V24, P58
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   MacPherson H, 2010, ACUPUNCT MED, V28, P83, DOI 10.1136/aim.2009.001370
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Paley CA, 2011, ACUPUNCTURE CANC PAI, V0, P0
   PALEY CA, 2010, ECAM ADV ACCESS, V0, P0
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202
   Petrut B, 2008, CURR ONCOL, V15, PS50, DOI 10.3747/co.v15i0.205
   Sandkühler J, 2000, PROG PAIN RES MANAG, V16, P359
   Sandkuhler J, 1997, J NEUROSCI, V17, P6483
   Sandkühler J, 2000, PAIN, V88, P113, DOI 10.1016/S0304-3959(00)00424-3
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Thompson JW, 2005, OXFORD TXB PALLIATIV, V0, P421
   Urch CE, 2005, J PAIN, V6, P837, DOI 10.1016/j.jpain.2005.08.005
   Urch CE, 2003, PAIN, V106, P347, DOI 10.1016/j.pain.2003.08.002
   White A, 2008, ACUPUNCT MED, V26, P111, DOI 10.1136/aim.26.2.111
NR 26
TC 3
Z9 4
U1 0
U2 10
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-5284
EI 
J9 ACUPUNCT MED
JI Acupunct. Med.
PD MAR 15
PY 2011
VL 29
IS 1
BP 
EP 
DI 10.1136/aim.2010.003087
PG 3
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 744FN
UT WOS:000289080400017
PM 21297175
DA 2026-01-16
ER

PT J
AU Paley, CA
   Johnson, MI
   Bennett, MI
AF Paley, Carole A
   Johnson, Mark I
   Bennett, Michael I
TI Acupuncture: a treatment for breakthrough pain in cancer?
SO BMJ supportive & palliative care
LA English
DT Review
AB CONTEXT: Patients with chronic cancer pain frequently suffer severe exacerbations  of pain intensity which are difficult to control adequately via pharmaceutical  management. Management of these episodes of breakthrough pain (BTP) presents a  challenge both to the physician and the patient, and supplemental 'rescue' doses  of opioids required to control BTP can produce intolerable side-effects and often  do not act rapidly enough to provide adequate analgesia. There is very little  evidence to support the use of acupuncture for BTP in cancer and few studies have  considered the rapidity of the analgesic response to acupuncture for any type of  pain. However, the available physiological evidence provides a convincing  rationale and one which warrants research. OBJECTIVE: The objective of this paper  is to debate the available physiological evidence for a rapid analgesic response  to acupuncture in the context of the needs of the patient with cancer BTP,  current interventions, acupuncture technique and the practical considerations  involved in administering treatment rapidly and safely. CONCLUSION: Current  evidence suggests that acupuncture has the potential to produce rapid and  effective analgesia when needles are inserted deeply enough and manipulated  sufficiently. For cancer BTP this represents a possible adjunctive treatment, and  consideration should be given to administering acupuncture alongside 'rescue'  doses of medication to 'kick-start' the analgesic response before the medication  takes effect. However, research is needed to provide evidence that acupuncture is  effective for BTP in cancer, and the feasibility, practicality and safety of  patients administering acupuncture themselves must also be taken into account.
C1 Research & Effectiveness Department, Airedale NHS Foundation Trust, Steeton, Keighley, UK.
NR 0
TC 0
SN 2045-436
EI 
J9 BMJ Support Palliat Care
PD DEC 1
PY 2011
VL 1
IS 3
BP 335
EP 8
DI 10.1136/bmjspcare-2011-000066
PG -327
WC Acupuncture Therapy; methods; Breakthrough Pain; etiology; Humans; Neoplasms; complications; Pain Measurement; Time Factors; Treatment Outcome
UT PubMed:24653480
PM 24653480
DA 2011-12-01
ER

PT J
AU Thicke, LA
   Hazelton, JK
   Bauer, BA
   Chan, CW
   Huntoon, EA
   Novotny, PJ
   Sloan, JA
   Wahner-Roedler, DL
AF Thicke, Lori A
   Hazelton, Jennifer K
   Bauer, Brent A
   Chan, Carl W
   Huntoon, Elizabeth A
   Novotny, Paul J
   Sloan, Jeff A
   Wahner-Roedler, Dietlind L
TI Acupuncture for treatment of noncyclic breast pain: a pilot study.
SO The American journal of Chinese medicine
LA English
DT Journal Article
AB Noncyclic breast pain is a common breast disorder prompting women to seek medical  evaluation. We aimed to perform a pilot study on the relief of noncyclic breast  pain using acupuncture. Thirty-seven women seen at a diagnostic breast clinic  between April 2003 and January 2009 were enrolled. Treatment consisted of four  acupuncture sessions over two weeks, with three months of follow-up. Response to  treatment was measured with use of a breast pain questionnaire, a quality of life  (QOL) questionnaire, and the Cleeland Brief Pain Inventory (BPI) assessed at  baseline, end of treatment, and three months after treatment. Data were analyzed  using standard descriptive statistics. Twenty-two patients completed four  acupuncture sessions. Pain described as throbbing and heavy decreased  significantly after acupuncture (p = 0.04 and p = 0.03, respectively). After  treatment, pain scores (on the 10-point BPI scale) decreased by an average of 3.5  points for the worst pain during the previous month (p = 0.001), by 2.7 points  for average pain (p < 0.001), and by 2.3 points for pain interference (p =  0.002). The percentage of patients reporting a clinically meaningful decrease of  2 points from baseline to the end of treatment included 67% (12/18) for the worst  pain, 65% (11/17) for average pain, and 56% (10/18) for pain interference. QOL  data showed no improvement in QOL measures (mental, physical, emotional, social,  or spiritual well-being). The results of this preliminary study suggest that a  randomized controlled trial may be warranted to evaluate the effect of  acupuncture on noncyclic breast pain, as well as the optimal frequency of  acupuncture treatments.
C1 Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
NR 0
TC 0
SN 1793-685
EI 
J9 Am J Chin Med
PD NOV 16
PY 2011
VL 39
IS 6
BP 1117
EP 29
DI 10.1142/S0192415X11009445
PG -1088
WC Acupuncture Points; Acupuncture Therapy; Adult; Breast Neoplasms; complications; Female; Follow-Up Studies; Humans; Mastodynia; etiology; Pilot Projects; Quality of Life; Treatment Outcome; Young Adult
UT PubMed:22083985
PM 22083985
DA 2011-11-16
ER

PT J
AU Mahfudh, SS
AF Mahfudh, Salma Said
TI Nurse's Role in Controlling Cancer Pain
SO JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
LA English
DT Article
DE nurse's; cancer pain; management
AB Nurses spend more time with patients than any other member of the healthcare team. They play a critical, active and very important part in controlling cancer patients' pain and alleviating suffering. In controlling cancer pain the nurse needs to understand the psychological state of the cancer patient, cancer pain, cancer pain treatment, deleterious effects of unrelieved cancer pain and patient's socio cultural background. She needs to understand that there are two types of pain, nociceptive and neuropathic pains and that 80% of the cancer patients in pain could have 2 or more than 4 different pains at the same time. Nurses' role in controlling cancer pain include believing the patient, assessing pain, identifying the root of the problem, planning the care, administering medication, evaluating effectiveness, ensuring good pain control and individualizing treatment. It also includes nursing interventions such as giving tender nursing care, preventing pain, educating, advocating, communicating, comforting, supporting, and counseling the patient. The nurse must use both pharmacological and non pharmacological treatments to individualize treatment, know all the drugs that are used for the treatment of Cancer Pain, how these drugs relieve pain and what their side effects are. She must use the WHO guidelines to treat pain and must choose the right drug, right dose, given at the right times, with the right intervals and to the right patient. She must evaluate effectiveness of treatment, give PRN doses for breakthrough pain and recommend for specific changes. The role of the nurse is to anticipate the patient's pain needs, advocate for the patient for what feels appropriate for him within his cultural context and incorporate the patient's belief. The nurse can physically relieve pain by promoting comfort, support painful area, gentleness in handling the patient and use nursing treatments. The nurse can recommend physiotherapy, (TENS)/Acupuncture, Occupational therapy, spiritual support, social worker, psychologist, and psychiatrist to address different types of pain. She must relieve both pain and other symptoms. and ensure that the patient has good sleep. She must show kindness, compassion and empathize with him. Each patient is unique the process of controlling cancer pain develops differently each time. The nurse's role is challenging, she must demonstrate that she is not only clinically proficient but culturally competent. She has to use creative assessment skills, clinical judgment, psychological support, advocacy and good communication skills in such a way that the contribution of drugs, nursing care, nursing and other non pharmacological treatments are maximized to the patient's benefit. When evaluating the overall care the nurse must find out what is the total effect of all approaches taken to relieve pain. Nurses can make a difference between a patient who suffers until the last breath of his/her life and a patient who is comfortable and dies pain free and in dignity.
C1 Obstet & Pain Management Certificates, Mina Al Fahal, Oman.
RP Mahfudh, SS (corresponding author), Obstet & Pain Management Certificates, POB 9,Code 116, Mina Al Fahal, Oman.
EM ssmahfudh@hotmail.com
NR 0
TC 6
Z9 10
U1 1
U2 32
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1077-4114
EI 
J9 J PEDIAT HEMATOL ONC
JI J. Pediatr. Hematol. Oncol.
PD OCT 15
PY 2011
VL 33
IS 
BP S146
EP S148
DI 10.1097/MPH.0b013e318230dfd8
PG 3
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 835ED
UT WOS:000296016700015
PM 21952573
DA 2026-01-16
ER

PT J
AU Mi, WL
   Mao-Ying, QL
   Wang, XW
   Li, X
   Yang, CJ
   Jiang, JW
   Yu, J
   Wang, J
   Liu, Q
   Wang, YQ
   Wu, GC
AF Mi, Wen-Li
   Mao-Ying, Qi-Liang
   Wang, Xiao-Wei
   Li, Xiu
   Yang, Chang-Jiang
   Jiang, Jian-Wei
   Yu, Jin
   Wang, Jun
   Liu, Qiong
   Wang, Yan-Qing
   Wu, Gen-Cheng
TI Involvement of spinal neurotrophin-3 in electroacupuncture analgesia and
SO The journal of pain
LA English
DT Journal Article
AB Although electroacupuncture (EA) has been proven to effectively relieve pain  associated with arthritis, the underlying mechanism of EA analgesia requires  further investigation. Here, the involvement of spinal neurotrophin-3 (NT-3) in  EA's analgesic effects on complete Freund's adjuvant (CFA)-induced inflammatory  pain was examined. The present study demonstrated that: 1) repeated EA  stimulation of ipsilateral GB30 and GB34 acupoints remarkably suppressed  CFA-induced hyperalgesia; 2) EA treatment markedly enhanced the upregulation of  spinal NT-3 mRNA and protein levels following CFA injection; 3) antisense  oligodeoxynucleotides (ODN) specifically against NT-3 intrathecally administered  during EA treatment for 7 days significantly attenuated the EA analgesia; and 4)  the suppressed expression of spinal GFAP (astrocytic marker), OX-42 (microglial  marker) as well as proinflammatory cytokines, interleukin (IL)-1β, IL-6 and tumor  necrosis factor (TNF)-α by EA treatment was significantly attenuated following  NT-3 antisense ODN delivery. These results suggested that endogenous NT-3 may be  involved in the analgesic effect of EA on inflammatory pain in rats, mediated  through the inhibition of spinal glial activity as well as proinflammatory  cytokine production. PERSPECTIVE: The present study may initiate a discussion on  the possible roles of NT-3/glia/cytokines in the therapeutic effects of  acupuncture and provide insight on the mechanism underlie the analgesic effects  of acupuncture on pain associated with arthritis.
C1 Department of Integrative Medicine and Neurobiology, Institute of Acupuncture Research, State Key Laboratory of Medical Neurobiology, Institutes of BrainScience, Shanghai Medical College, Fudan University, Shanghai, China.
NR 0
TC 0
SN 1528-844
EI 
J9 J Pain
PD JUN 18
PY 2011
VL 12
IS 9
BP 974
EP 84
DI 10.1016/j.jpain.2011.03.002
PG -890
WC Analgesia; methods; Animals; Arthritis; metabolism; Disease Models, Animal; Electroacupuncture; methods; Inflammation Mediators; physiology; Male; Neural Inhibition; genetics; Neuroglia; metabolism; Neurotrophin 3; genetics; RNA, Messenger; biosynthesis; Rats; Rats, Sprague-Dawley; Spinal Cord; metabolism; Up-Regulation; genetics
UT PubMed:21680256
PM 21680256
DA 2011-06-18
ER

PT J
AU Bao, T
   Ye, XB
   Skinner, J
   Cao, B
   Fisher, J
   Nesbit, S
   Grossman, SA
AF Bao, Ting
   Ye, Xiaobu
   Skinner, Janice
   Cao, Bing
   Fisher, Joy
   Nesbit, Suzanne
   Grossman, Stuart A.
TI The Analgesic Effect of Magnetic Acupressure in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy: A Randomized, Blinded, Controlled Trial
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Acupressure; pain; bone marrow aspiration and biopsy
ID acupuncture; pain; osteoarthritis; labor
AB Context. Bone marrow aspiration and biopsy (BMAB) is a frequently performed and painful procedure. Objectives. To evaluate the efficacy of magnetic acupressure in reducing pain in cancer patients undergoing BMAB. Methods. Cancer patients without previous acupuncture or acupressure experience were stratified by the number of prior BMAB and randomized to having magnetic acupressure delivered to either the large intestine 4 (LI4) acupoint or a sham site. The primary study endpoint was the patient's pain intensity rating during the procedure using a visual analogue scale (VAS). Results. Seventy-seven eligible patients received magnetic acupressure: 37 were randomized to treatment at the LI4 site arm and 40 at the designated sham site arm. There was no significant difference between the median pain scores of patients treated at the LI4 site and the sham site (P = 0.87). However, severe pain (VAS >= 7) was reported in only one patient (2.7%) treated at the LI4 site compared with eight patients (20%) at the sham site (P = 0.03). No patients experienced significant magnetic acupressure-related toxicities. Conclusion. Magnetic acupressure at the LI4 acupoint requires minimal training and expense and is well tolerated. Although its use did not significantly reduce median pain scores in patients undergoing BMAB, it does appear to reduce the proportion of patients with severe pain associated with this invasive procedure. J Pain Symptom Manage 2011; 41: 995-1002. (C) 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Bao, Ting] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21212 USA.
   [Bao, Ting] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21212 USA.
   [Ye, Xiaobu; Skinner, Janice; Cao, Bing; Fisher, Joy; Nesbit, Suzanne; Grossman, Stuart A.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
C3 University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine
RP Bao, T (corresponding author), Univ Maryland, Greenebaum Canc Ctr, 22 S Greene St,Room N9E24, Baltimore, MD 21212 USA.
EM tingbao@gmail.com
CR Dunlop TJ, 1999, SOUTHERN MED J, V92, P477, DOI 10.1097/00007611-199905000-00005
   Hantoushzadeh S, 2007, AUST NZ J OBSTET GYN, V47, P26, DOI 10.1111/j.1479-828X.2006.00674.x
   Helms JM, 2001, POINT LOCATIONS FUNC, V0, P0
   Kwon YD, 2006, RHEUMATOLOGY, V45, P1331, DOI 10.1093/rheumatology/kel207
   Lechtzin N, 2010, J ALTERN COMPLEM MED, V16, P965, DOI 10.1089/acm.2009.0531
   Mainwaring CJ, 1996, CLIN LAB HAEMATOL, V18, P285
   MILLIGAN DW, 1987, J CLIN PATHOL, V40, P696, DOI 10.1136/jcp.40.6.696
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   *NAT COMPR CANC NE, 2009, NCCN GUID AD CANC PA, V0, P0
   Nesheim BI, 2006, ACTA OBSTET GYN SCAN, V85, P441, DOI 10.1080/00016340500432523
   Portnow Jana, 2003, J NATL COMPR CANC NETW, V1, P435
   Sertel S, 2009, EUR ARCH OTO-RHINO-L, V266, P919, DOI 10.1007/s00405-008-0851-1
   Smith MJ, 2005, ARCH PHYS MED REHAB, V86, P1741, DOI 10.1016/j.apmr.2004.11.044
   Vanhelleputte PA, 2003, J PAIN SYMPTOM MANAG, V26, P860, DOI 10.1016/S0885-3924(03)00312-9
   Witt CM, 2006, ARTHRITIS RHEUM-US, V54, P3485, DOI 10.1002/art.22154
   Wolanskyj A P, 2000, CLIN LYMPHOMA, V1, P154, DOI 10.3816/CLM.2000.n.014
   Wu HS, 2007, J ALTERN COMPLEM MED, V13, P253, DOI 10.1089/acm.2006.5342
NR 19
TC 25
Z9 26
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUN 15
PY 2011
VL 41
IS 6
BP 995
EP 1002
DI 10.1016/j.jpainsymman.2010.08.012
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA 779VG
UT WOS:000291809700006
PM 21306863
DA 2026-01-16
ER

PT J
AU Paley, CA
   Johnson, MI
AF Paley, Carole A
   Johnson, Mark I
TI Acupuncture for cancer-induced bone pain: a pilot study.
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Letter
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD FEB 8
PY 2011
VL 29
IS 1
BP 71
EP 3
DI 10.1136/aim.2010.003087
PG -68
WC Acupuncture Therapy; methods; Aged; Aged, 80 and over; Bone and Bones; innervation; Female; Humans; Male; Middle Aged; Neoplasms; complications; Pain; etiology; Pain Management; Pain Measurement; Pilot Projects; Treatment Outcome
UT PubMed:21297175
PM 21297175
DA 2011-02-08
ER

PT J
AU Enblom, A
   Johnsson, A
   Hammar, M
   Steineck, G
   Börjeson, S
AF Enblom, Anna
   Johnsson, Anna
   Hammar, Mats
   Steineck, Gunnar
   Borjeson, Sussanne
TI The Nonpenetrating Telescopic Sham Needle May Blind Patients with Different Characteristics and Experiences When Treated by Several Therapists
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID trial comparing acupuncture; randomized clinical-trials; placebo needle; single-blind; radiotherapy; stimulation; sensation; real; pain
AB Background. Little is known which factors influence the blinding in acupuncture studies. Aim. To investigate if blinding varied between patients with different characteristics receiving verum or sham acupuncture. Methods. We randomised cancer patients to verum (n = 109) or sham acupuncture (n = 106) with a nonpenetrating telescopic sham needle for nausea. Level of blinding was compared between different sub-groups of patients using Bang's blinding index (BI) ranged -1 to 1 (-1 = all state the opposite treatment, 1 = all identify treatment). Results. Most patients in the verum (74 of 95; 78%, BI 0.72) and the sham (68 of 95; 72%, BI -0.60). acupuncture group believed they had received verum acupuncture. The probability for a patient to believe he/she received verum acupuncture was related to the received needling type (P = .003) and to the patient's belief in received treatment effects (P = .008). Hospital (P = .425), therapist (P = .434), previous acupuncture experience (P = .578), occurrence of nausea (P = .157), gender (P = .760), and age (P = .357) did not affect blinding. Conclusions. Blinding was successfully achieved irrespective of age, gender, acupuncture experience, treatment effect, or in which hospital or by which therapist the patient received treatment. Patients with higher belief in the effect of the treatment were more likely to believe they had received verum acupuncture.
C1 [Enblom, Anna] Linkoping Univ, Dept Med & Hlth Sci, Div Nursing Sci, S-58185 Linkoping, Sweden.
   [Enblom, Anna] Lund Univ, Swedish Inst Hlth Sci, Vardal Inst, S-22100 Lund, Sweden.
   [Enblom, Anna] Karolinska Inst, Osher Ctr, Dept Clin Neurosci, S-17177 Stockholm, Sweden.
   [Johnsson, Anna] Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden.
   [Johnsson, Anna] Linkoping Univ, Dept Clin & Expt Med, S-58185 Linkoping, Sweden.
   [Steineck, Gunnar] Karolinska Inst, Dept Oncol Pathol, Div Clin Canc Epidemiol, S-17177 Stockholm, Sweden.
   [Steineck, Gunnar] Sahlgrens Acad, Dept Oncol, Div Clin Canc Epidemiol, S-51345 Gothenburg, Sweden.
   [Borjeson, Sussanne] Linkoping Univ Hosp, Dept Oncol, Ctr Surg Orthoped & Oncol, S-58185 Linkoping, Sweden.
C3 Linkoping University; Lund University; Karolinska Institutet; Lund University; Skane University Hospital; Linkoping University; Karolinska Institutet; University of Gothenburg; Linkoping University
RP Enblom, A (corresponding author), Linkoping Univ, Dept Med & Hlth Sci, Div Nursing Sci, S-58185 Linkoping, Sweden.
EM anna.enblom@ki.se
FU Swedish Cancer Society; Vardal Institute; County Council of Ostergotland; University of Linkoping; Cancer & Traffic Injury Fund; Vardal Foundation-for Health Care Sciences and Allergy Research; Ostgota Cancer Fund; Osher Center of Karolinska Institute
CR Anna E, 2008, COMPLEMENT THER MED, V16, P288, DOI 10.1016/j.ctim.2008.02.012
   Bang HJ, 2004, CONTROL CLIN TRIALS, V25, P143, DOI 10.1016/j.cct.2003.10.016
   Borjeson S, 2007, EJC SUPPL, V5, P142, DOI 10.1016/S1359-6349(07)70622-5
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Desbiens NA, 2002, MED HYPOTHESES, V59, P227, DOI 10.1016/S0306-9877(02)00205-0
   Dincer F, 2003, COMPLEMENT THER MED, V11, P235, DOI 10.1016/S0965-2299(03)00124-9
   Elden H, 2008, BJOG-INT J OBSTET GY, V115, P1655, DOI 10.1111/j.1471-0528.2008.01904.x
   Enblom A, 2011, ACUPUNCT MED, V29, P94, DOI 10.1136/aim.2010.003384
   Ernst E, 2009, J PAIN SYMPTOM MANAG, V37, P709, DOI 10.1016/j.jpainsymman.2008.04.009
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Kolahi J, 2009, COMMUNITY DENT ORAL, V37, P477, DOI 10.1111/j.1600-0528.2009.00494.x
   Kou W, 2007, AM J CHINESE MED, V35, P753, DOI 10.1142/S0192415X07005247
   Lai XS, 2009, NEUROSCI LETT, V452, P194, DOI 10.1016/j.neulet.2009.01.052
   Lee MS, 2009, EVID-BASED COMPL ALT, V6, P59, DOI 10.1093/ecam/nep085
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Manheimer E, 2006, J CLIN EPIDEMIOL, V59, P107, DOI 10.1016/j.jclinepi.2005.06.003
   McManus Claire A, 2007, ACUPUNCT MED, V25, P36
   Moffet HH, 2008, J CLIN EPIDEMIOL, V61, P741, DOI 10.1016/j.jclinepi.2008.02.013
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Park H, 2002, AM J CHINESE MED, V30, P45, DOI 10.1142/S0192415X02000053
   Park J, 2005, ARCH INTERN MED, V165, P2026, DOI 10.1001/archinte.165.17.2026
   Park J, 1999, ACUPUNCT MED, V17, P110
   Park Jongbae, 2002, ACUPUNCT MED, V20, P168
   Sandberg M, 2004, EUR J PAIN, V8, P163, DOI 10.1016/S1090-3801(03)00090-9
   So EWS, 2009, HUM REPROD, V24, P341, DOI 10.1093/humrep/den380
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Takakura Nobuari, 2007, BMC COMPLEMENT ALTERN MED, V7, P31, DOI 10.1186/1472-6882-7-31
   Tan CW, 2009, ARCH PHYS MED REHAB, V90, P2141, DOI 10.1016/j.apmr.2009.08.142
   Tough EA, 2009, ACUPUNCT MED, V27, P118, DOI 10.1136/aim.2009.000737
   Trinh K V, 2003, CLINICAL ACUPUNCTURE AND ORIENTAL MEDICINE, V4, P71, DOI 10.1016/s1461-1449(03)00026-4
   Tsukayama H, 2006, CLIN J PAIN, V22, P346, DOI 10.1097/01.ajp.0000176359.94644.mL
   White AR, 2001, COMPLEMENT THER MED, V9, P237, DOI 10.1054/ctim.2001.0489
   White P, 2003, PAIN, V106, P401, DOI 10.1016/j.pain.2003.08.013
   Yoo SS, 2004, NEUROIMAGE, V22, P932, DOI 10.1016/j.neuroimage.2004.02.017
NR 35
TC 6
Z9 7
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2011
VL 2011
IS 
BP 1
EP 12
DI 10.1155/2011/185034
PG 12
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 800UJ
UT WOS:000293392700001
PM 21747890
DA 2026-01-16
ER

PT J
AU Wang, JY
   Xu, L
   Zhang, RX
   Lao, L
AF Wang, Ju-yong
   Xu, Ling
   Zhang, Rui-xin
   Lao, Lixing
TI [Traditional Chinese medicine for cancer pain].
SO Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
LA chi
DT Review
AB Pain is one of the common symptoms of cancer which seriously affects the quality  of life of the patients. Cancer pain is mainly treated with the three-step  method, biological therapy or nerve block therapy based on antitumor therapy.  However, up to 50 percent of patients with cancer-related pain do not receive  adequate pain relief, affecting their physical and psychological well-being, and  leading to a lower quality of life for the patient after conventional treatment.  Clinical observation suggests that traditional Chinese medicine may alleviate  cancer-related pain either by oral administration, topical administration,  acupuncture or other means with continuing non-addictive and non-drug-resistant  qualities. However, scientific evaluation of the efficacy of herbs in the  treatment of pain is insufficient; the underlying mechanisms are unclear and,  safety and toxicity remain a concern.
C1 Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
NR 0
TC 0
SN 
EI 1672-197
J9 Zhong Xi Yi Jie He Xue Bao
PD FEB 4
PY 2011
VL 9
IS 2
BP 129
EP 34
DI 10.3736/jcim20110202
PG -95
WC Drugs, Chinese Herbal; therapeutic use; Humans; Medicine, Chinese Traditional; Neoplasms; complications; Pain; drug therapy
UT PubMed:21288445
PM 21288445
DA 2011-02-04
ER

PT J
AU Enblom, A
   Tomasson, A
   Hammar, M
   Steineck, G
   Börjeson, S
AF Enblom, Anna
   Tomasson, Annica
   Hammar, Mats
   Steineck, Gunnar
   Börjeson, Sussanne
TI Pilot testing of methods for evaluation of acupuncture for emesis during
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
AB BACKGROUND: Many acupuncture studies are of weak methodological quality, possibly  due to lack of pilot testing. This pilot study tested design features, including  test of feasibility, compliance to treatment and data collection, level of  blinding success and the patients' potential perceived effects of the treatment,  in preparation for an efficacy study. METHOD: A modified single subject  experimental design was conducted. 10 cancer patients were randomised to verum  penetrating acupuncture or non-penetrating sham needles for 30 min 2-3 times/week  during radiotherapy over abdomen/pelvis. They answered test-retested emesis  questions (r=0.527-1.0) covering nausea, vomiting, use of antiemetics, wellbeing  and activities of daily living. RESULTS: Overall, the patients completed 98% of  the 345 emesis-questionnaire days and 101 of the 115 offered treatments. All  patients believed they received verum acupuncture. 10 patients experienced  antiemetic effects, seven relaxation, five pain-reduction and five experienced  sleep improvement. Two types of nausea questions showed absolute concordance  (r=1.0) (n of observations=456). Nausea was experienced by one of five verum  acupuncture treated patients (duration median 0% of the radiotherapy-days) and  four of five sham acupuncture treated patients (duration median 24% of the  radiotherapy-days). Patients experiencing nausea rated decreased wellbeing and  performance of daily activities compared to patients free from nausea.  CONCLUSIONS: All patients were blinded, complied with verum/sham treatments and  data-collection, and believed they had effects of the received treatment. The  methods for verum/sham treatment and data collection may thus be used in an  adequately powered randomised controlled study of the effect of acupuncture for  radiotherapy-induced emesis.
C1 Department of Medical and Health Sciences, Division of Nursing Science, Linköping University, Linköping, Sweden. anna.enblom@ki.se
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD APR 5
PY 2011
VL 29
IS 2
BP 94
EP 102
DI 10.1136/aim.2010.003384
PG 8
WC Activities of Daily Living; Acupuncture Therapy; Adult; Aged; Aged, 80 and over; Case-Control Studies; Double-Blind Method; Female; Health Status; Humans; Male; Middle Aged; Nausea; prevention & control; Neoplasms; radiotherapy; Pain; prevention & control; Pilot Projects; Relaxation; Research Design; Sleep; Surveys and Questionnaires; Vomiting; prevention & control
UT PubMed:21460396
PM 21460396
DA 2011-04-05
ER

PT J
AU Fan, XN
   Zhang, X
   Wu, LZ
AF Fan, Xiao-nong
   Zhang, Xue
   Wu, Lian-zhong
TI [Dynamic observation on therapeutic features of thalamic pain by mind calming,
SO Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese
LA chi
DT Journal Article
AB OBJECTIVE: To observe therapeutic features of thalamic pain by mind Calming,  blood activating and pain relief acupuncture and Carbamazepine. METHODS:  Crossover trial design was adopted. Eleven patients with confirmed diagnosis of  thalamic pain were randomly assigned to two groups according to the minimal  unbalance index method, i.e., Group I (Six patients received acupuncture first  and then Western medicine.) and Group II (Five patients received Western medicine  first and then acupuncture). The therapeutic course for each group was ten days.  There was a ten-day elution phase between the two therapeutic methods. The total  therapeutic course was thirty days. Eleven patients were enrolled in the two  groups for statistical analysis. The therapeutic efficacy was assessed with  visual analogue scale (VAS) and the pain assessment scale of Anderson Cancer  Center in the USA (MD Pain Evaluation value) respectively. The VAS and MD values  of the two groups were recorded every day to get the dynamic curve. RESULTS: The  VAS and MD values obviously decreased in the two groups after treatment (P<0.05).  The pain curves of the two groups showed a declining trend during the treatment.  A gradual and stable descending process was shown in the acupuncture group. But a  greater decrease first appeared in the Western medicine group, then a  comparatively greater decrease occurred after one platform stage, showing  ladder-shaped curve. CONCLUSIONS: Cumulative potency may be the main analgesic  effects of acupuncture. Western medicine may possibly play a role by rapid  initiate effect.
C1 The Third Grade Dose-Effect Relationship of Acupuncture Lab, Key Research Room of Acupuncture at Cerebropathy, State Administration of Traditional ChineseMedicine, The Key Laboratory of Acupuncture in Tianjin, Tianjin 300193.fanxiaonong@163.com
NR 0
TC 0
SN 
EI 1003-537
J9 Zhongguo Zhong Xi Yi Jie He Za Zhi
PD AUG 10
PY 2011
VL 31
IS 6
BP 741
EP 4
DI 
PG -737
WC Acupuncture Analgesia; methods; Aged; Carbamazepine; therapeutic use; Cross-Over Studies; Female; Headache; therapy; Humans; Male; Middle Aged; Pain Management; Pain Measurement; Thalamic Diseases; therapy; Treatment Outcome
UT PubMed:21823414
PM 21823414
DA 2011-08-10
ER

PT J
AU Paley, CA
   Johnson, MI
   Bennett, MI
AF Paley, Carole A
   Johnson, Mark I
   Bennett, Michael I
TI Should physiotherapists use acupuncture for treating patients with cancer-induced
SO Physiotherapy
LA English
DT Review
AB BACKGROUND: Patients suffering from pain due to bony metastases in cancer  represent a challenge to the physiotherapist as part of the multidisciplinary  team. Adequate pain relief improves quality of life and functional status, yet  conventional analgesia often has undesirable side-effects and non-pharmacological  treatments (e.g. some electrotherapies) may be contraindicated in cancer.  Acupuncture is a potential treatment for cancer-induced bone pain (CIBP) as it  has few side effects and is relatively easy to administer. There is a dearth of  research on the use of acupuncture in treating CIBP and some practitioners  express fears about treating cancer patients with acupuncture. OBJECTIVES: To  discuss the use of acupuncture for CIBP by reviewing the physiological rationale  for using acupuncture to treat CIBP and the risks and benefits of using  acupuncture in clinical practice. DATA SOURCES: Evidence was identified by  searching seven major databases: Cochrane Central Register of Controlled Trials  (CENTRAL), MEDLINE, EMBASE, CINAHL, PsycINFO, AMED and SPORTDiscus. Evidence was  synthesised by the authors to raise issues and discussion points within a  narrative review framework. FINDINGS: Available physiological evidence supports  potentially efficacious effects of acupuncture for reduction of CIBP. Clinical  literature suggests that acupuncture may be effective as an adjunctive treatment  for CIBP and that risks are manageable. However, there is a need for  well-designed randomised controlled trials to investigate efficacy and  effectiveness in patients. CONCLUSIONS: Acupuncture has the potential to provide  sustained background analgesia and/or rapid onset analgesia for breakthrough pain  if the appropriate points and techniques are used.
C1 Airedale NHS Foundation Trust, Steeton, Keighley BD206TD, UK. biodynamics.physiotherapy@tesco.net
NR 0
TC 0
SN 1873-146
EI 
J9 Physiotherapy
PD AUG 9
PY 2011
VL 97
IS 3
BP 256
EP 63
DI 10.1016/j.physio.2010.08.008
PG -193
WC Acupuncture Analgesia; standards; Bone and Bones; Evidence-Based Practice; Humans; Neoplasms; complications; Pain; physiopathology; Physical Therapy Modalities; standards; Risk Assessment
UT PubMed:21820545
PM 21820545
DA 2011-08-09
ER

PT J
AU Yuan, SY
   Qin, Z
   Liu, DS
   Yin, WQ
   Zhang, ZL
   Li, SG
AF Yuan, Shao-Ying
   Qin, Zhan
   Liu, Dong-Sheng
   Yin, Wei-Qiang
   Zhang, Zhao-Lei
   Li, Shen-Guo
TI [Acupuncture for chronic pelvic pain syndromes (CPPS) and its effect on cytokines
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
AB OBJECTIVE: To explore the effect of acupuncture on chronic pelvic pain syndromes  (CPPS), and its therapeutic mechanism. METHODS: Fourty-seven cases of CPPS were  treated with electroacupuncture on Zhongji (CV 3), Guilai (ST 29), Yinlingquan  (SP 9), Sanyinjiao (SP 6), Guanyuan (CV 4), Shuidao(ST 28), Xuehai (SP 10) and  Taichong (LR 3) as main acupoints. Chronic Prostatitis Symptom Index (CPSI) was  adopted to grade the severity of pain or discomforts. Additionally, the levels of  Interleukin-8 (IL-8), Interleukin-10 (IL-10) and Tumor necrosis factor-alpha  (TNF-alpha) in prostate fluid were detected and the correlation between those  changes and pain score was analyzed. RESULTS: After treatment, pain or discomfort  score in CPSI decreased remarkably as compared with that before treatment (P <  0.01). The levels of IL-8, IL-10 and TNF-alpha were lower than those before  treatment (P < 0.01, P < 0.05). The positive correlation was obtained between  IL-10 level and pain score (P < 0.05). The total effective rate was 89.4%  (42/47). CONCLUSION: Acupuncture has significant efficacy on CPPS through  reducing IL-10 level to ease pain, and reducing the levels of IL-8 and TNF-alpha  to relieve inflammatory reaction.
C1 Male Department of Zhuhai Branch of Guangdong Provincial TCM Hospital, Zhuhai 519000, China. ysy017@126.com
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD MAR 2
PY 2011
VL 31
IS 1
BP 11
EP 4
DI 
PG -7
WC Acupuncture Points; Acupuncture Therapy; Adult; Body Fluids; immunology; Chronic Disease; therapy; Humans; Interleukin-10; immunology; Interleukin-8; immunology; Male; Middle Aged; Pelvic Pain; immunology; Prostate; immunology; Tumor Necrosis Factor-alpha; immunology; Young Adult
UT PubMed:21355145
PM 21355145
DA 2011-03-02
ER

PT J
AU Bao, T
   Ye, X
   Skinner, J
   Cao, B
   Fisher, J
   Nesbit, S
   Grossman, SA
AF Bao, Ting
   Ye, Xiaobu
   Skinner, Janice
   Cao, Bing
   Fisher, Joy
   Nesbit, Suzanne
   Grossman, Stuart A
TI The analgesic effect of magnetic acupressure in cancer patients undergoing bone
SO Journal of pain and symptom management
LA English
DT Journal Article
AB CONTEXT: Bone marrow aspiration and biopsy (BMAB) is a frequently performed and  painful procedure. OBJECTIVES: To evaluate the efficacy of magnetic acupressure  in reducing pain in cancer patients undergoing BMAB. METHODS: Cancer patients  without previous acupuncture or acupressure experience were stratified by the  number of prior BMAB and randomized to having magnetic acupressure delivered to  either the large intestine 4 (LI4) acupoint or a sham site. The primary study  endpoint was the patient's pain intensity rating during the procedure using a  visual analogue scale (VAS). RESULTS: Seventy-seven eligible patients received  magnetic acupressure: 37 were randomized to treatment at the LI4 site arm and 40  at the designated sham site arm. There was no significant difference between the  median pain scores of patients treated at the LI4 site and the sham site  (P=0.87). However, severe pain (VAS ≥ 7) was reported in only one patient (2.7%)  treated at the LI4 site compared with eight patients (20%) at the sham site  (P=0.03). No patients experienced significant magnetic acupressure-related  toxicities. CONCLUSION: Magnetic acupressure at the LI4 acupoint requires minimal  training and expense and is well tolerated. Although its use did not  significantly reduce median pain scores in patients undergoing BMAB, it does  appear to reduce the proportion of patients with severe pain associated with this  invasive procedure.
C1 The University of Maryland Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21212, USA.tingbao@gmail.com
NR 0
TC 0
SN 1873-651
EI 
J9 J Pain Symptom Manage
PD FEB 11
PY 2011
VL 41
IS 6
BP 995
EP 1002
DI 10.1016/j.jpainsymman.2010.08.012
PG 7
WC Acupressure; methods; Biopsy, Needle; adverse effects; Bone Marrow; pathology; Female; Humans; Magnetic Field Therapy; methods; Male; Middle Aged; Neoplasms; complications; Pain; etiology; Single-Blind Method; Treatment Outcome
UT PubMed:21306863
PM 21306863
DA 2011-02-11
ER

PT J
AU Donald, GK
   Tobin, I
   Stringer, J
AF Donald, Graeme K.
   Tobin, Irene
   Stringer, Jacqui
TI Evaluation of acupuncture in the management of chemotherapy-induced peripheral neuropathy
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
ID randomized controlled-trial; placebo-controlled trial; diabetic-neuropathy; double-blind; pain; amitriptyline; pregabalin; efficacy
AB Aim To clinically evaluate the effectiveness of acupuncture when used in the management of chemotherapy-induced peripheral neuropathy (PN). Background During cancer treatment, certain chemotherapies can cause varying degrees of PN. Patients' quality of life can be seriously impaired through loss of sensation, pain or mobility problems. Conventional medications routinely used to manage neuropathic symptoms have poor side-effect profiles and there is little or no evidence justifying their use to treat chemotherapy-related neurotoxicities. There are studies suggesting that acupuncture may be an effective therapy in treating PN across a number of different aetiologies. Design A retrospective service evaluation. Method Patients (n=18) were referred for acupuncture by the medical staff and/or nurse specialists or they self-referred for treatment. A course of six weekly acupuncture sessions was offered to them, and their details were recorded on an evaluation form prior to session one. Points were selected by acupuncturists, based on patient presentation, and needles remained in situ for 30-45 min. Treatments took place in outpatient clinics, chemotherapy day case ward or a drop-in clinic based in a physiotherapy gym. The evaluation form was completed at the end of session 6 by a therapist who had not been involved in patient care. Results 82% (n=14) of patients reported an improvement in symptoms following their course of acupuncture; one patient with advanced disease died during the 6 weeks. Some patients derived additional benefits from the treatment including a reduction in analgesic use and improved sleeping patterns. The most common acupoints used were SP6 (n=18), ST36 (n=18) and LV3 (n=14). Conclusion Although these results are encouraging, they are uncontrolled. They suggest that acupuncture could be an option for these patients and controlled trials using validated patient-reported outcome measures are justified.
C1 [Donald, Graeme K.; Tobin, Irene; Stringer, Jacqui] Christie NHS Fdn Trust, Complementary Therapy Serv, Manchester M20 4BX, Lancs, England.
C3 Christie NHS Foundation Trust
RP Donald, GK (corresponding author), Christie NHS Fdn Trust, Complementary Therapy Serv, Wilmslow Rd, Manchester M20 4BX, Lancs, England.
EM graeme.donald@christie.nhs.uk
CR Abuaisha BB, 1998, DIABETES RES CLIN PR, V39, P115, DOI 10.1016/S0168-8227(97)00123-X
   Arezzo JC, 2008, BMC NEUROL, V8, P0, DOI 10.1186/1471-2377-8-33
   Collins SL, 2000, J PAIN SYMPTOM MANAG, V20, P449, DOI 10.1016/S0885-3924(00)00218-9
   Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Kaptchuk TJ, 1999, JAMA-J AM MED ASSOC, V281, P1270, DOI 10.1001/jama.281.14.1270
   Kautio AL, 2008, J PAIN SYMPTOM MANAG, V35, P31, DOI 10.1016/j.jpainsymman.2007.02.043
   Manni L, 2010, AUTON NEUROSCI-BASIC, V157, P9, DOI 10.1016/j.autneu.2010.03.020
   Napadow V, 2009, NEUROIMAGE, V47, P289, DOI 10.1016/j.neuroimage.2009.03.060
   Postma TJ, 2000, ANN ONCOL, V11, P509, DOI 10.1023/A:1008345613594
   Rao RD, 2007, CANCER-AM CANCER SOC, V110, P2110, DOI 10.1002/cncr.23008
   Rosenstock J, 2004, PAIN, V110, P628, DOI 10.1016/j.pain.2004.05.001
   Saif M Wasif, 2005, THER CLIN RISK MANAG, V1, P249
   Shlay JC, 1998, JAMA-J AM MED ASSOC, V280, P1590, DOI 10.1001/jama.280.18.1590
   Tong YQ, 2010, J ACUPUNCT MERIDIAN, V3, P95, DOI 10.1016/S2005-2901(10)60018-0
   Vondracek P, 2009, EUR J PAEDIATR NEURO, V13, P332, DOI 10.1016/j.ejpn.2008.06.011
   Watson CPN, 2003, PAIN, V105, P71, DOI 10.1016/S0304-3959(03)00160-X
   Wilkes Gail, 2007, SEMIN ONCOL NURS, V23, P162, DOI 10.1016/j.soncn.2007.05.001
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Zhang C, 2010, J TRADIT CHIN MED, V30, P13, DOI 10.1016/S0254-6272(10)60003-9
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou YH, 2009, AM J CLIN ONCOL-CANC, V32, P319, DOI 10.1097/COC.0b013e318173a520
NR 23
TC 70
Z9 82
U1 2
U2 32
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-5284
EI 
J9 ACUPUNCT MED
JI Acupunct. Med.
PD SEP 15
PY 2011
VL 29
IS 3
BP 230
EP 233
DI 10.1136/acupmed.2011.010025
PG 4
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 812XL
UT WOS:000294326700013
PM 21875929
DA 2026-01-16
ER

PT J
AU Mahfudh, SS
AF Mahfudh, Salma Said
TI Nurse's role in controlling cancer pain.
SO Journal of pediatric hematology/oncology
LA English
DT Journal Article
AB Nurses spend more time with patients than any other member of the healthcare  team. They play a critical, active and very important part in controlling cancer  patients' pain and alleviating suffering. In controlling cancer pain the nurse  needs to understand the psychological state of the cancer patient, cancer pain,  cancer pain treatment, deleterious effects of unrelieved cancer pain and  patient's socio cultural background. She needs to understand that there are two  types of pain, nociceptive and neuropathic pains and that 80% of the cancer  patients in pain could have 2 or more than 4 different pains at the same time.  Nurses' role in controlling cancer pain include believing the patient, assessing  pain, identifying the root of the problem, planning the care, administering  medication, evaluating effectiveness, ensuring good pain control and  individualizing treatment. It also includes nursing interventions such as giving  tender nursing care, preventing pain, educating, advocating, communicating,  comforting, supporting, and counseling the patient. The nurse must use both  pharmacological and non pharmacological treatments to individualize treatment,  know all the drugs that are used for the treatment of Cancer Pain, how these  drugs relieve pain and what their side effects are. She must use the WHO  guidelines to treat pain and must choose the right drug, right dose, given at the  right times, with the right intervals and to the right patient. She must evaluate  effectiveness of treatment, give PRN doses for breakthrough pain and recommend  for specific changes. The role of the nurse is to anticipate the patient's pain  needs, advocate for the patient for what feels appropriate for him within his  cultural context and incorporate the patient's belief. The nurse can physically  relieve pain by promoting comfort, support painful area, gentleness in handling  the patient and use nursing treatments. The nurse can recommend physiotherapy,  (TENS)/Acupuncture, Occupational therapy, spiritual support, social worker,  psychologist, and psychiatrist to address different types of pain. She must  relieve both pain and other symptoms. and ensure that the patient has good sleep.  She must show kindness, compassion and empathize with him. Each patient is unique  the process of controlling cancer pain develops differently each time. The  nurse's role is challenging, she must demonstrate that she is not only clinically  proficient but culturally competent. She has to use creative assessment skills,  clinical judgment, psychological support, advocacy and good communication skills  in such a way that the contribution of drugs, nursing care, nursing and other non  pharmacological treatments are maximized to the patient's benefit. When  evaluating the overall care the nurse must find out what is the total effect of  all approaches taken to relieve pain. Nurses can make a difference between a  patient who suffers until the last breath of his/her life and a patient who is  comfortable and dies pain free and in dignity.
C1 Obstetric and Pain Management Certificates, PO Box 9, Code 116, Mina Al Fahal, Sultanate of Oman. ssmahfudh@hotmail.com
NR 0
TC 0
SN 1536-367
EI 
J9 J Pediatr Hematol Oncol
PD OCT 5
PY 2011
VL 33 Suppl 2
IS 
BP S146
EP 8
DI 10.1097/MPH.0b013e318230dfd8
PG 1
WC Humans; Neoplasms; complications; Nurse's Role; Nurse-Patient Relations; Nursing Assessment; methods; Oncology Nursing; methods; Pain; etiology; Pain Management
UT PubMed:21952573
PM 21952573
DA 2011-10-05
ER

PT J
AU Paley, CA
   Bennett, MI
   Johnson, MI
AF Paley, Carole A.
   Bennett, Michael I.
   Johnson, Mark I.
TI Acupuncture for Cancer-Induced Bone Pain?
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID dorsal-horn; auricular acupuncture; rat model; complementary/alternative medicine; brain; electroacupuncture; stimulation; analgesia; modulation; mechanisms
AB Bone pain is the most common type of pain in cancer. Bony metastases are common in advanced cancers, particularly in multiple myeloma, breast, prostate or lung cancer. Current pain-relieving strategies include the use of opioid-based analgesia, bisphosphonates and radiotherapy. Although patients experience some pain relief, these interventions may produce unacceptable side-effects which inevitably affect the quality of life. Acupuncture may represent a potentially valuable adjunct to existing strategies for pain relief and it is known to be relatively free of harmful side-effects. Although acupuncture is used in palliative care settings for all types of cancer pain the evidence-base is sparse and inconclusive and there is very little evidence to show its effectiveness in relieving cancer-induced bone pain (CIBP). The aim of this critical review is to consider the known physiological effects of acupuncture and discuss these in the context of the pathophysiology of malignant bone pain. The aim of future research should be to produce an effective protocol for treating CIBP with acupuncture based on a sound, evidence-based rationale. The physiological mechanisms presented in this review suggest that this is a realistic objective.
C1 [Paley, Carole A.; Johnson, Mark I.] Leeds Metropolitan Univ, Fac Hlth, Leeds LS1 3HE, W Yorkshire, England.
   [Paley, Carole A.] Airedale Dist Gen Hosp, Keighley, W Yorkshire, England.
   [Paley, Carole A.; Bennett, Michael I.; Johnson, Mark I.] Leeds Pallium Res Grp, Leeds, W Yorkshire, England.
   [Bennett, Michael I.] Univ Lancaster, Int Observ End Life Care, Lancaster, England.
C3 Leeds Beckett University; University of Leeds; Lancaster University
RP Paley, CA (corresponding author), Leeds Metropolitan Univ, Fac Hlth, Leeds LS1 3HE, W Yorkshire, England.
EM biodynamics.physiotherapy@tesco.net
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005
   Bingel U, 2006, PAIN, V120, P8, DOI 10.1016/j.pain.2005.08.027
   Bingel U, 2008, PHYSIOLOGY, V23, P371, DOI 10.1152/physiol.00024.2008
   CAMPBELL A, 1999, ACUPUNCT MED, V17, P124, DOI 10.1136/AIM.17.2.124
   Campbell A, 1999, ACUPUNCT MED, V17, P113, DOI 10.1136/AIM.17.2.113
   Campbell Anthony, 2006, ACUPUNCT MED, V24, P118
   Carlsson Christer, 2002, ACUPUNCT MED, V20, P82
   Ceccherelli F, 2002, J ALTERN COMPLEM MED, V8, P341, DOI 10.1089/10755530260128032
   Chan Gunn C, 1989, ACUPUNCTURE IN MEDICINE, V6, P50
   Clohisy DR, 2003, CANCER-AM CANCER SOC, V97, P866, DOI 10.1002/cncr.11144
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Colvin L, 2008, EUR J CANCER, V44, P1083, DOI 10.1016/j.ejca.2008.03.001
   Diel IJ, 2006, EJC SUPPL, V4, P1, DOI 10.1016/j.ejcsup.2006.07.001
   Dillon M, 1999, PALLIATIVE MED, V13, P253, DOI 10.1191/026921699667999073
   Donovan-Rodriguez T, 2005, ANESTHESIOLOGY, V102, P132, DOI 10.1097/00000542-200501000-00022
   Ernst E, 2007, SUPPORT CARE CANCER, V15, P565, DOI 10.1007/s00520-006-0174-y
   Ernst E, 2003, PALLIATIVE MED, V17, P704, DOI 10.1191/0269216303pm816oa
   Ernst E, 2003, EUR J CANCER, V39, P2273, DOI 10.1016/S0959-8049(03)00604-X
   Eustachi A, 2009, INTEGR CANCER THER, V8, P56, DOI 10.1177/1534735408327996
   Filshie J, 2005, EJC SUPPL, V3, P107, DOI 10.1016/S1359-6349(05)80267-8
   Filshie J, 2001, ACUPUNCT MED, V19, P117
   FILSHIE J, 1990, ACUPUNCT MED, V8, P38
   Filshie Jacqueline, 2005, ACUPUNCT MED, V23, P171
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Freeman MD, 2009, J BRACHIAL PLEX PERI, V4, P0, DOI 10.1186/1749-7221-4-2
   Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815-04.2005
   Goblirsch MJ, 2005, J CELL BIOCHEM, V96, P682, DOI 10.1002/jcb.20589
   Gori L, 2007, EVID-BASED COMPL ALT, V4, P13, DOI 10.1093/ecam/nem106
   Guo HF, 1996, MOL BRAIN RES, V43, P157, DOI 10.1016/S0169-328X(96)00170-2
   HAN JS, 1986, ASIA PAC J PHARMACOL, V1, P17
   HAN JS, 1982, ANNU REV PHARMACOL, V22, P193, DOI 10.1146/annurev.pa.22.040182.001205
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Harding C, 2009, BJU INT, V103, P186, DOI 10.1111/j.1464-410X.2008.07884.x
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F
   Langevin HM, 2007, J ALTERN COMPLEM MED, V13, P355, DOI 10.1089/acm.2007.6351
   Langevin HM, 2006, HISTOCHEM CELL BIOL, V125, P487, DOI 10.1007/s00418-005-0138-1
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lee HJ, 2009, J EXP CLIN CANC RES, V28, P0, DOI 10.1186/1756-9966-28-102
   Leknes S, 2008, NAT REV NEUROSCI, V9, P314, DOI 10.1038/nrn2333
   Leng G, 1999, PALLIATIVE MED, V13, P163, DOI 10.1191/026921699676243035
   Lewith GT, 2005, EVID-BASED COMPL ALT, V2, P315, DOI 10.1093/ecam/neh110
   Lipton Allan, 2004, J SUPPORT ONCOL, V2, P205
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304-3959(02)00102-1
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   *MACM CANC REL, 2002, DIR COMPL THER SERV, V0, P0
   MacPherson H, 2001, ACUPUNCT MED, V19, P93
   MacPherson H, 2008, NEUROSCI LETT, V434, P144, DOI 10.1016/j.neulet.2008.01.058
   Mann F, 2000, REINVENTING ACUPUNCTURE: A NEW CONCEPT OF ANCIENT MEDICINE, V2nd, P0
   Mantyh P, 2006, EJC SUPPL, V4, P4, DOI 10.1016/j.ejcsup.2006.07.003
   MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304-3959(96)03267-8
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Qaseem A, 2009, ANN INTERN MED, V150, P148
   RAMPES H, 1999, ACUPUNCTURE SCI APPR, V0, P128
   Sandkuhler J, 1997, J NEUROSCI, V17, P6483
   Sandkühler J, 2000, PAIN, V88, P113, DOI 10.1016/S0304-3959(00)00424-3
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Shimoyama M, 2005, PAIN, V114, P221, DOI 10.1016/j.pain.2004.12.018
   Suzuki R, 2005, NEUROSIGNALS, V14, P175, DOI 10.1159/000087656
   Thompson JW, 2005, OXFORD TXB PALLIATIV, V0, P421
   Urch CE, 2005, J PAIN, V6, P837, DOI 10.1016/j.jpain.2005.08.005
   Urch CE, 2003, PAIN, V106, P347, DOI 10.1016/j.pain.2003.08.002
   Usichenko TI, 2008, ANAESTHESIA, V63, P1343, DOI 10.1111/j.1365-2044.2008.05632.x
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   White A, 2001, ACUPUNCT MED, V19, P84
   White A, 2008, AN INTRODUCTION TO WESTERN MEDICAL ACUPUNCTURE, V0, P0
   Wu MT, 1999, RADIOLOGY, V212, P133, DOI 10.1148/radiology.212.1.r99jl04133
   Xing GG, 2007, EXP NEUROL, V208, P323, DOI 10.1016/j.expneurol.2007.09.004
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   ZHOU ZF, 1981, SCI SINICA, V24, P1166
NR 75
TC 22
Z9 27
U1 1
U2 32
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2011
VL 2011
IS 
BP 1
EP 8
DI 10.1093/ecam/neq020
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 802PO
UT WOS:000293523700001
PM 21799687
DA 2026-01-16
ER

PT J
AU Running, A
   Turnbeaugh, E
AF Running, Alice
   Turnbeaugh, Elizabeth
TI Oncology Pain and Complementary Therapy: A Review of the Literature
SO CLINICAL JOURNAL OF ONCOLOGY NURSING
LA English
DT Review
ID cancer pain; massage therapy; neuropathic pain; bone pain; medicine; anxiety; electroacupuncture; intervention; acupuncture; relaxation
AB Half of all patients with cancer experience some level of pain, so pain management is an important topic for oncology nurses. Pharmacologic measures traditionally are the primary intervention for bone, visceral, neuropathic, and procedural pain; however, many patients are turning to an integrative approach of Western and complementary therapies for pain and symptom management. The authors explored the current evidence concerning the effectiveness of complementary therapies in relation to cancer pain and symptom control.
C1 [Running, Alice] Univ Nevada, Orvis Sch Nursing, Div Hlth Sci, Reno, NV 89557 USA.
   [Turnbeaugh, Elizabeth] St Marys Heil Rd Clin, Reno, NV USA.
C3 Nevada System of Higher Education (NSHE); University of Nevada Reno
RP Running, A (corresponding author), Univ Nevada, Orvis Sch Nursing, Div Hlth Sci, Reno, NV 89557 USA.
EM running@unr.edu
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2009, COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE) V4.0, V0, P0
   Unknown -, 2008, COMPLEMENTARY ALTERN, V0, P0
   Buttaro T, 2008, PRIMARY CARE COLLABO, V3rd, P0
   Cassileth BR, 2004, ONCOLOGIST, V9, P80, DOI 10.1634/theoncologist.9-1-80
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Cepeda MS, 2006, COCHRANE DB SYST REV, V2, P004843
   Chang VT, 2006, J PALLIAT MED, V9, P1414, DOI 10.1089/jpm.2006.9.1414
   *COLL ST SCHOL, 2011, LEV EV, V0, P0
   Corbin Lisa, 2005, CANCER CONTROL, V12, P158
   Currin J, 2008, CANCER NURS, V31, P214, DOI 10.1097/01.NCC.0000305725.65345.f3
   Evans S, 2008, ALTERN THER HEALTH M, V14, P52
   Gatlin Christine G, 2007, CLIN J ONCOL NURS, V11, P699, DOI 10.1188/07.CJON.699-704
   Guo R, 1995, J TRADIT CHIN MED, V15, P262
   *HEAL TOUCH INT, 2010, HEAL TOUCH POL HEAL, V0, P0
   Hughes D, 2008, ONCOL NURS FORUM, V35, P431, DOI 10.1188/08.ONF.431-442
   *INT CTR REIK TRAI, 2010, WHAT IS REIK, V0, P0
   Irnich D, 2002, SCHMERZ, V16, P114, DOI 10.1007/s00482-001-0128-8
   Jackson E, 2008, CLIN J ONCOL NURS, V12, P113, DOI 10.1188/08.CJON.113-120
   Jane SW, 2009, J PAIN SYMPTOM MANAG, V37, P754, DOI 10.1016/j.jpainsymman.2008.04.021
   Kerr H D, 1997, WMJ, V96, P57
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Lang EV, 2006, PAIN, V126, P155, DOI 10.1016/j.pain.2006.06.035
   Lee NP, 2008, THE JOURNAL FOR NURSE PRACTITIONERS, V4, P610, DOI 10.1016/J.NURPRA.2008.05.007
   Mansky PJ, 2006, CANCER J, V12, P425, DOI 10.1097/00130404-200609000-00011
   Mikhail A, 1997, NEPHROL DIAL TRANSPL, V12, P797, DOI 10.1093/ndt/12.4.797
   Miller KE, 2001, AM FAM PHYSICIAN, V64, P1227
   National Centre for Complementary and Alternative Medicine, 2009, WHAT IS CAM, V0, P0
   National Pain Foundation, 2009, CANC PAIN PALL CAR G, V0, P0
   PFISTER D, 2008, J CLIN ONCOLOGY S, V26, P0
   Pittler MH, 2008, CLIN J PAIN, V24, P731, DOI 10.1097/AJP.0b013e3181759231
   Post-White Janice, 2003, INTEGR CANCER THER, V2, P332, DOI 10.1177/1534735403259064
   Richardson J, 2006, J PAIN SYMPTOM MANAG, V31, P70, DOI 10.1016/j.jpainsymman.2005.06.010
   Shaiova L, 2006, CANCER J, V12, P330, DOI 10.1097/00130404-200609000-00002
   Standish LJ, 2008, AM J HOSP PALLIAT ME, V25, P298, DOI 10.1177/1049909108315916
   Stephenson NLN, 2007, ONCOL NURS FORUM, V34, P127, DOI 10.1188/07.ONF.127-132
   TROTTER JF, 1999, MEDICINE, V341, P2019
   Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
NR 41
TC 12
Z9 16
U1 0
U2 23
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 1092-1095
EI 1538-067X
J9 CLIN J ONCOL NURS
JI Clin. J. Oncol. Nurs.
PD AUG 15
PY 2011
VL 15
IS 4
BP 374
EP 379
DI 10.1188/11.CJON.374-379
PG 6
WC Oncology; Nursing
SC Oncology; Nursing
GA 805KD
UT WOS:000293724400007
PM 21810570
DA 2026-01-16
ER

PT J
AU Ferreira, AS
   Lopes, AJ
AF Ferreira, Arthur Sa
   Lopes, Agnaldo Jose
TI Chinese Medicine Pattern Differentiation and Its Implications for Clinical Practice
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Editorial Material
DE Chinese medicine-syndrome differentiation; Chinese medicine; preventive medicine; rehabilitation "health care delivery"
ID coronary-heart-disease; acupuncture treatment; blood-stasis; diagnosis; manifestations; cystitis; women
AB Chinese medicine practitioners apply the differentiation reasoning for decision-making. The wide scope of Chinese medicine intervention provides coverage of methods and techniques with applications to primary, secondary and tertiary levels of prevention. The rapid evolution of mathematical and computational techniques allowed the implementation of several models for pattern differentiation that were tested for several physiologic systems. Concurrently, it is argued that pattern differentiation might improve the efficacy of either traditional or conventional medical interventions. This article reviewed the influence of pattern differentiation into clinical practice organized by medical field: general pattern differentiation; genitourinary (recurrent cystitis); cardiovascular (coronary heart disease; arterial hypertension; angina pectoris); neurology (stroke); surgery; metabolic (diabetes mellitus); hepatic (cirrhosis); gastrointestinal (chronic superficial gastritis); orthopedic (low back pain; rheumatoid arthritis; cervical spondylosis; elbow arthritis); oncology (gastric mucosal dysplasia; lung cancer); gynecologic and obstetric manifestations (nausea and vomiting). The reviewed studies presented achievements that have contributed to the integration of Chinese medicine and evidence-based medicine in the treatment of many mild and severe diseases. Target diseases considered as major public health problems were also investigated and the results are promising regarding the possibility to treat guided by pattern differentiation.
C1 [Ferreira, Arthur Sa] Augusto Motta Univ, Lab Computat Modeling & Simulat Rehabil, Program Rehabil Sci, Rio De Janeiro, Brazil.
   [Lopes, Agnaldo Jose] Augusto Motta Univ, Lab Cardiopulmonar Anal, Rehabil Sci Postgrad Program, Rio De Janeiro, Brazil.
   [Lopes, Agnaldo Jose] Univ Estado Rio De Janeiro, Physiol Resp Lab, Rio De Janeiro, Brazil.
C3 Centro Universitario Augusto Motta (UNISUAM); Centro Universitario Augusto Motta (UNISUAM); Universidade do Estado do Rio de Janeiro
RP Ferreira, AS (corresponding author), Augusto Motta Univ, Lab Computat Modeling & Simulat Rehabil, Program Rehabil Sci, Rio De Janeiro, Brazil.
EM arthur_sf@ig.com.br
CR Alraek T, 2003, J ALTERN COMPLEM MED, V9, P651, DOI 10.1089/107555303322524508
   Alraek T, 2002, AM J PUBLIC HEALTH, V92, P1609, DOI 10.2105/AJPH.92.10.1609
   Alræk T, 2000, COMPLEMENT THER MED, V8, P260, DOI 10.1054/ctim.2000.0399
   Unknown -, 2003, CLIN ACUPUNCT ORIENT, V0, P0
   Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010
   Chen YL, 2009, CHIN J INTEGR MED, V15, P341, DOI 10.1007/s11655-009-0341-3
   Chu FY, 2010, CHIN J INTEGR MED, V16, P399, DOI 10.1007/s11655-010-9999-9
   Chuang-Chien Chiu, 2002, JOURNAL OF MEDICAL AND BIOLOGICAL ENGINEERING, V22, P219
   Feng Y, 2011, CHIN J INTEGR MED, V17, P333, DOI 10.1007/s11655-011-0615-4
   Ferreira AS, 2011, CHIN MED-UK, V6, P0, DOI 10.1186/1749-8546-6-1
   Ferreira Arthur Sa, 2009, CHIN MED, V4, P24, DOI 10.1186/1749-8546-4-24
   Flachskampf FA, 2007, CIRCULATION, V115, P3121, DOI 10.1161/CIRCULATIONAHA.106.661140
   Froom P, 2000, PREV MED, V31, P153, DOI 10.1006/pmed.2000.0689
   Fu WB, 2009, CHIN J INTEGR MED, V15, P426, DOI 10.1007/s11655-009-0426-z
   Fu XQ, 2011, CHIN J INTEGR MED, V17, P351, DOI 10.1007/s11655-011-0725-z
   Gu Wan-Li, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P842
   Gu Wan-li, 2007, ZHONG XI YI JIE HE XUE BAO, V5, P255
   Liu GP, 2010, BMC COMPLEM ALTERN M, V10, P0, DOI 10.1186/1472-6882-10-37
   Lu AP, 2009, CHIN J INTEGR MED, V15, P152, DOI 10.1007/s11655-009-0152-6
   Lu C, 2009, J ALTERN COMPLEM MED, V15, P1021, DOI 10.1089/acm.2009.0065
   Lu Y-h, 2007, CHIN. J. CLIN. PHARMACOL. THER, V12, P1144
   Luiz AB, 2011, CHIN MED-UK, V6, P0, DOI 10.1186/1749-8546-6-23
   Lukman S, 2007, COMPUT METH PROG BIO, V88, P283, DOI 10.1016/j.cmpb.2007.09.008
   Maciocia G, 1989, THE FOUNDATIONS OF CHINESE MEDICINE: A COMPREHENSIVE TEXT FOR ACUPUNCTURISTS AND HERBALISTS, V0, P0
   Macklin EA, 2006, HYPERTENSION, V48, P838, DOI 10.1161/01.HYP.0000241090.28070.4c
   MacPherson H, 2004, COMPLEMENT THER MED, V12, P38, DOI 10.1016/S0965-2299(03)00125-0
   Min ZH, 2010, CHIN J INTEGR MED, V16, P264, DOI 10.1007/s11655-010-0264-z
   Ryu H, 2010, J ALTERN COMPLEM MED, V16, P663, DOI 10.1089/acm.2009.0331
   Sallstrom S, 1996, COMPL THER MED, V4, P193
   Shen SW, 2011, CHIN J INTEGR MED, V17, P346, DOI 10.1007/s11655-011-0616-3
   Smith C, 2002, BIRTH-ISS PERINAT C, V29, P1, DOI 10.1046/j.1523-536X.2002.00149.x
   Su W, 2011, CHIN J INTEGR MED, V17, P272, DOI 10.1007/s11655-011-0702-6
   van Wietmarschen H, 2009, JCR-J CLIN RHEUMATOL, V15, P330, DOI 10.1097/RHU.0b013e3181ba3926
   Wang Y, 2009, COMPUT METH PROG BIO, V95, P249, DOI 10.1016/j.cmpb.2009.03.004
   Wang YL, 2009, CHIN J INTEGR MED, V15, P337, DOI 10.1007/s11655-009-0337-z
   Xu H, 2011, CHIN J INTEGR MED, V17, P163, DOI 10.1007/s11655-011-0661-y
   Yang Shouzhong, 2004, SYSTEMATIC CLASSIC OF ACUPUNCTURE AND MOXIBUSTION, V0, P0
   Yao KW, 2011, CHIN J INTEGR MED, V17, P200, DOI 10.1007/s11655-011-0667-5
   Zhang XP, 2011, CHIN J INTEGR MED, V17, P307, DOI 10.1007/s11655-011-0699-x
NR 49
TC 66
Z9 74
U1 4
U2 59
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD NOV 15
PY 2011
VL 17
IS 11
BP 818
EP 823
DI 10.1007/s11655-011-0892-y
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 842QL
UT WOS:000296614000003
PM 22057410
DA 2026-01-16
ER

PT J
AU Gilmour, J
   Harrison, C
   Asadi, L
   Cohen, MH
   Vohra, S
AF Gilmour, Joan
   Harrison, Christine
   Asadi, Leyla
   Cohen, Michael H
   Vohra, Sunita
TI Informed consent: advising patients and parents about complementary and
SO Pediatrics
LA English
DT Journal Article
AB Although research on complementary and alternative medicine (CAM) therapies is  still limited, systematic reviews have revealed sufficient evidence to conclude  that CAM can be effective for certain conditions. In this article we discuss  clinicians' responsibilities to inform parents/patients about CAM alternatives  and use the example of acupuncture for chemotherapy-induced nausea and vomiting.  Chemotherapy-induced nausea and vomiting remain significant adverse effects of  cancer therapy, and some patients cannot find relief with standard therapies.  When making decisions for a child with a life-threatening illness, parents must  consider all reasonable options and decide what is in the child's best interests.  A physician's failure to provide parents with relevant information regarding  therapies with the prospect of therapeutic benefit impedes their ability to make  an informed decision. Physicians have the ethical duty of beneficence; they must  be aware of current research in pain and symptom management and other aspects of  care. A physician's duty of care does not necessarily include the obligation to  provide information about therapies outside the range of conventional treatment  or those not yet supported in the medical literature. However, as CAM therapies  such as acupuncture become better studied and their safety and efficacy are  established, the scope of disclosure required may expand to include them. The  legal and ethical obligation to obtain informed consent to treatment requires  disclosure and discussion of therapies when there is reliable evidence of  potential therapeutic benefit. At the same time, the more limited state of  knowledge regarding effects of a particular therapy in the pediatric population  must be factored into decision-making when treating a child.
C1 Osgoode Hall Law School, York University, Toronto, Ontario, Canada.
NR 0
TC 0
SN 1098-427
EI 
J9 Pediatrics
PD NOV 9
PY 2011
VL 128 Suppl 4
IS 
BP S187
EP 92
DI 10.1542/peds.2010-2720H
PG 1
WC Acupuncture Therapy; ethics; Antineoplastic Agents; adverse effects; Canada; Child; Complementary Therapies; ethics; Disclosure; ethics; Ethics, Medical; Humans; Informed Consent; ethics; Liability, Legal; Male; Nausea; etiology; Parents; Physician-Patient Relations; Professional-Family Relations; United States; Vomiting; etiology
UT PubMed:22045862
PM 22045862
DA 2011-11-09
ER

PT J
AU Paley, CA
   Johnson, MI
   Tashani, OA
   Bagnall, AM
AF Paley, Carole A
   Johnson, Mark I
   Tashani, Osama A
   Bagnall, Anne-Marie
TI Acupuncture for cancer pain in adults.
SO The Cochrane database of systematic reviews
LA English
DT Journal Article
AB BACKGROUND: Forty percent of individuals with early or intermediate stage cancer  and 90% with advanced cancer have moderate to severe pain and up to 70% of  patients with cancer pain do not receive adequate pain relief. It has been  claimed that acupuncture has a role in management of cancer pain and guidelines  exist for treatment of cancer pain with acupuncture. OBJECTIVES: To evaluate  efficacy of acupuncture for relief of cancer-related pain in adults. SEARCH  STRATEGY: CENTRAL, MEDLINE, EMBASE, PsycINFO, AMED, and SPORTDiscus were searched  up to November 2010 including non-English language papers. SELECTION CRITERIA:  Randomised controlled trials (RCTs) evaluating any type of invasive acupuncture  for pain directly related to cancer in adults of 18 years or over. DATA  COLLECTION AND ANALYSIS: It was planned to pool data to provide an overall  measure of effect and to calculate the number needed to treat to benefit, but  this was not possible due to heterogeneity. Two review authors (CP, OT)  independently extracted data adding it to data extraction sheets. Quality scores  were given to studies. Data sheets were compared and discussed with a third  review author (MJ) who acted as arbiter. Data analysis was conducted by CP, OT  and MJ. MAIN RESULTS: Three RCTs (204 participants) were included. One high  quality study investigated the effect of auricular acupuncture compared with  auricular acupuncture at 'placebo' points and with non-invasive vaccaria ear  seeds attached at 'placebo' points. Participants in two acupuncture groups were  blinded but blinding wasn't possible in the ear seeds group because seeds were  attached using tape. This may have biased results in favour of acupuncture  groups. Participants in the real acupuncture group had lower pain scores at two  month follow-up than either the placebo or ear seeds group.There was high risk of  bias in two studies because of low methodological quality. One study comparing  acupuncture with medication concluded that both methods were effective in  controlling pain, although acupuncture was the most effective. The second study  compared acupuncture, point-injection and medication in participants with stomach  cancer. Long-term pain relief was reported for both acupuncture and  point-injection compared with medication during the last 10 days of treatment.  Although both studies have positive results in favour of acupuncture they should  be viewed with caution due to methodological limitations, small sample sizes,  poor reporting and inadequate analysis. AUTHORS' CONCLUSIONS: There is  insufficient evidence to judge whether acupuncture is effective in treating  cancer pain in adults.
C1 Research and Effectiveness Department, Airedale NHS Trust, Airedale General Hospital, Steeton, Keighley, West Yorkshire, UK, BD20 6TD.
NR 0
TC 0
SN 1469-493
EI 
J9 Cochrane Database Syst Rev
PD JAN 21
PY 2011
VL 0
IS 1
BP CD007753
EP CD007753
DI 10.1002/14651858.CD007753.pub2
PG 1
WC Acupuncture Therapy; methods; Acupuncture, Ear; methods; Adult; Humans; Neoplasms; complications; Pain; etiology; Pain Management; Pain Measurement; Randomized Controlled Trials as Topic
UT PubMed:21249694
PM 21249694
DA 2011-01-21
ER

